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Abstract
The type Iα cGMP-dependent protein kinase (PKG Iα) is an essential regu-
lator of vascular tone and systemic blood pressure. Located in the smooth muscle
of resistance vessels, PKG Iα stimulates vasodilation through the phosphorylation
of multiple intracellular substrates. Its primary regulator is the small molecule,
3’,5’-cyclic guanosine monophosphate (cGMP); however, the Iα isoform can also
be activated by oxidation. Despite the established physiological importance of
PKG Iα, the structural underpinnings of these two activation mechanisms are
largely unknown.
The work presented in this dissertation demonstrates the importance of
the cGMP-binding domain A (CBD-A) in regulating both of these mechanisms
of PKG Iα activation. Using a monomeric, N-terminally truncated form of PKG
Iα (∆53), Chapter 2 investigates the mechanism of inhibition through the au-
toinhibitory domain and the influence of dimerization on cooperative cGMP-
dependent activation and cyclic nucleotide selectivity. We observed that autoinhi-
bition occurs in cis, whereas cooperativity requires interprotomer contacts facili-
tated by the N-terminal dimerization domain. Furthermore, the loss of selectivity
for cGMP over cAMP of this construct suggests the dimerization domain plays a
critical role in preventing cross-reactivity with cAMP-dependent signaling. These
observations culminate into an overarching model wherein binding of cGMP to
CBD-A is necessary and sufficient for activation and cooperativity is driven by
the dimerization domain.
Chapter 3 investigates the cysteine residues that mediate oxidation-depend-
ent activation of PKG Iα. Using PKG Iα constructs with point mutations at spe-
cific cysteine residues, it was found that oxidation-dependent activation is driven
by C117 in CBD-A. Furthermore, the interprotomer disulfide bond that forms in
the dimerization domain at C42 does not contribute to this mechanism. Finally,
we propose a model wherein the disulfide bond that forms between C117 and
the adjacent cysteine at position 195 acts as a protective mechanism to prevent
activation and higher oxidation states form contacts with nearby residues in the
linker region of PKG Iα to disrupt binding of the adjacent autoinhibitory domain
to the catalytic domain.
Finally, Chapter 4 provides a discussion of the results presented herein in
context with previous studies and suggests future directions for the PKG field.
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Chapter 1
Introduction
1.1 Expression and sequence conservation of the type I
cGMP-dependent protein kinase (PKG I)
The cGMP-dependent protein kinase (PKG) is a member of the AGC
(PKA, PKG, and PKC) family of serine/threonine kinases. These enzymes are ac-
tivated by the small molecule, cyclic 3’5’ guanosine monophosphate (cGMP) and
phosphorylate intracellular substrates thereby controlling processes that range
from vascular reactivity to insulin secretion (Hofmann et al., 2009). PKG is a
ubiquitously-expressed enzyme found in diverse eukaryotic species, including api-
complexan parasites (e.g. plasmodium faliciparum and toxoplasmodia gondii),
insects (e.g. honey bees, mosquitoes, ants, and fruit flies), and vertebrates (e.g.
humans, cows, rats, mice, rabbit, and puffer fish) (Fitzpatrick and Sokolowski,
2004; Billker et al., 2009). In mammalian tissues, two genes, prkg1 and prkg2,
encode for PKG types I and II, respectively. PKG I is expressed as two splice
variants, PKG Iα and Iβ, of the prkg1 gene (Hofmann et al., 2009). Due to the
breadth of literature within the PKG field, this review will focus on the PKG type
I isoforms, α and β.
1.1.1 Sequence conservation of PKG I isoforms
The sequences of PKG Iα and Iβ are highly conserved across placental
mammals. As of Feb 19, 2018, the National Center for Biotechnology Information
(NCBI) protein database lists PKG Iα and Iβ sequences from 25 species across 8
1
orders within the mammalia placentalis subclass. The highest representation of
sequences are within the primates and rodentia classifications (Figure 1.1).
Figure 1.1: All currently available sequences (as of Feb. 19, 2018) of PKG I
isoforms expressed in placental mammals (mammalia placentalis) were obtained
from the National Center for Biotechnology Information (NCBI) database. Species
are organized by order and include the genus species information, common names,
and NCBI accession numbers for the Iα and Iβ isoforms. Sequences were aligned
in Jalview V2 using the Clustal OWS algorithm (Sievers et al., 2011; Waterhouse
et al., 2009). The full sequence alignment can be found in Appendix 2.
A comparison of PKG Iα and Iβ using BLOSUM62 scoring found that
the overall sequence identity across placental mammals is 88%, with the highest
variation occurring in the N-terminal dimerization (29% identity), autoinhibitory
domain (44% identity), and the two linker regions (6% identity) (Figure 1.2).
Their regulatory and catalytic domains are nearly 100% identical with only a
handful of species-specific residue differences between them (15/593 residues); of
these, most are conservative replacements (e.g. residue 227 in Iα is either an
Asp or a Glu). Thus, the only differences between PKG Iα and Iβ exist in their
2
N-termini.
1.2 Structural architecture of PKG I isoforms
PKG Iα and Iβ are homodimers with each protomer composed of an N-
terminal dimerization domain, an autoinhibitory domain, a regulatory domain
containing two cGMP binding sites, and a catalytic domain (Pinkse et al., 2009)
1.2. As a result of alternative-splicing of the prkg1 gene, PKG Iα and Iβ are iden-
tical from the beginning of their regulatory domains to the C-terminus (residues
78-671 in Iα and 93-686 in Iβ) (Orstavik et al., 1992, 1997). The differences
in their dimerization and autoinhibitory domains have been shown to impart iso-
form specific differences in cGMP-dependent activation and targeting to substrates
(Casteel et al., 2010; Qin et al., 2015; Ruth et al., 1991).
Figure 1.2: PKG Iα and Iβ Domain Architecture. PKG I isoforms are homod-
imers with the same overall domain architecture, which consists of a dimerization
domain, an autoinhibitory domain, a regulatory domain containing two in-tandem
cGMP binding sites (A and B), and a catalytic domain. The regions between the
dimerization, autoinhibitory, and regulatory domains are separated by linker re-
gions 1 and 2. The residues that span the specific domains within PKG Iα and Iβ
are indicated below the schematic.
3
1.2.1 Dimerization Domain
The N-terminal dimerization domain is a left-handed, coiled-coil, leucine
zipper motif (Landgraf et al., 1991; Atkinson et al., 1991; Qin et al., 2015; Casteel
et al., 2010). The structure is characterized by a heptad repeat of amino acids
(abcdefg) where residues a and d are typically hydrophobic and residues e and
g are typically hydrophilic. The leucine zipper of PKG Iα spans residues 2-47
(Qin et al., 2015; Casteel et al., 2010; Ruth et al., 1991). In addition to its
leucine and isoleucine residues, there are also four non-leucines/ isoleucines at the
d positions that provide additional non-hydrophobic interhelical contacts (Phe7,
Lys14, Lys28, Cys42) (Figure 1.3) (Qin et al., 2015). One of these residues,
Cys42, is unique to the Iα isoform and forms an interprotomer disulfide bond
in the presence of oxidizing agents, such as hydrogen peroxide (Burgoyne et al.,
2007; Landgraf et al., 1991). The leucine zipper of PKG Iβ spans residues 4-
53, and also contains four non-leucine/ isoleucine residues at d positions (Lys13,
Arg20, Lys34, and Tyr48) (Casteel et al., 2010). These non-canonical residues
in both isoforms primarily form contacts with residues at the e position of the
opposing helix. Though the majority of the non-canonical residues are basic,
their differences in position within the helices likely prevent PKG I protomers
from forming heterodimers both in vitro and in vivo.
The outer residues of the PKG Iα and Iβ leucine zippers impart isoform
specific charge distributions across their surfaces that mediate substrate targeting
and localization (Figure 1.3- top panel)(Schlossmann and Desch, 2009). Several re-
views have focused on the substrate specificities of the Iα and Iβ isoforms (Hofmann
et al., 2000, 2009; Hofmann and Wegener, 2013; Schlossmann and Desch, 2009).
Most substrates are phosphorylated by a single isoform, while others, such as va-
sodilator stimulated phosphoprotein (VASP), can be phosphorylated by either Iα
4
Figure 1.3: Dimerization domains of PKG Iα (PBD 4R4L) and Iβ (PDB 3NMD).
Electrostatic surface models show the charge distribution patterns for each isoform
(top) (basic = blue; acidic = red; white = neutral). The cartoon models show the
residues within the helices (middle). The sequences show interprotomer contacts
between homodimers (bottom). Canonical and non-canonical residues at the a
or d positions are denoted with vertical lines, Xs, or brackets. Residues at the a
position within the helical repeat (abcdefg) are highlighted with yellow boxes.
or Iβ. Thus far, more than 20 PKG I substrates have been identified (Hofmann
et al., 2009; Hofmann and Wegener, 2013; Schlossmann and Desch, 2009). Even
though the phosphorylation sites have been identified, only the specific binding
interfaces between the PKG I dimerization domains and myosin-binding subunit
(MBS) of myosin light-chain phosphatase (MYPT1) (Blanton et al., 2013; Lee
et al., 2007; Sharma et al., 2008, 2017; Surks et al., 1999; Surks, 2007; Zhou,
2011), the Ras homolog gene family member A (RhoA) (Kato et al., 2012), the
general transcription factor regulator, TFII-I, and the inositol 1,4,5-trisphosphate
receptor-associated PKG substrate (IRAG) (Casteel et al., 2005) have been eluci-
dated using biochemical or structural methods (PKG Iα-MBS and MYPT1; PKG
Iβ-TFII-I and IRAG).
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Substrate targeting has been shown to be integral in regulating PKG sig-
naling (Blanton et al., 2013; Michael et al., 2008; Ramchandran et al., 2014).
Mutation of the first four leucines/isoleucines within the dimerization domain of
PKG Iα has been shown to be sufficient in disrupting phosphorylation of the sub-
strates RhoA and MYPT1 in vascular smooth muscle cells. Despite this effect
on targeting to that full-length substrate, the mutant construct was able to be
activated in a cGMP-dependent manner and phosphorylated a peptide substrate.
Introduction of these mutations into a mouse model (LZM) also disrupted PKG
Iα signaling (Ramchandran et al., 2014). These experiments highlight the impor-
tance of distinguishing substrate targeting from activation defects.
1.2.2 Autoinhibitory Domain
The autoinihibitory domain is a critical component of PKG I activation
and spans residues 51-68 and 66-83 in PKG Iα and Iβ, respectively. When PKG I
is inactive, the autoinhibitory domain binds to the catalytic domain and acts as
a pseudosubstrate (Aitken et al., 1984; Francis et al., 1996; Wolfe et al., 1987).
Autoinhibition of the catalytic domain is mediated by Gly62 (PKG Iα) and Ala77
(PKG Iβ) within the conserved G/AISAEP sequence (Kemp et al., 1988; Fran-
cis et al., 1996). These residues are thought to occupy the phosphate acceptor
site (P0) to prevent substrate phosphorylation in a mechanism similar to PKA
holoenzyme formation (Francis et al., 1996). It is thought that cGMP induces
structural reorganization of the regulatory domain and acts to relieve this autoin-
hibition (Alverdi et al., 2008; Zhao et al., 1997). The functional importance of
this domain was confirmed by the generation of the truncation mutant PKG Iα
∆77. This construct can be generated endogenously through trypsin cleavage at
Arg77 and was found to be constitutively active due to loss of its autoinhibitory
sequence (Heil et al., 1987; Landgraf et al., 1990; Scholten et al., 2007). Fur-
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thermore, activated PKG Iα has been shown to have increased exposure of the
autoinhibitory domain and the putative substrate binding region of the catalytic
domain, suggesting these two regions are likely in contact with each other in the
inactive state (Alverdi et al., 2008).
Research has suggested the cyclic nucleotides, cAMP and cGMP, can both
stimulate autophosphorylation of PKG I isoforms primarily within the autoin-
hibitory domain (Aitken et al., 1984; Hofmann and Flockerzi, 1983; Takio et al.,
1983). Initial experiments using PKG Iα purified from bovine lung indicated
cyclic nucleotide-dependent differences in the sites of autophosphorylation. In-
cubation with cAMP predominantly stimulated autophosphorylation at Ser50,
Thr58, Ser72, and Ser84, whereas cGMP predominantly stimulated autophospho-
rylation at Thr58 (Aitken et al., 1984). A more recent examination using recom-
binant PKG Iα corroborated these results, and also noted autophosphorylation at
Ser44 with cAMP (van de Waterbeemd et al., 2014). In PKG Iβ, the major sites of
autophosphorylation were found to occur at Ser63 and Ser79 (Smith et al., 1996).
No cyclic nucleotide-dependent differences in the sites were observed; however,
autophosphorylation was slower with cGMP than cAMP. In addition, the basal
activity of autophosphorylated PKG Iβ was increased up to 4-fold compared to
the non-autophosphorylated form (Francis et al., 1996; Smith et al., 1996). This
may be due to the location of these sites in the P+2 position within the pseudo-
substrate region. In contrast, the autophosphorylation sites of PKG Iα flank the
pseudosubstrate region; therefore, it is unknown whether this same increase in
basal activity would occur.
The physiological significance of PKG I autophosphorylation is an under-
studied area of investigation. Autophosphorylation has been suggested to mediate
ubiquitination and intracellular turnover for PKG Iα, but not PKG Iβ (Dey et al.,
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2009). On its surface, this model is plausible given that maximum autophospho-
rylation of PKG I isoforms requires 1-2 h. However, this would suggest PKG Iβ
turnover occurs through a different mechanisms (Aitken et al., 1984; Hofmann
and Flockerzi, 1983; Smith et al., 1996; van de Waterbeemd et al., 2014).
1.2.3 Regulatory Domain
The regulatory domains of PKG Iα and Iβ are identical and contain two
tandem cyclic nucleotide binding sites (A and B sites) per protomer. Despite this
similarity, PKG Iα and Iβ have distinct cGMP-dependent activation properties,
with activation constants (Ka values) of approximately 100 nM and 1-2 µM, re-
spectively (Gill et al., 1976; Richie-Jannetta et al., 2003; Ruth et al., 1991, 1997;
Moon et al., 2015). This 10-20-fold difference is attributed to their distinct N-
termini. It was found that the leucine zipper domain, the autoinhibitory domain,
and the linker region just before the start of the regulatory domain (Linker 2; Fig-
ure 1.2) are important for conferring these isoform-specific properties (Ruth et al.,
1997). Furthermore, the leucine zipper and the autoinhibitory domains appear
to work synergistically and have the greatest influence since swapping of either
domain from PKG Iα into PKG Iβ was sufficient to achieve a 4-fold reduction in
the Ka for cGMP (Ruth et al., 1997).
Binding of cGMP to the A site (slow dissociation, high affinity) before
binding to the B site (fast dissociation, low affinity site) (Corbin and Doskeland,
1983; Zhao et al., 1997). The difference in binding affinities between the sites
is surprising since the residues involved in cyclic nucleotide binding are mostly
conserved between the A-site and the B-site (Table 1.1). It was suggested that a
conserved threonine in both sitesThr177/192 and Thr301/316 (Iα and Iβ number-
ing, respectively) acts as a selectivity filter for binding cGMP over cAMP (Kim
et al., 2011). However, isothermal titration calorimetry (ITC) measurements of
8
Table 1.1: Predominant residues that bind to cGMP in the cyclic nucleotide
binding domains of PKG I
Cyclic Nucleotide Position A-site (α/β) Å B-site (α/β) Å Binding Affinity
Guanine moiety- O L155/170 N/A R280/295 3.0 Moderate
Guanine moiety- NH2 K152/166 4.5 R268/283 4.3 Weak
Phosphate- O/OH R176/191 2.8 R300/315 2.9 Moderate
Phosphate- O/OH T177/192 2.5 T301/316 2.6 Moderate
Ribose- OH E166/181 2.4 E290/305 2.4 Strong
Interacting residues were determined based on the cGMP-bound regulatory
domain structure (PDB 4Z07; residues 106-212 and 121-227 in PKG Iα and Iβ,
respectively (Kim et al., 2015)).
the isolated A-site indicated binding constants (KD) of 12 and 27 nM for cGMP
and cAMP, respectively, suggesting this threonine alone poorly discriminates be-
tween the two. From these data, it was postulated that the selectivity for cGMP
of the full-length kinase is conferred through the B-site. To corroborate this, a
neutron diffraction structure of the isolated cGMP-bound B-site identified a con-
served arginine residue (Arg281/296) that forms contacts with O6 and N7 of the
guanine moiety (Huang et al., 2014). In the A-site, the residue at the equivalent
position within the structure is a leucine (Leu155/ 170) (Kim et al., 2011, 2016).
The predominant contacts between residues in the A- and B-sites with cGMP are
shown in Figure 1.4.
The crystal structures of PKG I that have been solved thus far have only in-
cluded isolated dimerization and regulatory domain components (Campbell et al.,
2017; Huang et al., 2014; Kim et al., 2011, 2016; Osborne et al., 2011). Since the
N-terminal dimerization and autoinhibitory domains are known to influence the
characteristics of the regulatory domain, these structures provide an incomplete
picture of PKG I activation with cGMP. The crystal structure solved by Osborne
et al. (2011) shows a helical segment at the C-terminal end of the B-site that was
found to form interprotomer contacts with the hydrophobic pocket of another B
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Figure 1.4: Alignment of the A and B cyclic nucleotide binding domains of PKG
I bound to cGMP (PDB 4Z07): A. The A (green) and B (gray) cyclic nucleotide
binding sites were selected and aligned in PyMOL using CE-align (A-site residues
121-217; B-site residues 240-340; RMSD = 1.585744). B. Structures of cAMP and
cGMP. The red squares indicate the groups that are distinct between the two. C.
Enlarged image of the cyclic nucleotide binding domain. The residues that bind
to the guanine moiety are shown as sticks (α/β numbering: L155/170, R280/295,
K152/K166, R268/283). Some of the residues that bind to the cyclic phosphate
and ribose sugar are also shown (α/β numbering: T177/192, T301/316, E166/181,
E290/305). The yellow and orange dashed lines indicate the interactions with the
A-site and B-site residues, respectively.
site (Figure 1.5). This ”switch helix” provided the structural basis for developing
cGMP-independent, peptidic activators. The most potent peptide that mimics
the helical segment observed in the crystal structure, S1.5, was found to only ac-
tivate PKG Iα and had no effect on PKG Iβ (Moon et al., 2015). This result was
unexpected since the regulatory domain sequences are identical between the two
isoforms. Thus, a large gap exists in the PKG field regarding how the N-terminal
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Figure 1.5: Regulatory domain of PKG Iα (PDB 3SHR): A. The crystal structure
of the regulatory domain of PKG Iα (residues 78-356) shows the cGMP binding
domains, A and B, as well as interprotomer contacts between the B-sites. Chains
A (green) and B (gray) are represented as a surface rendering. B. This interaction
is primarily mediated through the hydrophobic residues within the switch helical
(knob) and the nest regions. The inset shows the knob/nest interaction viewed
from the top of the structure with a semi-transparent surface rendering. Residues
F351, F352, A353, N354, and L355 contribute to the knob, while the residues
F221, W288, and F320 contribute to the nest.
dimerization and autoinhibitory domains modulate the regulatory domain to con-
fer isoform specific characteristics.
1.2.4 Catalytic Domain
PKG I contains a C-terminal catalytic domain that phosphorylates target
substrates by transferring the γ-phosphate from ATP onto serine or threonine
residues. This region is encompassed by residues 360-671 and 375-686 in PKG
Iα and β, respectively. Due to the lack of a crystal structure of this region, the
PKG field has relied on biochemical and biophysical approaches to investigate
this region as well as structures of the PKA catalytic domain. In the inactive
state, the site of catalysis is occluded through binding to PKG I’s autoinhibitory
domain, and binding of cGMP induces a conformational change that relieves this
inhibition (Alverdi et al., 2008; Chu et al., 1997; Heil et al., 1987; Landgraf et al.,
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1990; Wall et al., 2003; Zhao et al., 1997). A summary of the major evidences for
this model have been described in the ”Autoinhibitory Domain” and ”Regulatory
Domain” subsections of this review.
The catalytic domains of protein kinases are highly conserved in both their
tertiary structure and the residues responsible for catalytic activity (Hanks et al.,
1988; Hanks and Quinn, 1991). All catalytic domains have two lobes (N and C)
with the interface between them forming the site of catalysis (Bastidas et al.,
2013; Knighton et al., 1991; Taylor and Kornev, 2011; Zheng et al., 1993). The
N-lobe contains the glycine-rich loop (G-X-G-X-X-G), which binds ATP, and the
Mg2+ binding loop, which coordinates two Mg2+ ions essential for stabilizing the
phosphate groups of ATP and transfer of the γ-phosphate. The N-lobe also con-
tains other conserved residues that coordinate with C-lobe components to create
the active site. The C-lobe contains the bulk of the residues required for catalysis,
which are predominantly found in the catalytic loop, the activation loop, and the
substrate binding segment. The catalytic loop contains an aspartate that acts
as a catalytic base to deprotonate the serine/threonine hydroxyl oxygen on the
substrate. The DFG motif of the activation loop, along with the N-lobe residues,
helps position the Mg2+ ions. The activation loop also contains a phosphorylated
threonine residue that coordinates the active site components by forming contacts
with the catalytic loop, the activation loop, and the αC helix on the N-lobe (Basti-
das et al., 2013; Steichen et al., 2012). In PKG I, mutation of this residue (T517)
to alanine completely abolished catalytic activity (Feil et al., 1995).
The putative substrate binding segment of the catalytic domain (residues
611-671 and 626-686 in PKG Iα and Iβ, respectively) is also located on the C-
lobe and contains acidic, basic, and hydrophobic residues that dictate substrate
specificity (Alverdi et al., 2008; Hofmann et al., 1992; Dostmann et al., 1999).
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Figure 1.6: Structure of the catalytic domain of PKA (PDB 1ATP). Since all
kinase domains have the same overall architecture, the catalytic domain of PKA
is used as a model for PKG. A. This domain is composed of an N- and C-lobe
with the conserved loops important for catalysis shown in color (Glycine rich
loop-yellow; Catalytic loop- red; Activation Loop- green; P+1 Loop- orange). B.
ATP and Mn2+ ions are shown coordinated in the active site by D166, K168,
and N171. C. Phosphorylated T197 in the activation loop integrates the active
site components through contacts with other activation loop residues (T195 and
K189) as well as R165 in the catalytic loop and H87.
The consensus sequence for PKG I is X-R-R-K-S/T-X-X-X with two arginines
positioned at the P-3 and P-2 positions, a lysine at the P-1 position, a serine or
threonine residue at the P0 position, and typically hydrophobic or basic residues
at the P+1 position (Francis et al., 2010; Tegge et al., 1995). This sequence was
determined using synthetic peptides that subsequently served as the foundation
for developing peptidic inhibitors of PKG I (Dostmann et al., 1999, 2000, 2002;
Nickl et al., 2010; Pinkse et al., 2009; Taylor et al., 2004; Tegge et al., 1995). The
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autoinhibitory domains of PKG Iα and Iβ mimic this consensus sequence and bind
to the catalytic cleft in the inactive state. Interestingly, PKG Iα contains only
one arginine at the P-2/-3 positions while Iβ contains two (Hofmann et al., 1992;
Francis et al., 2010). This notable difference provides one potential mechanism
by which isoform-dependent differences in their kinetic profiles may be conferred.
1.2.5 Models of the spatial orientations of PKG domains
1.2.5.1 Models of PKG have been influenced by PKA
The cGMP-dependent protein kinase (PKG) was discovered in 1970, and
its expression in mammalian tissues was determined shortly thereafter in 1972
(Hofmann and Sold, 1972; Kuo and Greengard, 1970). During the latter half of
the 1970s and the early 1980s, most of the work on PKG focused on obtaining
pure, homogenous preparations of PKG Iα and Iβ from bovine lung and aorta
for further characterization (Gill et al., 1976; Lincoln et al., 1977; Hofmann and
Flockerzi, 1983; Corbin and Doskeland, 1983; Wolfe et al., 1987). This work
coincided with the discovery and initial characterization of the cAMP-dependent
protein kinase (PKA) (Glass and Krebs, 1979; Kuo et al., 1970). Thus, PKG
and PKA have always been closely linked in the literature. The discovery that
these kinases are highly homologous further solidified this association (Lincoln
et al., 1977; Hashimoto et al., 1982; Takio et al., 1983, 1984). Since structures of
PKA were the first to be solved by x-ray crystallography, PKA has served as a
model for understanding PKG, particularly regarding the spatial organization of
its domains (Huggins et al., 1994; Kim et al., 2007; Knighton et al., 1991).
The sequences of PKG and PKA are approximately 35% identical and have
the same overall domain organization, which consists of an N-terminal dimeriza-
tion domain, an autoinhibitory domain, a regulatory domain that binds cyclic
nucleotides, and a C-terminal catalytic domain (Takio et al., 1984; Huang et al.,
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2014). Their dimerization domains mediate subcellular localization—PKA is teth-
ered through its association with AKAPs (A-kinase anchoring proteins), whereas
most literature in the field suggests PKG is targeted directly to its substrates
(Taylor et al., 2004; Hofmann and Wegener, 2013; Schlossmann et al., 2003). In
addition, the catalytic domains of both kinases are autoinhibited by peptidic re-
gions that mimic their preferred substrate consensus sequences (Francis et al.,
2010; Hofmann et al., 1992; Kreegipuu et al., 1998). Finally, each dimeric PKG
and PKA regulatory domain binds four cyclic nucleotide molecules (two with
high affinity and two with low affinity) that mediate cooperative activation of
the kinases (Byeon et al., 2010; Dostmann et al., 1996; Kim et al., 2007; Richie-
Jannetta et al., 2006; Su et al., 1995; Wu et al., 2004). Despite these similarities,
a few notable difference exist between PKG and PKA. Each PKG protomer con-
tains a regulatory and catalytic domain, whereas PKA regulatory and catalytic
domains are expressed as separate protomers (Takio et al., 1984). Thus, disso-
ciation between PKG’s regulatory and catalytic domains is constrained by the
peptide backbone. Furthermore, the locations of the high and low affinity cyclic
nucleotide binding sites are reversed in PKG and PKA (PKG: A=high, B=low;
PKA: A=low, B=high) (Alverdi et al., 2008; Zhao et al., 1997). In light of these
similarities and differences, several groups have proposed models that describe
the overall domain organization of PKG as it relates to function. The major evi-
dences describing the overall shape of PKG I and the two predominating models
that have emerged in the field—the tweezer and the switch model—are discussed
below.
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1.2.5.2 The tweezer model of PKG domain organization—the pro-
tomers function independently
The overall dimensions of PKG I were first determined by size exclusion
chromatography and small angle x-ray scattering (Chu et al., 1997; Zhao et al.,
1997). PKG Iα was found to adopt an overall ellipsoidal shape, and that cGMP
binding induces a change in conformation into a more extended, asymmetrical
shape (Zhao et al., 1997). These reorientations were suggested to occur through
domain reorganization, likely through flexible linker regions between domains,
rather than through changes in secondary structure. Significant reorganization can
occur through cGMP binding to the A-site alone; however, binding to both cGMP
sites is required to induce the full shape change. Overall, it was proposed that
the apo structure of PKG has three regions: an N-terminal dimerization domain
and two regions each composed of a regulatory and catalytic domain. This model,
though not explicitly stated, is the likely precursor of the tweezer model wherein
each R:C complex can operate independently to perform catalytic function. This
model would also suggest that cooperative cGMP-dependent activation is driven
through crosstalk between the A- and B-sites of individual protomers.
Further investigation into the interdomain contacts formed in PKG I were
deduced using truncated constructs of PKG Iα and Iβ without catalytic domains
(PKG Iα 1-348; PKG Iβ 1-363). It was found that the Stokes radii were not ap-
preciably different between full-length and truncated PKG Iα and Iβ, even though
the truncated constructs were half the masses of their full-length counterparts
(Richie-Jannetta et al., 2006). These results suggested that the interface between
the N-terminus (dimerization, autoinhibitory, and regulatory domains) and the
catalytic domain is quite large and results in a highly compact R:C complex. To
investigate the domain reorganization induced by cGMP binding, Alverdi et al.
(2008) used hydrogen/deuterium exchange mass spectrometry. Their results in-
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dicated that residues involved in cGMP binding domains become less solvent
exposed upon activation, whereas the autoinhibitory region and substrate bind-
ing region of the catalytic domain become more solvent exposed. This provided
further evidence of the autoinhibitory domain’s function in occluding the catalytic
domain in the inactive state. Similar to the previous publication, this study de-
picts R:C protomers as independent, catalytic entities.
1.2.5.3 The switch model of PKG domain organization—crosstalk oc-
curs between protomers
The first x-ray crystal structure of PKG I included only the regulatory
domain (residues 78-356 using PKG Iα numbering) Osborne et al. (2011), and
provided the first opportunity to connect the structures of the cGMP-binding
domains with previous biochemical analyses. In addition, the structure showed
interprotomer contacts between the B-sites of opposing protomers, wherein a he-
lical segment at the end of the B-site docks into a hydrophobic pocket on the
opposing site. Mutational disruption of the residues implicated in this interaction
and SAXS analyses of 78-326 (without helical domain) and 78-356 (with helical
domain) were used to show that this crosstalk between protomers occurs in so-
lution (Osborne et al. (2011) and unpublished data). Further experiments were
performed using mixed dimers of PKG Iα that were composed of protomers con-
taining mutations at either E167A and T517A, which rendered the regulatory
and catalytic domains, respectively, inactive. These mixed dimers retained cat-
alytic activity, suggesting the regulatory domain of one protomer could control
the activity of the opposing catalytic domain (unpublished data, Dostmann Lab).
Thus, the second model of PKG I suggests activation involves crosstalk between
protomers (in trans regulation) rather than independently functioning protomers.
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1.3 Intracellular modulation of PKG I activity in the car-
diovascular system
The primary intracellular modulator of PKG I is the small molecule, cGMP
(Hofmann and Wegener, 2013; Surks, 2007). Cyclic GMP is produced from guany-
lyl cyclases in a nitric oxide- or natriuretic peptide-dependent manner (soluble
and particulate GC, respectively) (Hofmann et al., 2009). The cGMP-dependent
activation of PKG I was first determined to play an important role in vascular
relaxation (Francis et al., 1988; Sausbier et al., 2000). This finding corroborated
an earlier observation that the amount of PKG detected per dry weight of tissue
correlated with the degree of vascularization (Hofmann et al., 1992).
1.3.1 cGMP-dependent activation of PKG in resistance vessels
Resistance vessels, which comprise the small arteries and arterioles, are the
primary regulators of systemic blood pressure. They achieve this by controlling
vessel diameter through the contraction and relaxation of smooth muscle (Bayliss,
1902). Vessels respond to both short-term and longterm effectors (Ayada et al.,
2015; Cowley, 1992; Raven and Chapleau, 2014). Short term effectors include
circulating factors found in the blood and neuronal stimulation (e.g. baroreceptor
reflex), while longterm effectors primarily stem from the kidney to regulate blood
volume (Dunn et al., 2007; Wadei and Textor, 2012). In addition to systemic
factors, the diameter of resistance vessels is controlled locally through response to
frictional forces from circulating blood and mechanical stretch from blood pulses
(Hahn and Schwartz, 2009). The culmination of these global and local factors
maintain constant downstream blood flow (Hahn and Schwartz, 2009; Tucker and
Bhimji, 2018).
Resistance vessels are composed of three layers: the tunica intima, the tu-
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nica media, and the tunica externa (Tucker and Bhimji, 2018). The innermost
layer, the tunica intima, is composed of endothelial cells that are in direct contact
with the lumen. The middle layer, the tunica media, is composed of smooth mus-
cle, elastin, and collagen while the tunica externa is the outermost layer composed
of collagen, connective tissue, and elastic fibers, which provide structural rigidity.
There are numerous factors that stimulate vasorelaxation by targeting sur-
face receptors on endothelial cells (Vanhoutte et al., 2016). In response, endothe-
lial cells release three primary molecules: endothelium-derived hyperpolarizing
factor (EDHF), prostaglandins, and nitric oxide (Dautzenberg and Just, 2013).
EDHF is produced within the first 30 s of a stimulus and its signal rapidly decays.
In contrast, prostaglandins and nitric oxide initiate within 30-60 s of a stimulus
and are considered to be the elements that contribute to prolonged responses by
the vasculature.
Endothelial nitric oxide synthase (eNOS) produces nitric oxide as part of
the urea cycle through the conversion of L-arginine to citrulline (Vanhoutte et al.,
2016). Nitric oxide (a dissolved gas) passively diffuses through the plasma mem-
brane into the smooth muscle layer where it activates soluble guanylyl cyclase
(sGC) to produce cGMP (Friebe and Koesling, 2003). PKG I activated by cGMP
phosphorylates multiple intracellular targets, which culminate in vasodilation by
modulating calcium flux from both the extracellular space and intracellular, endo-
plasmic reticulum stores (Felbel et al., 1988; Harnett and Biancani, 2003; Lincoln
et al., 1990; Morgado et al., 2012; Surks and Mendelsohn, 2003).
Vascular smooth muscle cells express both isoforms of PKG I–α and β
(Keilbach et al., 1992). Calcium flux from the extracellular space is controlled
by calcium channels expressed on the plasma membrane (Harnett and Biancani,
2003; Vanhoutte et al., 2016; Tayo and Bevan, 1987). The Iα isoform directly tar-
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Figure 1.7: Regulation of vascular tone by endothelium-derived nitric oxide (NO).
Top: Increased release of endothelium-derived nitric oxide (NO) by endothelial ni-
tric oxide synthase (eNOS) is caused by both physical factors (increases in shear
stress and temperature lowering) and neurohumoral mediators (through activation
of specific endothelial cell membrane receptors). Bottom: Vascular smooth muscle
cell contraction is caused by an increase in cytoplasmic Ca2+ concentration either
from endoplasmic reticulum stores or influx through Ca2+ channels at the plasma
membrane. Calcium ions bind to calmodulin (CaM), and the calciumcalmod-
ulin complex activates myosin light-chain kinase (MLCK). MLCK phosphorylates
myosin light chain, which leads to cross-bridge formation between the myosin
heads and the actin filaments and subsequent smooth muscle contraction. This
process is counterbalanced by relaxation mechanisms stimulated by endothelial
NO. NO activates soluble guanylyl cyclase (sGC), which produces cGMP from
GTP. Cyclic GMP-dependent activation of PKG I initiates phosphorylation of
multiple intracellular targets that collectively result in decreased cytosolic Ca2+
and decreased actin-myosin cross-bridges to cause relaxation. (Vanhoutte et al.,
2016)
gets the large conductance calcium channel (BKCa), which causes efflux of potas-
sium ions, resulting in membrane hyperpolarization, and a subseuqent inhibition
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of voltage-dependent calcium channels (VDCC) (Fukao et al., 1999; Kyle et al.,
2013; Robertson et al., 1993; Sausbier et al., 2000; Schubert and Nelson, 2001).
Calcium flux through the endoplasmic reticulum is controlled by the sarcoen-
doplasmic reticulum calcium transport ATPase (SERCA) pump and the inositol
triphosphate receptor (IP3R), respectively (Harnett and Biancani, 2003; Tayo and
Bevan, 1987; Vanhoutte et al., 2016). This system is targeted by both PKG Iα
and Iβ. PKG Iα-dependent phosphorylation of regulator of G-protein signaling 2
(RGS2) induces RGS2 translocation to the plasma membrane. Here, it inhibits
Gq-dependent signaling of contractile agonists, such as angiotensin II, endothelin-
1, and norepinephrine, to suppress inositol triphosphate (IP3) production (Hof-
mann et al., 2006; Tang et al., 2003; Sun et al., 2005; Wu et al., 2003). PKG Iβ
phosphorylates the inositol trisphosphate receptor-associated cGMP-kinase sub-
strate (IRAG) (Geiselhoringer et al., 2004; Schlossmann et al., 2000). These two
processes block IP3R-mediated calcium efflux from the endoplasmic reticulum.
Furthermore, phosphorylation of the SERCA pump modulator, phospholamban,
by PKG Iβ leads to increased calcium uptake into the endoplasmic reticulum
(Hofmann et al., 1992; Lalli et al., 1999; Koller et al., 2003). Through these mech-
anisms, PKG I signaling leads to an overall decrease in free, cytosolic calcium. Fi-
nally, PKG I also acts directly on the cytoskeletal contractile machinery. Smooth
muscle contraction and relaxation is dependent on the balance of phosphorylated
and unphosphorylated myosin light chain (MLC), which are controlled by the ac-
tivities of myosin light chain kinase (MLCK) and myosin light chain phosphatase
(MLCP), respectively (Vanhoutte et al., 2016). PKG Iα directly phosphorylates
the myosin phosphatase targeting subunit 1 (MYPT1) to increase the activity of
MLCP (Yuen et al., 2011). PKG Iα also phosphorylates RhoA, thereby inhibit-
ing its effect on MYPT1 through Rho kinase (ROCK) (Jin and Burnett, 2006;
Kato et al., 2012; Sharma et al., 2017; Surks et al., 1999; Surks and Mendelsohn,
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2003). These two mechanisms lead to an increase in MLCP activity to increase
levels of unphosphorylated MLC. Furthermore, the decrease in global intracellular
calcium described above disrupts calmodulin-dependent activity of MLCK (Wu
et al., 1998). The increase in the unphosphorylated form disrupts actin binding
and polymerization, culminating in smooth muscle relaxation (Chen et al., 2008).
Thus, PKG I isoforms are central regulators of vasodilation.
Based on the current list of known PKG I substrates, there is a strikingly
disproportionate number of proteins that are phosphorylated by PKG Iα com-
pared with Iβ(Schlossmann and Desch, 2009; Hofmann et al., 2014). A previous
study using murine models determined that PKG I in smooth muscle is essential,
and rescue through knock-in of either isoform was sufficient to restore normal
vascular function (Weber et al., 2007). This would suggest that either PKG Iβ’s
effect on blocking calcium release from the endoplasmic reticulum is sufficient
for vasorelaxation or that there are other targets of PKG Iβ that have yet to be
identified.
1.3.2 Oxidation-dependent activation of PKG Iα
In addition to activation via a cGMP-dependent mechanism, PKG Iα be-
comes constitutively active in the presence of oxidizing agents, such as heavy
metals, hydrogen peroxide, and ambient oxygen (Burgoyne et al., 2007; Land-
graf et al., 1991). This effect can be blocked with the cysteine-modifying agents,
maleimide or iodoacetimide. In the first study that described this mechanism
of activation, three disulfide bonds were suggested to form in oxidized PKG Iα
(Landgraf et al., 1991). The first was an interprotomer disulfide bond between
C42 and C42’ in the N-terminal dimerization domain. This covalent attachment
between 75 kDa protomers was observed as a 150 kDa band by denaturing, non-
reducing SDS-PAGE. The second and third disulfide bonds were intraprotomer
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and suggested to form between C117 and C195 in the A site and C312 and C195
in the B-site and catalytic domain, respectively. These sites were identified by
HPLC and Edman degradation; however, it was unclear whether one or both of
the disulfide bonds actually formed. Of the three sites, only the first two have
been confirmed in crystal structures (Osborne et al., 2011; Qin et al., 2015).
The observation that oxidative activation only occurs with PKG Iα, and
not PKG Iβ, is important to note, because it has heavily influenced the recent
literature (between 2007-2017) (Burgoyne et al., 2007, 2012, 2013a; Burgoyne and
Eaton, 2013a,b; Burgoyne et al., 2013b,c; Kalyanaraman et al., 2017; Khavandi
et al., 2016; Nakamura et al., 2015; Prysyazhna et al., 2012, 2016; Rudyk et al.,
2012). Since PKG Iα and Iβ are splice variants of the same gene (prkg1 ), they only
differ in their N-terminal dimerization and autoinhibitory domains (approximately
residues 1-100). C42 is the only cysteine residue unique to PKG Iα; thus, it
has been suggested that the interprotomer disulfide bond between C42 and C42’
must be the primary player in oxidative activation. This conclusion is further
supported by the observation that hydrogen peroxide only decreased cytosolic
Ca2+ in cells expressing PKG Iα, but not Iβ (Muller et al., 2012). However, this
hypothesis has resulted in a shortcoming within the field since analyses of the
other disulfide bonds presented in the Landgraf et al. (1991) study were never
performed (Burgoyne et al., 2007).
Oxidation of PKG Iα appears to affect activation and substrate targeting.
Both are required for PKG Iα phosphorylation of intracellular substrates, and
disruption of either is sufficient to disrupt PKG Iα signaling (Feil et al., 1995;
Michael et al., 2008; Ramchandran et al., 2014). C42 in PKG Iα appears to be
invariant across PKG I amino acid sequences of placental mammals obtained from
the NCBI database (Appendix 2), suggesting this residue may have an important
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intracellular function. Since C42 is located at the end of the dimerization do-
main—the region that mediates substrate targeting—it has been suggested that
the disulfide bond between C42 and C42’ may also alter substrate binding. In-
direct binding measurements of oxidized PKG Iα have only been demonstrated
for a few substrates: the BKCa channel, RhoA, MYPT1, and RGS2 (Burgoyne
et al., 2007; Nakamura et al., 2015); enhanced binding was observed for the BKCa
channel, RhoA, and MYPT1, but not RGS2. Thus, PKG Iα activated by oxida-
tion may only target a subset of intracellular proteins. This hypothesis is further
supported by previous intracellular studies using cardiomyocytes that expressed
fluorescently-labeled wild-type PKG Iα or C42S (Nakamura et al., 2015). This re-
port found that incubation with hydrogen peroxide induced translocation of both
PKG Iα constructs to the plasma membrane within 10 minutes. After 1-2 h, PKG
Iα redistributed throughout the cytosol; however, C42S remained tethered to the
plasma membrane. Thus, the interprotomer disulfide bond may regulate PKG Iα
localization by altering its affinities for different substrates.
This has been further suggested by mutational studies that have disrupted
either substrate targeting through the dimerization domain or catalytic function
(Blanton et al., 2013; Casteel et al., 2005; Feil et al., 1995; Surks et al., 1999).
As most studies on oxidized PKG Iα have been performed under intracellular or
physiological conditions, it remains unclear how substrate targeting and activity
are independently affected by this mechanism, and whether both are controlled
by the interprotomer disulfide bond at C42. The role of C42 in the oxidative
activation of PKG Iα has been questioned in a recent paper by Kalyanaraman
et al. (2017), which found that the mutant, C42S, could still be activated by
hydrogen peroxide. This is in contrast to previous studies using a PKG Iα C42S
knock-in mouse model, which observed a hypertensive phenotype caused by a
24
sustained increased in blood pressure (Prysyazhna et al., 2012)
More recently, other potential effects on PKG Iα resulting from oxidizing
intracellular conditions have been investigated. It has been suggested that 8-
nitro-cGMP, a derivative of cGMP formed in the presence of high concentrations
of reactive oxygen species or nitric oxide, can adduct to C42 and C195 in PKG Iα
(Akashi et al., 2016). Moreover, S-guanylation of C195 correlated with constitutive
activation. Since the protein coverage of PKG Iα peptides by mass spectrometry
was only 26%, it is possible that other sites could be observed with increased
coverage. It would be interesting to determine whether S-guanylation at C117,
the residue previously suggested to form a disulfide bond with C195, also results in
PKG Iα activation. The model of the A-site presented in the manuscript indicates
a distance of approximately 22 Å from C8 of the guanine moiety to C195. This
model seems unlikely given that the optimum distance for disulfide bond formation
is approximately 6 Å. More plausibly, 8-nitro-cGMP binds to the cyclic nucleotide
binding pocket in the A-site, and a second molecule adducts to C195. Regardless,
these results highlight the importance of the A-site in regulating PKG Iα activity.
Hydrogen sulfide, a purported endothelium-derived hyperpolarizing factor
(EDHF), has also been reported to induce oxidative activation of PKG Iα (Bara-
gatti et al., 2013; Stubbert et al., 2014). Since the pKa of H2S is approximately
6.8, it will be predominantly deprotonated at physiological pH and reactive with
oxidants. The authors suggest the HS-S-SH intermediate could result in sulfhy-
dration of cysteine residues in PKG Iα, which can be resolved by proximal cysteine
residues within the kinase to form inter- or intraprotomer disulfide bonds. How-
ever, this mechanism would still require oxidizing agents, which could activate
PKG Iα without an intermediary player. Thus, it remains unclear whether hydro-
gen sulfide plays an integral role in PKG Iα activation.
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1.3.3 Oxidized PKG Iα signaling in the cardiovascular system
There are many intracellular sources of hydrogen peroxide, including NADPH
oxidases (NOX), superoxide dismutases (SOD), and in the mitochondial electron
transport chain (Trachootham et al., 2008). Depending on the isoform, NOX
complexes can either produce superoxide (O2
•-) or hydrogen peroxide (H2O2)
(Burtenshaw et al., 2017). Superoxide can be converted to hydrogen peroxide
by SOD. Since hydrogen peroxide is membrane permeable, both endothelial and
smooth muscle cells are potential sources in the vasculature (Burtenshaw et al.,
2017). Hydrogen peroxide itself is a weak oxidizing agent compared to other reac-
tive oxygen species since it does not contain unpaired electrons. However, it can
also react with iron to form hydroxyl radicals (•OH), which have greater oxidizing
potential (Ardanaz and Pagano, 2006). The interconversion of reactive oxygen
species makes studying their effects in cells particularly challenging.
NOX isoforms have been shown to have different effects in the vasculature
(Burtenshaw et al., 2017; Sag et al., 2017). In general, NOX1 and 2 are associated
with conditions characterized by endothelial and smooth muscle cell dysfunction,
such as atherosclerosis, hypertension, and peripheral vascular disease. These pro-
cesses occur through decoupling of eNOS-dependent NO synthesis, conversion
of NO to peroxynitrite (ONOO-), and subsequent transition of endothelial and
smooth muscle cells to migratory cells. Furthermore, NOX4—the only NOX fam-
ily member that directly produces hydrogen peroxide—has been associated with
cardioprotection by increasing NO bioavailability and preventing the transition of
endothelial and smooth muscle cells to migratory cells (Gray et al., 2016; Rashdan
and Lloyd, 2015; Ray et al., 2011). Thus, pathogenic and non-pathogenic condi-
tions appear dependent on the types of ROS produced, with strong, fast oxidizers
associated with pathogenic conditions and weak, slow oxidizers associated with
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non-pathogenic conditions. PKG Iα is broadly distributed throughout the cytosol
of smooth muscle cells. Thus, oxidized PKG Iα is likely spatially and temporally
limited by ROS production.
1.4 Aims of the present study
The work presented in this dissertation demonstrates the importance of the
cGMP-binding domain A (CBD-A) in regulating both the cGMP- and oxidation-
dependent mechanisms of PKG Iα activation. Using a monomeric, N-terminally
truncated form of PKG Iα (∆53), Chapter 2 investigates the mechanism of in-
hibition through the autoinhibitory domain and the influence of dimerization on
cooperative cGMP-dependent activation and cyclic nucleotide selectivity. We ob-
served that autoinhibition occurs in cis, whereas cooperativity requires interpro-
tomer contacts facilitated by the N-terminal dimerization domain. Furthermore,
the loss of selectivity for cGMP over cAMP of this construct suggests the dimer-
ization domain plays a critical role in preventing cross-reactivity with cAMP-
dependent signaling. These observations culminate into an overarching model
wherein binding of cGMP to CBD-A is necessary and sufficient for activation and
cooperativity is driven by the dimerization domain.
Chapter 3 investigates the cysteine residues that mediate oxidation-dependent
activation of PKG Iα. Using PKG Iα constructs with point mutations at specific
cysteine residues, it was found that oxidation-dependent activation is driven by
C117 in CBD-A. Furthermore, the interprotomer disulfide bond that forms in the
dimerization domain at C42 does not contribute to this mechanism. Finally, we
propose a model wherein the disulfide bond that forms between C117 and the
adjacent cysteine at position 195 acts as a protective mechanism to prevent ac-
tivation and higher oxidation states form contacts with nearby residues in the
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linker region of PKG Iα to disrupt binding of the adjacent autoinhibitory domain
to the catalytic domain. Finally, Chapter 4 provides a discussion of the results
presented herein in context with previous studies and suggests future directions
for the PKG field.
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2.1 Abstract
The type I cGMP-dependent protein kinases serve essential physiological
functions, including smooth muscle relaxation, cardiac remodeling, and platelet
aggregation. These enzymes form homodimers through their N-terminal dimeriza-
tion domains, a feature implicated in regulating their cooperative activation. Pre-
vious investigations into the activation mechanisms of PKG I isoforms have been
largely influenced by structures of the cAMP-dependent protein kinase (PKA).
Here, we examined PKG Iα activation by cGMP and cAMP by engineering a
monomeric form that lacks N-terminal residues 1-53 (∆53). We found that the
construct exists as a monomer as assessed by whole-protein mass spectrometry,
size-exclusion chromatography, and small-angle X-ray scattering (SAXS). Recon-
struction of the SAXS 3D envelope indicates that ∆53 has a similar shape to
the heterodimeric RIα:C complex of PKA. Moreover, we found that the ∆53 con-
struct is autoinhibited in its cGMP-free state and can bind to and be activated
by cGMP in a manner similar to full-length as assessed by surface plasmon res-
onance spectroscopy (SPR). However we found that the ∆53 variant does not
exhibit cooperative activation, and its cyclic nucleotide selectivity is diminished.
These findings support a model in which, despite structural similarities, PKG
Iα activation is distinct from PKA, and its cooperativity is driven by in trans
interactions between protomers.
2.2 Introduction
Cyclic GMP-dependent protein kinases (PKG) are members of the AGC
kinase family (PKA/PKG/PKC). They are conserved in eukaryotes, and ubiq-
uitously expressed throughout the human body (Hofmann et al., 2009; Keilbach
et al., 1992). These kinases regulate critical processes such as vascular tone, car-
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diac remodeling, and platelet aggregation (Bian and Murad, 2007; Hofmann et al.,
2009; Kemp-Harper and Schmidt, 2009; Potter et al., 2009). The primary activa-
tor of PKG isoforms is the second messenger cyclic-3,5-guanosine monophosphate
(cGMP) (Hofmann et al., 2009). In vascular smooth muscle, activated PKG I
phosphorylates intracellular targets including myosin phosphatase target subunit
1 (MYPT1), regulator of G-protein signaling 2 (RGS2), inositol trisphosphate
receptor-associated cGMP-kinase (IRAG), and the large conductance calcium-
activated potassium channel (KCa1.1 or BK) resulting in vasodilation (Ammen-
dola et al., 2001; Antl et al., 2007; Robertson et al., 1993; Sausbier et al., 2000;
Schmidtko et al., 2008; Schubert and Nelson, 2001).
PKG I is expressed as two splice variants that form homodimers (α/β)
(Keilbach et al., 1992; Orstavik et al., 1997; Wernet et al., 1989). In both iso-
forms, each protomer is composed of a dimerization domain formed by a leucine
zipper (LZ), followed by an autoinhibitory domain segment, a regulatory domain
containing two cGMP-binding sites (A and B), and a catalytic domain (Figure
1a) (Pfeifer et al., 1999). PKG Iα and Iβ have low sequence conservation in their
dimerization and autoinhibitory domains, and this difference is thought to both
control the activity and response of the kinase to cGMP as well as mediate its tar-
geting to specific substrates (Ruth et al., 1997; Ammendola et al., 2001; Blanton
et al., 2013; Casteel et al., 2005, 2010; Kato et al., 2012; Lee et al., 2007). How the
regulatory and catalytic domains interact in the inactive state and communicate
to control cooperative activation have remained unsettled questions for the field
(Dostmann et al., 1996; Richie-Jannetta et al., 2006). In the inactive state, it has
been hypothesized that the autoinhibitory domain of PKG I occupies the catalytic
cleft formed between the N and C-terminal lobes and acts as a pseudo-substrate
in a manner similar to the cAMP-dependent protein kinase (PKA) (Alverdi et al.,
2008).
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PKG isoforms share sequence homology with PKA (28% and 41% iden-
tity in its regulatory domain and catalytic domain, respectively). Consequently,
current models of the relationship between PKG I structure and function have
been overwhelmingly influenced by studies of PKA. However, PKA is expressed
as separate catalytic and regulatory domains and PKG exists as a single polypep-
tide chain (Huang et al., 2014; Osborne et al., 2011; Zhao et al., 1998). Structural
and biochemical studies of PKA have demonstrated an in cis mechanism for PKA
activation (Byeon et al., 2010; Su et al., 1995; Wu et al., 2004). The sequential
binding of cAMP to two coupled binding sites (A and B) within the regulatory
subunit constitutes the physical basis for cooperativity in both cAMP binding
and kinase activation. While it is known that full-length PKG I dimers also ex-
hibit cooperative activation, it is unknown whether cooperativity is driven by the
regulatory domain (in a fashion similar to PKA) or whether the dimeric state
influences this effect (Moon et al., 2015; Ruth et al., 1997; Osborne et al., 2011).
It has been suggested that the N-terminal domains in the hinge region
between the leucine zipper and autoinhibitory domains in PKG I are highly flex-
ible, and structural models of PKG I have depicted the N-terminus protruding
from the holoenzyme (regulatory and catalytic domain complex) (Alverdi et al.,
2008; Francis and Corbin, 1994; Pfeifer et al., 1999). While it has been widely
suggested that dimerization is essential for catalytic function, it has never been
experimentally tested in the Iα variant. Informed by previous models, we hy-
pothesized that PKG Iα could be truncated to generate a functional monomer by
removing the flexible N-terminus (zipper and hinge). Moreover, we surmised that
this construct would retain cGMP-dependent activation due to the inclusion of the
autoinhibitory domain. In this study, we provide the biochemical and biophysical
characterization of PKG Iα ∆53 (subsequently referred to as ∆53) by demonstrat-
ing its monomeric architecture, phosphorylation state, cGMP-binding properties,
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and the kinetic characteristics of its cGMP-dependent activation. Through the
use of the ∆53 construct, we address the following: 1) whether PKG Iα is inhibited
in cis or in trans ; 2) how cyclic nucleotide binding and selectivity of the A-site
is linked to activation; and 3) a putative mechanism by which cGMP-mediated
cooperativity is derived in PKG. Our data indicate that PKG Iα can form an
in cis autoinhibited complex. Furthermore, cooperative activation of PKG Iα by
cGMP—in contrast to PKA—relies on interactions within the homodimeric regu-
latory domain. We conclude that cooperativity is driven in part by the N-terminal
dimerization domain by localizing PKG monomers within close proximity during
cGMP binding to form in trans interprotomer interactions.
2.3 Results
2.3.1 Design, Expression, and Purification of ∆53
The design of a monomeric form of PKG Iα was accomplished using a bioin-
formatic approach by comparing to a previously-solved structure of the homolog,
PKA, in a heterodimeric complex with its regulatory domain (Figure 3.1a-b).
The complex of RIα:C (PDBID: 2QCS) was chosen due to the high sequence con-
servation of its autoinhibitory segment with PKG Iα and the availability of its
three-dimensional coordinates (Figure 3.1c). A multiple sequence alignment of
the PKG Iα autoinhibitory fragment with that of known isoforms of PKA was
performed. The distance from the first residue (Lys92) to the start of the autoin-
hibitory sequence in the RIα:C structure was used to determine that the residue
equidistant from the autoinhibitory sequence in PKG Iα was Pro56 (Figure 3.1b).
We hypothesized that, in a similar fashion to RIα:C, the autoinhibitory segment
preceding the canonical A/GISAE pseudo-substrate segment would confine the
P+1 loop of the catalytic domain and make further contacts with the C-terminal
tail, glycine-rich loop, and the F-helix from the large lobe (Kim et al., 2007,
33
2005). As a consequence, and as to not exclude residues that may be important
for autoinhibition, ∆53 was engineered to begin at Ile54.
Following expression and purification of ∆53 (Figure 3.2a), we examined
the kinase by size exclusion chromatography (Figure 3.2b). Both the apo and
cGMP-bound forms exhibited reproducible elution profiles centered at 14.8 mL
and 14.7 mL, respectively, indicative of a 70 kDa species according to molecu-
lar weight standards (Figure S1). The addition of cGMP appeared to have a
negligible effect on the elution volume of the protein, suggesting that dimer for-
Figure 2.1: Design of the ∆53 construct based on sequence homology
with PKA R-domains. A) The domain architecture of PKG Iα (charcoal) de-
picting the truncation of the dimerization domain to generate ∆53 (red) alongside
PKA RIα (cyan) and PKA catalytic (grey) domains. The domain architecture is
described as D/D : dimerization domain, AI : autoinhibitory domain, cGMP-
A/B: cGMP binding sites, SW : switch helix (Osborne et al., 2011), N/C-lobe:
catalytic domain B) A multiple sequence alignment shaded by BLOSUM62 score
is shown for PKG Iα relative to PKA regulatory domain isoforms. The autoin-
hibitory sequences of PKG I (red) and PKA:RIα (cyan) are outlined. C) The
crystal structure of the RIα:C heterodimer (2QCS) detailing the contacts between
the autoinhibitory domain segment beginning at K92 (cyan) and the catalytic
domain (grey).
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mation was not present in the apo or cGMP-saturated samples. ∆53 was further
examined by time-of-flight (TOF) mass spectrometry to determine its mass and
phosphorylation state (Figure 3.2c). A mass of 70,511 Da, corresponding to a
mono-phosphorylated, monomeric species was observed. We also discovered the
presence of a doubly phosphorylated species comprising 20% of the total ion con-
tent (70,591 Da). Tandem mass spectrometry analyses of trypsin-digested samples
were used to confirm the primary phosphorylation site at T517 (full-length en-
zyme numbering scheme) located in the activation loop of the catalytic domain
(Table 2.1). This phosphorylation site has been previously identified in full-length
PKG Iα, and is required for catalytic activity (Feil et al., 1995). To confirm this,
we also examined preparations of full-length PKG Iα and found a single phos-
phorylation site corresponding to T517 (Table 2.3). Based on previous studies,
the minor phosphorylation site observed for ∆53 was suspected to reside in the
autoinhibitory domain (Aitken et al., 1984; van de Waterbeemd et al., 2014).
However, the peaks corresponding to the peptide containing the autophosphory-
lated pseudosubstrate sequence, (R)AQGISAEPQTYR(S) (residues 61-72), were
of high intensity and suggested no phosphorylations were present.
2.3.2 SAXS Analysis
The results presented thus far indicate that ∆53 exists as a monomer in so-
lution. In an effort to characterize the low-resolution solution structure of the au-
toinhibited complex, we utilized size exclusion chromatography coupled to small-
angle X-ray scattering wherein during analysis single species associated with ∆53
was observed (SEC-SAXS, Table 2.5,2.6,2.7). Concurrent Guinier calculation dur-
ing data collection indicated a constant Rg across the sample peak (Figure 3.3a).
The averaged scattering intensity curve (Iq vs q) for ∆53, which was obtained by
averaging frames 410-459 of the SEC-SAXS peak, exhibited a linear Guinier plot
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Figure 2.2: Biophysical characterization of ∆53. A) Coomassie-stained 12%
SDS-PAGE of PKG Iα full-length and ∆53 under denaturing and reducing con-
ditions. B) Size exclusion chromatography traces of ∆53 in its apo (black) and
cGMP-saturated (red) forms. C) A raw m/z trace (inset) and the deconvoluted
TOF-MS displaying the two predominant masses observed for ∆53 corresponding
to singly and doubly phosphorylated species. The mass correlated to the location
of an unphosphorylated monomer is also denoted.
(Figure 3.3b and inset, Table 2.5, 2.6, 2.7). The Guinier indicated the presence
of a monodisperse system with no evidence of aggregation. A Kratky plot of
the data suggested the presence of a well-folded species (Figure 3.3c). The P(r)
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curve calculated from the scattering intensity contained a single peak at ∼30 Å
that smoothly decayed to a maximum linear dimension (Dmax) of 97 Å (Figure
S2). When compared to the P(r) curve of the homologous PKA heterodimer upon
which we based our construct, RIα:C (green), both showed a single peak at 34 Å,
but the RIα:C heterodimer had an extended Dmax of ∼130 Å . Comparison of the
∆53 P(r) to that observed for a different PKA heterodimer, RIIβ:C (red), demon-
strated that they have nearly identical dimensions (Table 2.4) (Vigil et al., 2005).
Predicted X-ray scattering from the crystal structures of the PKA RIα:C,
PKA RIIβ:C, and Pf PKG from P. falciparum (a monomeric species containing 4
cGMP binding sites and a catalytic domain) was conducted using both CRYSOL
and FoXS (Table 2.5, 2.6, 2.7) (Schneidman-Duhovny et al., 2013; Schneidman-
Duhovny et al.). The best fit of the experimental SAXS data to the predicted
scattering was obtained from RIα:C using CRYSOL with constant subtraction (χ2
= 0.82, Figure 3.3d, Table 2.5, 2.6, 2.7). Using the the RIIβ:C heterodimer in
the same analysis resulted in a poorer fit to the experimental data (χ2 = 1.25).
The Pf PKG fits were poor using CRYSOL (χ2 = 9.21), but acceptable with the
FoXS server (χ2 = 1.29, Table 2.5, 2.6, 2.7, Figure 2.11). We also found that
the Rg values calculated using the predicted scattering curves for both the PKA
RIα:C and RIIβ:C heterodimer crystal structures were in closer agreement with
the measured and calculated values for ∆53 (Table 2.5, 2.6, 2.7). Next, DAMMIF
and DAMMIN modeling was implemented. Using SUPCOMB, the resulting av-
eraged and filtered DAMMIF/DAMMIN ab initio three-dimensional envelope ac-
commodated both crystal structure models of the RIα:C and RIIβ:C heterodimers
with little protrusion outside of the envelope (Figure 3.3e-f, Table 2.5, 2.6, 2.7).
Among the 3D models examined, these data cumulatively suggest ∆53 adopts a
shape most similar to PKA RIα:C.
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Figure 2.3: SEC-SAXS analysis of PKG Iα ∆53 in the autoinhibited
state. A) SEC-SAXS trace of ∆53 depicting scattering intensity (red circles,
right axis) and Rg values (black circles, left axis) estimated from Guinier plots
of each detector exposure frame. B) The intensity profile (Iq vs q) for ∆53 was
derived from the averaging of frames 410-459 from panel (a). C) Kratky plot of
the scattering profile of ∆53 determined using the averaged scattering data from
panel (B) D) The resulting fit and residual plot of the intensity profile (Iq vs q)
for ∆53 by CRYSOL (allowing constant subtraction) for RIα:C (PDBID: 2QCS,
green) and RIIβ:C (PDBID: 4WBB, red). The 3D envelope of the scattering
curve derived from ∆53 (grey balls) fit to the crystal structures of (E) RIα:C
(NSD=1.06) and (F) RIIβ:C (NSD=1.09) heterodimers.
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2.3.3 Binding and Activation of Full-length PKG Iα and ∆53 with
cNMP
Finally, we studied the activation kinetics of ∆53. No significant differences
in basal activity were observed between PKG Iα full-length and ∆53, indicating
that the monomeric construct was autoinhibited at levels comparable to previous
reports (Moon et al., 2015; Ruth et al., 1997). Moreover, the cGMP-dependent
activation of ∆53 and full-length PKG Iα were analogous with respect to their
maximum velocities of 4.0 and 3.9 µmol/min*mg, respectively (Figure 3.4Ba).
These results indicate that the cGMP-dependent fold-stimulation of ∆53 is in-
distinguishable from full-length. However, differences between the two constructs
were observed with respect to their activation constants and degree of cooperativ-
ity. We observed Ka values and Hill coefficients corresponding to 182 nM (nH=1.6)
for PKG Iα full-length and 250 nM (nH=1.0) for ∆53 (p<0.0001 for both mea-
surements). When we tested the activation profiles of full-length and ∆53 PKG Iα
with cAMP, we observed that the full-length enzyme exhibited cooperative activa-
tion, while again ∆53 was non-cooperative. Comparisons of the fold-difference in
activation by cGMP and cAMP for both enzymes demonstrated that the removal
of the N-terminus of PKG Iα reduced the selectivity for cyclic nucleotide from
58-fold (full-length) to 3.5-fold (∆53), representing an overall 16-fold decrease in
selectivity for cGMP over cAMP.
To probe how binding of cyclic nucleotide correlates with the activities of
the enzymes, we measured cGMP and cAMP binding to PKGIα constructs by
surface plasmon resonance (SPR) spectroscopy. Binding of cyclic nucleotides was
fit using a two-site binding model since the regulatory domain of PKGIα contains
two cGMP sites per monomer. To determine cooperativity of the binding, we
also fit the data using a one-site model with Hill coefficient. PKG Iα full-length
exhibited an almost 3-fold weaker affinity for cGMP than ∆53 (FLKD=7.9 µM
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Figure 2.4: Biochemical characterization of ∆53. A) Domain diagram de-
picting the constructs used for the activation and binding studies. B) Activation
of PKG constructs. Data are represented as the mean ± SD. Ba) Activation of
PKG Iα full-length (black) and ∆53 (red) with cGMP. Significant differences in ac-
tivation by individual cGMP concentrations were confirmed by two-way ANOVA
(p<0.005), and denoted by an asterisk. Bb) Normalized activation of PKG Iα
(black) and ∆53 (red) with cGMP (solid lines) and cAMP (dotted lines). Shaded
areas depict the mean KD ± SD of the high affinity cyclic nucleotide binding site
for cGMP (solid) and cAMP (dashed). C) cNMP binding curves associated with
PKG constructs in (A) as measured by SPR spectroscopy. Data are represented
as the mean ± SD and fit with a two-site binding model. Ca) Binding curves
showing cGMP (solid lines) and cAMP (dotted lines) association with full-length
PKG Iα full-length (black), and ∆53 (red). Cb) Binding curves denoting PKG
Iα:1-326 (blue) and PKG I:78-326 (green) with cGMP (solid lines) and cAMP
(dotted lines).
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and ∆53KD=2.9 µM), when fit with a one-site model (Table 2.2). However, when
fit with a two-site binding model, the ratio dropped to 1.6-fold. Moreover, both
constructs displayed negative cooperativity in binding cGMP (FLnH=0.60 and
∆53nH=0.74). When cAMP binding was measured for the two constructs, the KD
values for their high affinity sites increased by over thirty-fold. However, cAMP
binding remained negatively cooperative in both enzymes. In binding to either
cyclic nucleotide, we found that the low-affinity site demonstrated much weaker
binding than the high affinity site.
To distinguish the cyclic nucleotides sites responsible for activation in the
full-length PKG Iα kinase, we mutated the glutamic acid residues in the Phe-Gly-
Glu (FGE) motif of the phosphate binding cassettes within the A-site (E168G)
and the B-site (E292A). Since the glutamate residue is involved in binding to the
2’-hydroxyl from the ribose, mutation of this site in PKA has been shown to dis-
rupt cyclic nucleotide binding (Diller et al., 2001; Ogreid et al., 1988; Steinberg
et al., 1987; Su et al., 1995; Zawadzki and Taylor, 2004). Mutation of the A-site
(E168GPKGIα) completely abolished cGMP-dependent activation of the full-length
kinase (Figure S4). These results demonstrate that a functional A-site is necessary
for kinase activity. Moreover, when we examined the cGMP-dependent activation
of E292APKG Iα, we observed cooperative (nH=1.45) stimulation of the kinase with
a Ka of 95 nM.
In an effort to further examine the contribution of the N-terminus and
the catalytic domain on cyclic nucleotide binding selectivity, we purified two con-
structs of the regulatory domain of PKG Iα. The first construct, 1-326PKG Iα,
contains the N-terminus and cGMP-binding regulatory domain, whereas the sec-
ond construct, 78-326PKG I, contains only the regulatory domain. When we exam-
ined binding of cGMP to 1-326PKG Iα and 78-326PKG I, we found that the one-site
model KD shifted significantly compared to values observed for full-length PKG
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Table 2.1: Phosphopeptides of ∆53 PKG Iα.
Precursor MH+ (Da) z Start End Sequence Modifications Retention Time (min) Intensity (x103)
1320.665 2.0 61 72 (R)AQGISAEPQTYR(S) 19.71 9,523
2262.055 2.7 515 533 (K)TWTFCGTPEYVAPEIILNK(G) PO4-T517 44.89 1,591
2182.082 2.7 515 533 (K)TWTFCGTPEYVAPEIILNK(G) 42.80 123
2390.150 3.0 514 533 (K)KTWTFCGTPEYVAPEIILNK(G) PO4-T517 41.03 260
2310.173 3.0 514 533 (K)KTWTFCGTPEYVAPEIILNK(G) 39.02 10
Iα and ∆53 (Figure S5). For 1-326PKG Iα, the two-site binding model showed that
the KD value for cGMP binding to the A-site increased by 8-fold compared to the
full-length enzyme (Table 2.2). Furthermore, binding of cAMP showed a drastic
decrease in selectivity for cGMP over cAMP. The B-site showed a clear selectivity
for cGMP over cAMP (4-fold). However, when the N-terminus was excluded in
78-326PKG I, we observed no difference in the affinities for cGMP and cAMP in the
high affinity A-site. The B-site retained a clear selectivity for cGMP over cAMP
(10-fold).
2.4 Discussion
PKG activation has been extensively studied by traditional biochemical
methods and, more recently, using modern biophysical approaches (Casteel et al.,
2010; Huang et al., 2014; Kim et al., 2011; Osborne et al., 2011; Wall et al., 2003).
These investigations sought to determine the architecture of the homodimeric ki-
nase in its basal and activated states, the order and selectivity of cGMP binding,
and, by extension, the origin of its cooperativity. The generation of a functional,
monomeric form of PKG Iα is a useful tool for investigating the molecular basis
of these long-observed biochemical phenotypes.
PKG Iα ∆53 purified from Sf 9 cell extracts exists as a mixture of mono-
and diphosphorylated forms; no unphosphorylated form was detected. The pri-
mary phosphorylation site, T517, was found in high abundance by time-of-flight
mass spectrometry (TOF-MS) (Figure3.2c, Table 2.1). Phosphorylation of T517,
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which is located in the activation loop of the catalytic domain, is essential for
catalytic activity (Feil et al., 1995). In the PKA catalytic domain, the analogous
phosphorylation at T197 forms contacts with other activation loop residues, the
catalytic loop, and the αC-helix to integrate the active site components (Steichen
et al., 2012; Zheng et al., 1993). It has been hypothesized that phosphorylated
T517 in PKG serves a similar function since the lack of phosphorylation or mu-
tation of this residue renders PKG inactive (Feil et al., 1995). The presence of
this phosphorylation site in ∆53 corroborates the cGMP-dependent activation ob-
served by our phosphotransferase assays. In regard to the second, less abundant
phosphorylation site, we had hypothesized that this residue would be located in
the autoinhibitory domain based on previous published data (Aitken et al., 1984;
Takio et al., 1983; van de Waterbeemd et al., 2014). Analysis of autoinhibitory
domain residues suggested S64 and T70 were not phosphorylated (parent peptide
Ala61-Arg72; Table 2.1). Another potential site, T58, has previously been iden-
tified as the major site that is autophosphorylated most rapidly in the presence
of cGMP in vitro or cAMP in native PKG I preparations isolated from bovine
lung (Aitken et al., 1984; Takio et al., 1983). Since Sf 9 cells endogenously express
adenylyl cyclases, we hypothesized that T58 could be the minor phosphorylation
site (Kawabe et al., 1996; Lee et al., 2000). However, our LC-MS/MS data could
not confirm the precise location. These results are in agreement with previously
published results that observed the phosphorylation at T517, but were also un-
successful in identifying the second site (Alverdi et al., 2008). Furthermore, these
results suggest that neither its dimerization through the N-terminal dimerization
domain nor exposure to cGMP are required for activation loop phosphorylation.
Despite the presence of these two phosphorylation states, we consistently
observe a compact, monodisperse, monomeric species in solution by size exclu-
sion chromatography (SEC) (Figure 3.2b). In addition, the elution profile of
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∆53 did not change with the addition of cGMP, suggesting that it maintains its
monomeric state even during long-lived exposure. In an effort to reconstruct the
three-dimensional shape of inactive ∆53 and confirm its monomeric character, we
collected data by SEC-SAXS and compared the reconstructed 3D-envelope to the
crystal structures and SAXS data from two PKA heterodimers (PDBID: 2QCS
and 4WBB) and Pf PKG (PDBID: 5DYK). We found that ∆53 adopts a similar
shape to that of the PKA RIα:C heterodimer (2QCS) based on the best fit of the
atomistic modeling in CRYSOL to the scattering data (χ2 0.82) (Figure 3.3d, Ta-
ble 2.5, 2.6, 2.7). In addition, the crystal structure is readily accommodated by the
3D envelope calculated from the ∆53 SAXS data (NSD = 1.06, Figure 3.4f). These
data concurred with previously published results for the apo state of monomeric
PKG Iβ ∆1-52 (Table 2.4) (Wall et al., 2003). PKG Iβ ∆1-52 contains 18 addi-
tional residues upstream of its autoinhibitory domain compared to PKG Iα ∆53.
Considering the high overlap between these two truncated constructs in the SAXS
analyses, this suggests that the linker in Iβ ∆1-52 adopts a compact conformation
relative to the regulatory-catalytic domain complex. Based upon these data, we
propose a model wherein each monomer within the dimeric PKG Iα complex can
be autoinhibited by its own regulatory domain and autoinhibitory sequence (Fig-
Table 2.2: Binding and Activation of PKG Iα Constructs
Binding (SPR) Activation (32PO4-assay)
One-site Model Two-site Model
PKG Iα Construct cNMP KD (µM) nH KDHi (µM) KDLo (µM) N KA (µM) nH N
Full Length cGMP 7.9 ± 1.1 0.60 ± 0.04 1.6 ± 0.3 90.2±33.9 6 0.182 ± 0.004 1.58± 0.06 12
cAMP 387 ± 37 0.76 ± 0.03 51.7 ± 25.4 685±174 5 10.80 ± 0.67 1.75 ± 0.09 6
∆53 cGMP 2.9 ± 0.4 0.74 ± 0.06 1.0 ± 0.4 19.1±16.7 6 0.250 ± 0.010 0.97 ± 0.03 5
cAMP 297 ± 21 0.76 ± 0.03 36.6 ± 9.2 509±62 4 0.860 ± 0.157 0.81 ± 0.06 6
1-326 cGMP 21.3 ± 1.3 0.81 ± 0.03 8.4 ± 2.5 74.4±38.6 6 - -
cAMP 64.3 ± 5.3 0.72± 0.03 16.9 ± 3.9 312 ± 112 4 - -
78-326 cGMP 30.0 ± 1.1 0.90 ± 0.02 3.2 ± 3.1 35.5±4.4 6 - -
cAMP 340 ± 10 0.92 ± 0.02 4.8±3.1 350±10 4 - -
The data are represented as the mean ± SD. -, not measured.
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ure 3.5 top).
Finally, we report that ∆53 is activated by cGMP at concentrations similar
to the full-length kinase (Figure 3.4Ba). A previous study by Richie-Jannetta et
al and a more recent study by Kim et al expressed truncated forms of PKG Iβ
(∆1-53 and ∆1-55) to investigate the influence of the dimeric interface on cGMP-
dependent activation (Richie-Jannetta et al., 2003; Kim et al., 2016). Both studies
described significant shifts in the activation constants of the truncated Iβ con-
structs. These results contrast with our observations of PKG Iα. ∆53 does not
exhibit an appreciable shift in the activation constant compared to the full-length
enzyme. These results support the longstanding conclusion that PKG Iα and β
are enzymatically distinct due to differences in their N-termini (Hofmann et al.,
2009; Lee et al., 2000, 2007; Moon et al., 2015; Ruth et al., 1997).
Interestingly, ∆53 does not exhibit cooperative cGMP-dependent activa-
tion (Figure 3.4Ba). The loss of cooperativity has been previously reported for
PKG Iβ, wherein full length PKG Iβ (nH = 2.1) becomes noncooperative when
the N-terminus is removed (∆1- 52 PKG Iβ) (Moon et al., 2015; Kim et al.,
2016). In addition, we observed that cAMP also cooperatively activates the full-
length kinase (nH=1.75), but not ∆53 (nH=0.81). These results suggest that the
cooperative activation is mediated by the N-terminus through the facilitation ho-
modimer formation. The N-terminal dimerization domains of PKG Iα and Iβ are
left-handed, coiled-coil, leucine zipper (LZ) motifs. The LZ is characterized by
a heptad repeat of amino acids (abcdefg) where residues a and d are typically
hydrophobic and residues e and g are typically hydrophilic. The leucine zipper of
PKG Iα spans residues 1-47. In addition to its leucine and isoleucine residues, there
are also four non-leucine/isoleucine residues at the d positions that provide ad-
ditional non-hydrophobic interhelical contacts (Phe7, Lys14, Lys28, Cys42) (Qin
et al., 2015). One of these residues, C42, is unique to the Iα isoform and forms an
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interprotomer disulfide bond in the presence of oxidizing agents, such as hydrogen
peroxide (Burgoyne et al., 2007; Landgraf et al., 1991). The leucine zipper of PKG
Iβ spans residues 4-53, and also contains four non-leucine/ isoleucine residues at
the d positions (Lys13, Arg20, Lys34, and Tyr48) (Casteel et al., 2010). Although
the majority of the non-canonical residues are basic, their differences in position
within the helices and the overall discrepancy in length of the helices are reasons
why PKG I protomers have not been shown to form heterodimers either in vitro
or in vivo.
It is well-characterized that the cGMP A-site in the regulatory domain
is the high affinity binding site, and, thus, is the first to bind cyclic nucleotide
(Huang et al., 2014; Kim et al., 2011; Zhao et al., 1998). Our data of PKG Iα full-
length and ∆53 agree with these previously published results and indicate a clear
selectivity for cGMP over cAMP in the A-site (Table 2.2). To further test the
contributions of the A- and B-sites on PKG Iα activity, we measured the activities
of E167GPKG Iα and E292APKG Iα. We found that disruption of cyclic nucleotide
binding to the B-site did not have an appreciable effect on activity (Figure S4).
In contrast, disruption of cyclic nucleotide binding to the A-site completely abol-
ished activity. These data collectively support the importance of the A-site in
regulating activation of PKG Iα. However, previous studies using isolated regula-
tory domain constructs have suggested that the A-site is non-selective for cyclic
nucleotide (Kim et al., 2011; Osborne et al., 2011). These results suggest selec-
tivity for cGMP binding to the A-site must be controlled through regions outside
of the regulatory domain.
To investigate the influence of regions outside of the regulatory domain on
the cyclic nucleotide-dependent characteristics of PKG Iα, we expressed and puri-
fied two additional constructs: 1-326PKG Iα and 78-326PKG Iα. PKG Iα without its
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Figure 2.8: Putative model of activation of FL and ∆53 PKG Iα The model
depicted hypothesizes that one cyclic nucleotide bound to the high-affinity A-site
is sufficient to activate both the full-length and ∆53 PKG Iα constructs. Cooper-
ativity arises the in trans interaction of protomers at the knob/nest site and not
from cooperative cyclic nucleotide binding. In the ∆53 construct, cooperativity
is not observed and cannot be facilitated due to the lack of dimerization. The
organization of the full-length enzyme must also lend itself to generate a cGMP
selectivity filter for the A-site based upon our full-length and truncated data.
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catalytic domain (1-326PKG Iα) showed a significant decrease in binding affinity
for cGMP and loss of selectivity for cGMP over cAMP in the A-site compared
to the full-length construct (Table 2.2). Selectivity was only slightly reduced in
the B-site, and the values agree with those measured previously for the isolated
B-domain (Kim et al., 2011). These results differ from the binding and nucleotide
selectivity results observed for PKG Iα full-length and ∆53. Thus, these charac-
teristics seem to be integrated into the architecture of the inactive holoenzyme.
The initial comparison of the activation curves for full-length and ∆53 to
the one-site binding model indicates a large disparity between the concentration
of cGMP required for full saturation of the A and B-sites and the minimum con-
centration required for full activation. Early measurements of cyclic nucleotide
binding with 3H-cGMP observed a significant difference in the KD values for cGMP
binding at 4 and 30 (Landgraf and Hofmann, 1989). Our measurements for cGMP
are consistent with these early experiments. When a two-site model is applied to
the binding data, we can directly correlate the KD for the A-site with the Vmax for
activation. This model is reasonable since there are two cGMP binding sites with
distinct binding affinities. Furthermore, this effect is observed for both cGMP and
cAMP, equally (Figure 3.4). This implies that full-length PKG Iα only requires
that half of the A-sites are occupied to stimulate full activation. These data, which
also suggest the B-site is non-essential for kinase activity, are further supported
by the fact that the KD for the B-site (∼90 µM) is higher than estimated intra-
cellular concentrations of cGMP (∼10 nM - 10 µM) (Francis et al., 2005; Nausch
et al., 2008; Trivedi and Kramer, 1998). Moreover, we observe that mutation of
the nucleotide binding cassette in the B-site does not appreciably affect activa-
tion of the full-length kinase (Figure S4). Thus, we can also conclude that binding
studies that are either directed toward the isolated PKG regulatory domains or
employ equilibrium-exchange of radiolabeled cyclic nucleotides are limited; and
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future studies should examine these effects in the context of the intact holoen-
zymes.
These SPR measurements also indicate that binding of cGMP to both full-
length and ∆53 is negatively cooperative (nH<1), which indicates that binding of
cGMP to subsequent sites becomes more difficult with increasing concentrations.
These results suggest a lack of avidity between cyclic nucleotide binding domains
A and B, and this has been corroborated by recent structural evidence Kim et al.
(2016). These observations stand in contrast to PKA where the origins of coop-
erativity has been directly linked to the regulatory domain, wherein binding of
cAMP into the B-site enhances binding for the A-site through intra-subunit con-
tacts (Su et al., 1995; Byeon et al., 2010; Kim et al., 2007). It has been suggested
that the cooperativity observed for PKG activation arises from a similar mecha-
nism (Alverdi et al., 2008; Huang et al., 2014; Kim et al., 2011). However, the
loss of cooperative activation in PKG Iα through disruption of the dimer via two
mechanisms: 1) by removing residues that allow for N-terminal dimerization (this
study) and 2) via mutation of residues forming the knob-nest interface - suggests
that this is not the case (Osborne et al., 2011).
Finally, we propose a model based on our findings wherein autoinhibition
of PKG Iα is driven in cis. The high affinity A-site provides cyclic nucleotide
selectivity through contacts outside of the regulatory domain and cooperative ac-
tivation of PKG Iα is driven in trans, facilitated by the N-terminus - which ensures
monomers are close enough to form necessary interprotomer contacts (Figure 5).
These data reinforce our earlier hypothesis that cooperative activation of the ki-
nase is not driven through cooperative binding of cyclic nucleotides to the regula-
tory domain within the same protomer. Rather, it is driven through an inducible
dimeric interface mediated by the switch helix (Moon et al., 2013, 2015). There-
fore, we conclude that the mechanism driving cooperativity in PKG Iα lies in the
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interface between protomers and not between cGMP binding sites within the same
protomer.
2.5 Experimental Procedures
2.5.1 Sequence Alignments
Sequences for PKG Iα and PKA regulatory domain isoforms were down-
loaded from the NCBI and Uniprot repositories (ncbi.nlm.nih.gov; UniProt.org)
and uploaded to JalView Desktop (Waterhouse et al., 2009). The following ac-
cession numbers were used: NP 001091982 (PKG Iα Homo sapiens), NP 776861
(PKG Iα Bos taurus), NP 001013855 (PKG Iα Mus musculus), NP 001099201
(PKG Iα Rattus norvegicus), NP 037313 (PKA RIα Rattus norvegicus), NP 997637
(PKA RIα Homo sapiens), NP 001068669 (PKA RIβ Bos taurus), NP 001240819
(PKA RIβ Mus musculus) NP 062137 (PKA RIIα Rattus norvegicus), P12367
(PKA RIIα Mus musculus), NP 001178296 (PKA RIIα Bos taurus), NP 004148
(PKA RIIα Homo sapiens), P31324 (PKA RIIβ Mus musculus), NP 001025191
(PKA RIIβ Rattus norvegicus), NP 002727 (PKA RIIβ Homo sapiens), P31322
(PKA RIIβ Bos taurus). A multiple sequence alignment using CLUSTAL-O with
the default parameters was accomplished using the JalView Desktop interface
(Sievers et al., 2011).
2.5.2 Maintenance of Sf 9 cells
Sf 9 cells were purchased from Life Technologies. Frozen cell stocks were
prepared according to the Growth and Maintenance of Insect Cell Lines Manual
(Life Technologies). Typically, one vial containing Sf 9 cells (1 x 106 cells/vial in
freezing medium (80% supplemented Grace’s Insect Medium (Gibco), 10% fetal
bovine serum (FBS; Sigma), and 10% DMSO) was suspended in 15 mL Grace’s
medium (Life Technologies) supplemented with 5% fetal bovine serum (Sigma)
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and 10 µg/mL gentamicin (Sigma). Cells were grown in a 75 cm2 flask until
cells reached 80% confluency. Cells were detached from the flask and suspended
in Sf900 III medium (Life Technologies) supplemented with 1x lipids (Sigma),
1% poloxamer 81 (Sigma), and 10 µg/mL gentamicin (Sigma). Sf 9 cells were
maintained in suspension at 27, 80 rpm and passaged every 3.5 days to 1.2 x 106
cells/mL.
2.5.3 Expression of PKG Iα constructs in Sf 9 cells
Full-length PKG Iα (Bos taurus) was amplified and cloned into pFAST
Bac-HTA (Invitrogen) as previously described (Dostmann et al., 2000). PKG Iα
54-671 (∆53) was amplified by PCR from bovine PKG Iα 1-671 using forward and
reverse primers containing NcoI and XhoI cut sites, respectively: 5’-GGC GCC
ATG GAT ATC GGC CCC CGG ACC ACC-3’ (sense); 5’-ATG CCT CGA GAC
CTA TTA GAA GTC TAT GTC CCA TCC TGA-3’ (antisense) (Integrated DNA
Technologies). The resulting product was cloned into pFastBac-HTA (Invitrogen)
using NcoI, XhoI, and DNA ligase (New England Biolabs). Site-directed mutage-
nesis was performed on the full-length PKG Iα construct in pFAST Bac-HTA to
produce E167G and E292A using the following primers: 5-AAG GTG TTT GGA
GGG TTG GCT A-3 (E167G- sense); 5-ATA GCC AAC CCT CCA AAC ACT
T-3 (E167G- antisense); 5-GGA AAA GGA GAT TGG TTT GGA GCG AAA
GCC TTG-3 (E292A- sense); 5-TTC CCC CTG CAA GGC TTT CGC TCC
AAA CC-3 (E292A- antisense). Transposition of the full-length PKG Iα, mutant,
and ∆53 genes into bacmid using DH10 Bac E. coli, confirmation of its insertion
by PCR, and transfection into Sf 9 cells to produce baculovirus was performed
following the Bac-to-Bac Baculovirus Expression System Manual (Life Technolo-
gies). Third amplification viruses were used at dilution ratios of approximately
1:500 to express both constructs (virus:Sf 9 cells). At 72 hours post-infection,
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cultures were harvested by centrifugation at 500 ×g for 10 min. Pellets were re-
suspended in lysis buffer (10 mM TES, 300 mM NaCl, 5 mM imidazole, pH 7) at
a volume of 20 mL per liter of Sf 9 cells, flash frozen in liquid nitrogen, and stored
at -80°C.
2.5.4 Expression of PKG I regulatory domain constructs in E. coli
The PKG I regulatory domain contructs (78-326PKG I and 1-326PKG I) were
amplified by PCR from the full-length PKG Iα gene using forward and reverse
primers containing BamHI and EcoRI cut sites, respectively: PKG I-78-f 5’-CGG
GAT CCA TGC AGG CAT TCC GGA AGT TC-3’(sense), PKGI-1-f 5’-TGG
GGA TCC AGC GAG CTG GAG-3’ (sense), PKG I-326-r 5’-TCG AAT TCC
ATG CTA TTA TAA TCC TCC AAT CAA ATG-3’ (antisense). The respective
fragments were ligated into BamHI/EcoRI-digested pRSET-A using T4 ligase
(NEB). Both constructs were expressed in Rosetta2 E. coli (Novagen). Overnight
cultures were used to inoculate 1L of TB supplemented with 50µg/mL ampicillin
and 25µg/mL chloramphenicol and subsequently grown at 37, 220 rpm to an
OD600 = 0.8. Expression was induced by the addition of IPTG (1 mM final), and
the induced cultures were incubated overnight at 25 at 220 rpm. E. coli were
harvested by centrifugation at 1500 ×g for 30 min, and the resulting bacterial
pellets were flash frozen in liquid nitrogen and stored at -80.
2.5.5 Purification of PKG Iα constructs
Protease inhibitors (Roche) were dissolved in 50 mL of lysis buffer and
added to 1L of pelleted Sf 9 cells containing either PKG Iα full-length, E167G,
E292A, or ∆53 (B. taurus). Sf 9 cell pellets were thawed on ice for 40 min followed
by gentle mixing. Resuspended cell pellets were lysed using a French pressure cell
(2 passes at >1,500 bar; SLM-AMINCO) or by passing cells through a 22.5 gauge
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needle (3 passes).
Bacterial pellets containing 78-326PKG I were resuspended by vortexing in
50 mL of lysis buffer supplemented with protease inhibitors (Roche) and were
lysed using a French pressure cell (5 passes at >1,500 bar; SLM-AMINCO).
All cell lysates were clarified by centrifugation at 30,000 ×g for 30 min
at 4 and passed through a 0.22 µm PES syringe filter (Millipore). The resulting
clarified, filtered lysates were loaded onto a 5 mL prepacked Ni-IMAC column
(Bio-Rad) using a P-1 peristaltic pump (GE) and washed with 5 column volumes
of lysis buffer and 6 column volumes of mid-wash buffer (lysis buffer supplemented
with 30 mM imidazole). Proteins were eluted from the column with elution buffer
(lysis buffer supplemented with 250 mM imidazole) using a Profinia FPLC (Bio-
Rad). Peak fractions containing PKG Iα were pooled and analyzed by SDS-PAGE.
PKG Iα was dialyzed against 4 L of 50 mM MES, 300 mM NaCl, 1 mM TCEP,
pH 6.9 using 12-14 kDa MWCO dialysis tubing and 1 L against 50 mM MES, 300
mM NaCl, 1 mM TCEP, 10% glycerol, pH 6.9. Aliquots of PKG Iα were flash
frozen in liquid nitrogen and stored at -80 °C.
2.5.6 Analytical size exclusion chromatography (SEC)
Samples containing 0.5 mg of PKG Iα ∆53 (apo or preincubated with 5
µM cGMP) were loaded sequentially onto a Superdex 200 10/300 column (GE)
connected to an kta PURE FPLC (GE) and eluted isocratically in 50 mM MES,
300 mM NaCl, 1 mM TCEP, pH 6.9 (apo) or buffer supplemented with 5 µM
cGMP (bound). Peak fractions were examined for the presence of PKG Iα ∆53
by SDS-PAGE. Peaks were analyzed with Unicorn 6.4 (GE) and plotted using
DataGraph (Visual Data Tools).
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2.5.7 Phosphotransferase assays
Activation of PKG Iα constructs by cyclic 3’,5’-guanosine monophosphate
(cGMP; BioLog) was assessed by measuring phosphorylation of a synthetic pep-
tide substrate (W15, TQAKRKKSLAMA) with γ-32P-ATP similar to the method
described previously (Dostmann et al., 2000). Each 100 µL reaction contained 20
µL of 5x MES Mix (250 mM MES, 5 mM MgOAc, 50 mM NaCl, pH 6.9), 10
µL of 100 mM DTT, 10 µL of 10 mg/mL BSA (Cohn’s fraction V; Sigma), 10
µL of 100 µM W15, 10 µL of cGMP (0-5 µM), 20 µL of 5 nM PKG Iα (in 50
mM MES, 1 mM TCEP, pH 6.9), 10 µL of ATP mix (γ-32P-ATP in 1 mM ATP;
approximate specific activity = 200 cpm/min), and 10 µL of H2O. Reactions were
performed at 30°C and initiated with the addition of either PKG Iα or ATP mix.
Blank reactions were performed by substituting the PKG I and cGMP with H2O.
Reactions were quenched after 1.5 or 3 min by spotting onto P81 phosphocellu-
lose (Whatman and Reaction Biology Corp.) and washing with 0.8% phosphoric
acid. Determination of 32P incorporation into W15 substrate was measured by
liquid scintillation. Data were analyzed using Excel (Microsoft) and Prism v7
(GraphPad) and then plotted using DataGraph (Visual Data Tools).
2.5.8 Measurement of cGMP binding by surface plasmon resonance
(SPR) spectroscopy
SPR measurements were conducted on a SR7500 dual-channel surface plas-
mon resonance spectrometer connected to an SR7100 autosampler utilizing a stan-
dard, dual-channel flow cell (Reichert Technologies). All steps were performed at
25 °C. Gold sensorchips coated with a 1500 nm linear polycarboxylate hydrogel
(HC1500M, Xantec) were installed on the instrument and pre-equilibrated with
SPR buffer (50 mM MES, 150 mM NaCl, 1 mM EDTA, 0.05% Tween20, 1 mM
TCEP, pH 6.9) at 20 µL/min. Sensorchips were washed sequentially with a so-
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lutions of 2 M NaCl and 10 mM NaOH for 5 min each, followed by 2 min with
SPR buffer. The sensorchip was activated for 5 min with a solution of freshly
prepared, degassed 100 µM N-hydroxysuccinimide (NHS) and 200 µM 1-ethyl-3-
(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) dissolved in 1 mL
of 500 mM MES pH 5.5. PKG constructs were diluted to 1 µM in 20 mM NaOAc
pH 5.0 (500 µL) and injected into the left channel for 10 min until 10,000-15,000
µRIU was observed in the difference channel. Excess protein was washed from the
surface for 5 min. Any remaining reactive groups on the sensorchips were deacti-
vated by injecting 1 M ethanolamine pH 8.5 into both channels for 5 min and then
washing with SPR buffer for 1 min. Solutions of cyclic nucleotides were prepared
using the same SPR buffer used during the PKG I coupling steps. During cNMP
binding experiments, solutions were injected at 50 µL/min for 1 min (association)
and then washed with SPR buffer for 3 min (dissociation). All injected solutions
were prepared in clear or amber borosilicate screw-top glass vials with robotic
screw-top vial closures (Fisher Scientific). Data were reduced using Scrubber (Bi-
oLogic). Data were fit to one-site (with Hill coefficient) and two-site (specific
binding) models using GraphPad Prism (GraphPad Software) and plotted using
DataGraph (Visual Data Tools).
2.5.9 Mass Spectrometry
All LC-MS measurements were performed using a Xevo G2-XS quadrupole
time-of-flight (QTOF) mass spectrometer connected to an Acquity ultra perfor-
mance liquid chromatography system (UPLC) (Waters Corp.) in positive electro-
spray ionization (ESI) mode. Mass spectrometry of intact protein was achieved
using a Jupiter 5-µm 300-Å, 1-mm x 150-mm C4 column (Phenomenex). Condi-
tions: LC flow = 80 µL/min; A = water with 0.1% formic acid; B = acetonitrile;
isocratic flow = 0-1 min with 90% A and 10% B, 1-4 min ramp to 10% A and
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90% B; Scan range = 500 2000 m/z. Approximately 2 pmol of PKG ∆53 was
injected per run. The resulting spectra were processed using MassLynx v4.1 and
the deconvolution software, MaxEnt (Waters Corp.).
LC-MS/MS was performed to determine specific phosphorylation sites as
follows: Two 150-pmol aliquots of dried PKG ∆53 or PKG Iα full-length enzyme
were resuspended in 25 µL of 50 mM ammonium bicarbonate buffer (pH 8.5) and
30 µL of 0.02% ProteaseMAX (Promega). A 5-µL aliquot of sequencing grade
trypsin (Promega) was added at a 1:20 ratio (enzyme to substrate). Samples were
incubated overnight at 37°C and acidified with formic acid to obtain a final con-
centration of 0.5%. The samples were evaporated and resuspended in 10 µL of 98%
water, 2% acetonitrile, 0.1% formic acid prior LC-MS analyses. UPLC separation
of the tryptic peptides was performed on an Acquity HSS T3 1.8-µm, 1.0 x 150
mm column (Waters Corp.). UPLC conditions: LC flow = 50 µL/min; column
temperature = 45°C; A = water and 0.1% formic acid; B = acetonitrile and 0.1%
formic acid; linear gradient from 98% A and 2% B to 65% A and 35% B over 50
min. Approximately 30 pmol of digested PKG ∆53 was injected. All samples were
analyzed by data independent acquisition between 100-2000 m/z using the MSE
mode with alternating low (4 V) and high energy (15-40 V) acquisitions. The MSE
data were processed using ProteinLynx Global Server v3.0.1 (Waters Corp.) that
searched against a consolidated database that included human cGMP-dependent
protein kinase 1 (Q13976) and included possible modifications, including phos-
phorylations.
2.5.10 Size exclusion chromatography- small angle x-ray scattering
(SEC-SAXS)
SAXS data pertaining to ∆53 was collected at the Stanford Synchrotron
Radiation Lightsource BL4-2 using an MX225-HE detector (Rayonix). A 35 µL
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sample of 6 mg/mL PKG Iα ∆53 was injected onto a Superdex 200 3.2/30 column
(GE) and eluted isocratically using an Ettan FPLC (GE) at 0.05 mL/min in 50
mM MES, 300 mM NaCl, 1mM TCEP, pH 6.9 supplemented with 5 mM DTT as
a radical scavenger. The eluant stream was connected in-line to a 1.5 mm quartz
capillary positioned 1.7 m from the detector. Data were collected using a wave-
length of 1.127 Å with a 1 second/frame exposure rate at 22°C. A total of 600
frames were collected with a measurement range of 0.0087 - 0.5126 Å-1. Frames
410-459 containing the peak corresponding to ∆53 PKG were averaged and sub-
tracted from the background (45 averaged frames of buffer alone). The data was
truncated to exclude the range of 0.0087-0.016 Å-1 due to radiation-induced ag-
gregation and above 0.19 Å-1 for all subsequent analyses. The scattering curve,
Guinier and P(r) functions, and Porod volume were calculated using the PRIMUS
program suite (Konarev et al., 2003). DAMMIF/DAMMIN/DAMMAVER/DAMFILT
was used to generate a total of 20 models, of which 19 were used to calculate the
final 3-D envelope. Models were excluded based upon their NSD to the mean
using DAMSEL. The excluded model was determined to have a NSD that was
two times the standard deviation from the mean of all NSD scores using a cross-
correlation matrix created. SUPCOMB was further used to fit the averaged 3-D
envelope to existing heterodimeric structures of PKA RIα:C (PDBID: 2QCS),
RIIβ:C (PDBID: 4WBB), and Pf PKG (PDBID:5DYK) (Franke and Svergun,
2009; Volkov and Svergun; Kozin and Svergun, 2001). Radii of gyration were
calculated from the predicted scattering curves of the RIα:C and RIIβ:C het-
erodimers (using PDBID: 2QCS and 4WBB, respectively) using the FoXS and
ATSAS servers (https://modbase.compbio.ucsf.edu/foxs/ and https://www.embl-
hamburg.de/biosaxs/atsas-online) (Schneidman-Duhovny et al., 2013; Schneidman-
Duhovny et al.). Data were deposited in the SASBDB using the identifier SAS-
DDS4 (Valentini et al., 2015).
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2.9 Supplemental Information
Table 2.3: Phosphopeptides of full-length PKG Iα.
Precursor MH+ (Da) z Start End Sequence Modifications Retention Time (min) Intensity (x103)
2,390.15 2.95 514 533 (K)KTWTFCGTPEYVAPEIILNK(G) PO4-T517 41.60 1,619
2,310.18 2.98 514 533 (K)KTWTFCGTPEYVAPEIILNK(G) 39.67 29
2,262.06 2.61 515 533 (K)TWTFCGTPEYVAPEIILNK(G) PO4-T517 45.10 5,863
2,182.09 2.6 515 533 (K)TWTFCGTPEYVAPEIILNK(G) 43.36 440
Table 2.4: Small Angle X-ray Scattering Results.
Rg (Å)
Construct Derived Calculated Dmax (Å) V (Å
3 x 103)
PKG Iα ∆53 29.71 ± 0.58 30.23 ± 0.25 96.77 105
PKG Iβ ∆1−52
∗
29.4 ± 0.1 - 90 -
PKA: RIαAB/C
† 36.4 ± 0.6 - 120 96
PKA: RIαAB/C (calc.)
‡ - 29.62 - -
PKA: RIIβAB/C
† 29.1 ± 1.0 - 90 99
PKA: RIIβAB/C (calc.)
‡ - 29.11 - -
∗ Wall et al. (2003)
†Vigil et al. (2005)
‡ Calculated using the FoXS server; https://modbase.compbio.ucsf.edu/foxs/index.html
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Fig S1
Figure 2.9: Molecular weight standard curve corresponding to elution on Superdex
S200 10/300 column. The standards 1) Thyroglobulin (670 kDa), 2) γ-globulin
(158 kDa), 3) Ovalbumin (44 kDa), 4) Myoglobin (17 kDa), and 5) Vitamin
B12 (1.3 kDa) are displayed. The dashed red line corresponds to the predicted
molecular weight and elution volume (14.6 mL) for ∆53 PKG Iα. The observed
elution volume for ∆53 is 14.8 mL.
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Figure 2.10: P(r) profiles comparing the experimentally measured scattering pro-
files of ∆53 (black, left axis) from this study, and RIα heterodimer (green, right
axis), and RIIβ heterodimer (red, right axis) from Vigil et al.
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Figure 2.11: Predicted versus experimental scattering for ∆53 with residual plots.
Predicted scattering of crystal structures are shown for PKA RIα:C (green) het-
erodimer, PKA RIIβ:C heterodimer (red), and Pf PKG (blue). A) CRYSOL fit
with constant subtraction. B) CRYSOL fit without constant subtractionC) FoXS
fit using default parameters. D) The 3D envelope of the DAMMIF ab initio model
based on the SAXS data obtained for ∆53 (grey balls) fit to the crystal structure
of Pf PKG (PDBID: 5DYK, NSD=1.09). E) View of Pf PKG structure without
overlay of 3D envelope.
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Figure 2.12: Activation data for A-site (E167G, green) and B-site (E292A, violet)
mutants compared to full-length (black) and ∆53 PKG Iα (red). The A-site
mutant is unable to activate in a cGMP-dependent manner while the B-site mutant
is active and displays a similar activation curve (Ka = 95 nM) and cooperativity
(nH = 1.45) to full-length (Ka = 180 nM, nH = 1.58).
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Figure 2.13: One-site models with Hill coefficient fits for A) cGMP and B) cAMP
binding to full-length (black), ∆53 (red), 1-326 (blue) and 78-326 (green).
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Chapter 3
Intraprotomer disulfide bond formation stimulates
constitutive activation of the type Iα cGMP-dependent
protein kinase
3.1 Abstract
The type I cGMP-dependent protein kinase (PKG I) is an essential regu-
lator of vascular tone. It has been demonstrated that the type Iα isoform can be
constitutively-activated by oxidizing conditions. However, the amino acid residues
implicated in this phenomenon are not fully elucidated. To investigate the molecu-
lar basis for this mechanism, we studied the effects of oxidation using recombinant
wild-type, truncated, and mutant constructs of PKG I. Using an in vitro assay,
we observed that oxidation with hydrogen peroxide (H2O2) resulted in constitu-
tive, cGMP-independent activation of PKG Iα. PKG Iα C42S and a truncation
construct that does not contain C42 (∆53) were both constitutively activated by
H2O2. In contrast, oxidation of PKG Iα C117S maintained its cGMP-dependent
activation characteristics, though oxidized PKG Iα C195S did not. To corroborate
these results, we also tested the effects of our constructs on the PKG Iα-specific
substrate, the large conductance potassium channel (KCa1.1). Application of wild-
type PKG Iα activated by either cGMP or H2O2 increased the open probabilities
of the channel. Neither cGMP- or H2O2-activation of PKG Iα C42S significantly
increased channel open probabilities. Moreover, cGMP-stimulated PKG Iα C117S
increased KCa1.1 activity, but this effect was not observed under oxidizing condi-
tions. Finally, we observed that PKG Iα C42S caused channel flickers, indicating
dramatically altered KCa1.1 channel characteristics compared channels exposed to
wild-type PKG Iα. Cumulatively, these results indicate that constitutive activa-
tion of PKG Iα proceeds through oxidation of C117 and further suggests that the
formation of a sulfur acid is necessary for this phenotype.
3.2 Introduction
Blood pressure is maintained in part through constriction and relaxation
of smooth muscle cells in the peripheral vasculature. During vasorelaxation,
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endothelium-derived nitric oxide or circulating natriuretic peptides activate guany-
lyl cyclases, which produce 3,5-cyclic guanosine monophosphate (cGMP) (Friebe
and Koesling, 2003). This second messenger binds to and activates the cyclic
GMP-dependent protein kinase I (PKG), a homodimeric enzyme that is expressed
as two isoforms in vascular smooth muscle cells (VSMCs), PKG Iα and Iβ (Hof-
mann et al., 2009). PKG Iα acts as a central regulator of vasorelaxation by modu-
lating global and local Ca2+ levels within the cell. Its phosphorylation targets in-
clude the large conductance calcium-activated potassium channel (BKCa, KCa1.1),
which causes membrane hyperpolarization and inhibition of voltage-dependent
calcium channels (VDCCs) (Fukao et al., 1999; Sausbier et al., 2005; Schubert
and Nelson, 2001). PKG Iα also phosphorylates the myosin phosphatase targeting
subunit 1 (MYPT1), the small GTP-binding protein (RhoA), and the regulator
of G-protein signaling 2 (RGS2), which mediate the downstream cytoskeletal re-
arrangement necessary for vascular relaxation (Kato et al., 2012; Sun et al., 2005;
Yuen et al., 2011, 2014).
This signaling cascade and physiological effects associated with cGMP-
dependent activation of PKG Iα are well-established (Hofmann et al., 2009). Un-
der oxidizing conditions, PKG Iα is known to be constitutively active (Burgoyne
et al., 2007; Landgraf et al., 1991; Muller et al., 2012). Several studies have
suggested that a residue unique to the N-terminus of PKG Iα, C42, may be the
source of this constitutive activation (Burgoyne et al., 2007; Khavandi et al., 2016;
Prysyazhna et al., 2012; Rudyk et al., 2012). The proposed mechanism involves
the formation of an intramolecular disulfide bond between C42 and C42 from the
opposing protomer in the homodimeric holoenzyme. Since this disulfide bond is
located in the substrate targeting region of the kinase, it has been hypothesized
that oxidation at this site also modulates targeting to substrates by altering the
geometry of this domain (Burgoyne et al., 2007; Landgraf et al., 1991). These
observations have been consequential toward understanding the role of oxidizing
agents, such as hydrogen peroxide, in both physiological and pathophysiological
processes within the vasculature (Chan and Baumbach, 2013a,b; Gray et al., 2016;
Kim et al., 2017; Patel et al., 2017; Rashdan and Lloyd, 2015; Schiffrin, 2012).
Both activation and substrate targeting are required for PKG I-dependent
signaling, and disruption of either of these mechanisms is sufficient to alter normal
physiological processes (Blanton et al., 2013; Casteel et al., 2005; Feil et al., 1995;
Surks et al., 1999). In this study, we sought to isolate these two facets of PKG Iα
signaling by studying the effects of oxidation using recombinant wild-type, trun-
cated, and mutant constructs of PKG I. We found that both PKG Iα and Iβ are
activated by oxidation, though its effect on PKG Iα is more pronounced. Further-
more, both PKG Iα C42S and ∆53 PKG Iα (a truncation mutant that does not
contain C42) are activated by oxidation. Using PKG Iα C117S and C195S to test
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the influence of a previously observed disulfide bond, we observed that oxidation
at C117 is necessary and sufficient for oxidative activation of PKG Iα . Finally,
we corroborated these in vitro results by measuring the PKG Iα -dependent acti-
vation of the KCa1.1 channel. Taken together, these data support the hypothesis
that oxidative disruption of PKG localization and constitutive activation are sep-
arate phenomena, although they have significant effects on PKG signaling in the
vascular smooth muscle.
3.3 Results
3.3.1 Oxidation of PKG Iα abrogates cGMP-dependent activation
Under oxidizing conditions, there are two confirmed sites where disulfide
bonds form in the PKG Iα holoenzyme. They are an interprotomer disulfide bond
between Cys42 and Cys42 and an intraprotomer disulfide bond between Cys117
and Cys195 (Figure 1A) (Landgraf et al., 1991). These disulfide bonds have also
been identified in recent structural studies of the isolated domains (Figure 1B, C)
(Landgraf et al., 1991; Osborne et al., 2011; Qin et al., 2015). The first disulfide
bond between C42-C42 forms at the C-terminal region of the dimerization domain
(Figure 1B). Cys42 is one of four non-leucine/isoleucine residues at d positions
within the coiled-coil and is unique to this isoform (Figure S1A). The second
disulfide bond in cGMP-A forms between C117 and C195 and is proximal to the
cGMP binding pocket (Figure 1C).
To characterize the oxidative phenotype, recombinant PKG Iα from Sf 9
cells was used for in vitro phosphotransferase assays, wherein changes in kinase
activity could be monitored. First, we confirmed that PKG Iα activity under
reducing conditions (WTred) were consistent with previous studies (Moon et al.,
2015, 2018). Exposure to increasing concentrations of cGMP activated the kinase
in a cooperative manner (nH = 1.7) by 20-fold at a half maximal concentration
of 200 nM (Figure 2A, Table 1). We next examined how increasing H2O2 con-
centrations affected PKG Iα activity. WTred was exposed to H2O2 and kinase
activity was monitored under apo and saturating cGMP conditions (Figure 2B).
A maximum response was observed at 500 µM, wherein we observed a reduction
in the maximal velocity paired with a peak in the minimum velocity. At 1 mM
H2O2, we observed a relative loss of activity the presence and absence of cGMP,
suggesting that exposure of the enzyme to H2O2 had compromised the kinases
catalytic function. To expand our understanding of the conditions in which to
measure the oxidative phenotype, the fold-activation of PKG Iα was monitored
over a timed exposure to 500 µM H2O2 (Figure 2C). After 30 minutes of exposure,
we observed the greatest effect on the cGMP-dependent activation of the kinase
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wherein the fold-activation was reduced by approximately 90% to 2.5 (Table 1).
These conditions were used for all subsequent measurements of the oxidation phe-
notype relating to cGMP-dependent activity.
Next, we tested the cGMP-dependent activation of oxidized PKG Iα. Oxi-
dation resulted in a 5-6-fold increase in basal activity in the absence of cGMP (1.13
µmol/min×mg; p<0.001 compared to WTred; Figure 2A). In contrast, the addition
of up to 4 µM cGMP increased the activity by only 2.5-fold (2.77 µmol/min×mg).
Moreover, the activation of WTox with cGMP indicated a decreased sensitivity
for the cyclic nucleotide. In agreement with previous studies, analysis of wild-
type PKG Iα by non-reducing SDS-PAGE showed that increasing concentrations
of H2O2 resulted in formation of an interprotomer disulfide bond. (Figure 2D).
In determining whether our PKG I constructs formed the interprotomer disulfide
bond using non-reducing, SDS-PAGE electrophoresis, preliminary experiments in-
dicated that removal of the reducing agent from the storage buffer would expose
the enzymes to ambient air; prior studies have used this method to activate PKG
Iα by oxidation (Fig S1) [11, 35]. We sought to avoid the contribution from ambi-
ent air by retaining the reducing agent, tris-carboxyethyl phosphine (TCEP), in
the buffer and adding H2O2 to levels which would overcome its reducing capacity.
Since TCEP is degraded by H2O2 through oxidation to a phosphine oxide at a 1:1
ratio, the excess H2O2 could be calculated (Han et al., 1996; Tan et al.). Both the
added (black) and final (H2O2 minus TCEP; red) H2O2 concentrations are shown.
3.3.2 Cysteine mutants of PKG Iα probe oxidation-induced constitu-
tive activation
Next, we examined whether the oxidized phenotype in PKG Iα is regulated
by formation of the interprotomer disulfide bond between C42 and C42. To achieve
this, we measured the activities of reduced and oxidized PKG Iα C42S (C42Sred
and C42Sox) (Figure 3A, Table 1). When the mutant was measured under reducing
conditions, we observed a similar basal activity to WTred (0.32 µmol/min×mg).
However, when activated by cGMP, the maximal velocity was reduced by ap-
proximately 50% reduction compared to WTred (2.31 µmol/min×mg), resulting
in a 7-fold stimulation of activity. Moreover, C42Sred showed a 3-fold shift in the
activation constant (Ka = 580 nM, p<0.001 compared to WTred) and a loss of
cooperative, cGMP-dependent activation (nH=0.8). For C42Sox, we observed a
significant increase in basal activity (1.103 µmol/min×mg; p<0.001 compared to
C42Sred); however, the maximal activity was unchanged (2.357 µmol/min×mg)
and displayed similar kinetic characteristics to WTox. Examination of C42Sox by
non-reducing, denaturing SDS-PAGE did not show evidence of an intramolecular
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disulfide bond between protomers (Figure 3E).
Due to the similar increases in basal activity between WTox and C42Sox
in response to H2O2, we next utilized ∆53 PKG Iα—a truncation construct of
PKG Iα that lacks the N-terminus (and C42) but retains cGMP-dependent acti-
vation (Moon et al., 2018). ∆53red activity in the absence of cGMP was similar
to wild-type PKG Iα (Figure 3B). In the presence of increasing concentrations of
cGMP, ∆53 activity increased by 20-fold with a Ka for cGMP that was similar
to wild-type PKG Iα (216 nM). When oxidized with H2O2, ∆53ox exhibited ki-
netic features similar to the WTox and C42Sox constructs. The 7-fold increase
in basal activity of ∆53ox to 1.380 µmol/min×mg decreased its cGMP-dependent
fold-activation to 1.1. Thus, ∆53 displayed the highest sensitivity to oxidation.
Like C42S, SDS-PAGE analyses showed that ∆53 does not form an interprotomer
disulfide bond in the presence of H2O2 (Figure 3E).
Since PKG Iα and Iβ are splice variants of the prkg1 gene, within the
same species they are completely identical in their cGMP-binding and catalytic
domains (with 98% sequence identity across placental mammals). However, their
N-terminal dimerization, autoinhibitory, and linker regions only retain 26% se-
quence identity (Figure S1). Thus, C42 in the N-terminus of Iα is not conserved
in PKG Iβ. Upon ruling out the contribution of C42 on the oxidation-dependent
activation phenotype of PKG Iα, we hypothesized that any effect of oxidation may
originate within the sequence-conserved regulatory domain. To test this, we first
examined reduced and oxidized PKG Iβ . PKG Iβ stimulated by cGMP under
reducing conditions displayed a cooperative, 86-fold stimulation of activity with
a Ka of 1.21 µM (Table 1, Figure S3). When PKG Iβ was oxidized with H2O2, a
10-fold increase in basal activity was observed (0.42 µmol/min×mg) paired with a
1.3-fold decrease in maximal velocity (2.780 µmol/min×mg), resulting in a reduc-
tion of the cGMP-stimulated fold activation to 6.6. In addition, under oxidizing
condition, the activation constant for PKG Iβ decreased by 1.4-fold (Ka = 0.86
µM) and cooperativity was reduced to 1.2.
In addition to the interprotomer disulfide bond between C42 and C42’,
Landgraf et al. also confirmed the presence of an intraprotomer disulfide bond
between C117 and C195. This disulfide bond has been observed in the crystal
structure of the PKG I regulatory domain (PDB 3SHR) (Osborne et al., 2011).
Due to its location in the first cGMP-binding domain (CNB-A), we hypothesized
that this disulfide bond may control oxidative activation of PKG Iα. To test this,
we expressed and purified the PKG Iα C117S mutant. Under reducing conditions,
C117Sred had a low basal activity that was similar to PKG Iα wild-type (Figure
3C). Furthermore, activation of C117Sred with cGMP increased the activity by
26-fold with positive cooperativity (nH = 1.4), resulting in a maximum velocity
of 4.09 µmol/min×mg and a Ka of 130 nM. In contrast to PKG Iα wild-type,
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stimulation of C117Sox by cGMP resulted in only a slight increase in basal activ-
ity and no significant change in its maximal velocity compared to C117Sred (3.81
µmol/min×mg). However the Ka for cGMP was slightly increased and the co-
operativity was slightly decreased (nH = 1.2) compared to C117Sred. These data
suggest that the response to H2O2 is highly attenuated by introduction of the
C117S mutation.
To determine whether oxidative activation is dependent on disulfide bond
formation with C195, we next examined the C195S construct. Under reducing
conditions, the overall kinetic profile of C195Sred was not significantly different to
WTred; however, the basal and maximal activities were slightly higher, resulting
in an overall fold activation of 10.8 after stimulation with cGMP. (Figure 3D,
Table 3.1). Under oxidizing conditions, we observed kinetics consistent with the
WTox phenotype. This included a significant increase in basal activity and a de-
crease in the maximal velocity, suggesting oxidation at C195 is not necessary for
oxidation-dependent activation.
3.3.3 Analysis of KCa1.1 channel activity during exposure to PKG Iα
Phosphorylation of the KCa1.1 channel by PKG Iα has been shown to in-
crease its open probability, resulting in increased K+ flux to the extracellular space
(Alioua et al., 1995; Kyle et al., 2013; Schubert and Nelson, 2001). To examine
the effects of both substrate targeting and activation of the channel, we measured
KCa1.1 channel currents by inside-out patch clamp configuration using exogenous
application of reduced or oxidized PKG Iα constructs (Figure 4A). Under reducing
and cGMP-stimulating conditions, wild-type PKG Iα increased the open proba-
bility of the KCa1.1 channels by 3.2-fold compared to control patches (p<0.001).
PKG Iα that was pretreated with H2O2 and then added to the extracellular face of
the patch in the absence of cGMP also increased the open probability by 3.1-fold
(p<0.02).
Application of C42Sred under cGMP-saturating conditions did not result in
a significant increase in channel open probability compared to control (NPexp/NPocontrol
= 1.4), whereas C42Sox resulted in a slightly higher increase in the open prob-
ability of the channels to 2.1-fold over baseline. Furthermore, we observed that
the channel kinetics in the presence of C42S were altered under these conditions
(Figure 4Ba). Examination of the channel dwell times show that KCa1.1 patches
exposed to cGMP-activated C42Sred had a shortened mean open dwell time of 1.0
ms compared to baseline (5.8 ms) (Figure 4Bb, S4). However, when wild-type
PKG Iαred was applied to the patch, we saw a significant but smaller decrease in
mean open dwell time (baseline = 4.6 ms and PKG Iα = 3.7 ms) (Figure 4Bb, S4).
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The comparison of these differences by non-parametric Hodges-Lehmann analysis
indicated that the change in dwell time in response to kinase addition was greater
for C42S than wild-type PKG Iα (Figure 4Bb). To determine whether the change
in KCa1.1 currents caused by C42S was dependent on activity, channel recordings
in the presence of C42Sred was also measured under symmetrical K
+ in the ab-
sence of cGMP and ATP (Figure S5). The short channel openings (flickers) were
observed at both +40 and -40 mV, indicating that the effect was independent
from C42S activity and membrane polarity.
Finally, application of C117Sred under cGMP-saturating conditions signif-
icantly increased the open probability of the channel compared to the control
condition (Figure 4A, p<0.02). However, C117S that was pretreated with H2O2
(C117Sox) had no effect on KCa1.1 channel open probability (p=0.2413). As a
control, application of 500 nM hydrogen peroxide directly to the bath solution
did not significantly alter channel open probabilities. As a control, no effect on
channel activity was observed with the addition of 500 nM H2O2—the concentra-
tion that equaled the maximum final concentration of H2O2 in the bath solution
after addition of PKG Iαox constructs.
Table 3.1: cGMP-Dependent Phosphotransferase Activity
Reduced Oxidized
Constructs Vmin
† Vmax
† Vmax/Vmin Ka (µM) ∗ nH ∗ N Vmin † Vmax † Vmax/Vmin Ka (µM) ∗ nH ∗ N
PKG Iα WT 0.22 ± 0.00 4.39 ± 0.03 20.0 0.20 ± 0.00 1.7 ± 0.0 12 1.13 ± 0.08 2.77 ± 0.03 2.5 N/A N/A 16
C42S 0.32 ± 0.06 2.31 ± 0.18 7.3 0.58 ± 0.03 1.1 ± 0.1 14 1.10 ± 0.03 2.36 ± 0.11 2.1 0.13 ± 0.01 1.6 ± 0.2 6
∆53 0.18 ± 0.16 3.95 ± 0.30 21.6 0.22 ± 0.03 0.9 ± 0.1 7 1.38 ± 0.19 1.58 ± 0.36 1.1 N/A N/A 6
C117S 0.16 ± 0.10 4.09 ± 0.13 26.0 0.12 ± 0.01 1.4 ± 0.1 6 0.65 ± 0.14 3.81 ± 0.10 5.9 0.20 ± 0.00 1.2 ± 0.1 6
C195S 0.43 ± 0.02 4.67 ± 0.12 10.9 0.27 ± 0.01 1.8 ± 0.1 6 0.86 ± 0.02 3.20 ± 0.05 3.7 1.22 ± 0.11 0.8 ± 0.1 6
PKG I β WT 0.04 ± 0.01 3.62 ± 0.26 86.1 1.21 ± 0.03 1.9 ± 0.1 7 0.42 ± 0.03 2.78 ± 0.10 6.6 0.86 ± 0.03 1.2 ± 0.1 6
† The velocity values indicate the µmol of peptide substrate (W15)
phosphorylated per min per mg of PKG (µmol/min*mg) and are represented as
the mean ± the standard deviation.
∗ Values were obtained from non-linear regression fit analyses and are
represented as the means ± standard deviations. Not applicable (N/A) values
indicate the data for that condition could not be fit to a non-linear regression.
3.4 Discussion
PKG Iα is an essential signaling molecule in the vasculature and can be
activated by cGMP or oxidation (Burgoyne et al., 2007; Dostmann et al., 2000;
Francis et al., 1996; Heil et al., 1987; Ruth et al., 1991). The first study to describe
that PKG Iα can be constitutively activated by oxidation used cupric cations as
the oxidizing agent (Landgraf et al., 1991). This activity was found to be blocked
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Figure 3.1: Putative sites of oxidative activation in PKG Iα A) Linear do-
main diagram depicting the homodimeric PKG Iα and the sites of cysteine residues
hypothesized to be involved in the oxidative phenotype. Structures denoting the
location of disulfide bonds identified in the N-terminal dimerization domain (B)
and the cGMP A-site (C) from PKG Iα (PDBIDs: 4R4L and 3SHR, respectively).
by iodoacetimide, which indicated involvement of cysteine residues in this mech-
anism. Moreover, three possible disulfide bonds were identified by non-reducing
SDS-PAGE and Edmann degradation: an interprotomer disulfide bond between
C42 and C42, an intraprotomer disulfide bond between C117 and C195, and an
intraprotomer disulfide bond between C312 and C518. Of the three, the last disul-
fide bond could not be definitively confirmed.
Previous analyses of PKG I isoforms determined that PKG Iα, but not
PKG Iβ, exhibits sensitivity to oxidation (Burgoyne et al., 2007; Muller et al.,
2012). Thus, it was concluded that C42—the only cysteine residue unique to
PKG Iα—must be the primary regulator of oxidation-dependent activation (Bur-
goyne et al., 2007). Moreover, formation of this interprotomer disulfide bond
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Figure 3.2: Initial characterization of the PKG Iα oxidative phenotype.
A) cGMP-dependent activation under reducing (solid line, N=12) and oxidiz-
ing (500 µM H2O2, 30 min, dashed line, N=16) conditions. B) PKG Iα activity
plotted against increasing concentrations of H2O2. Activity was measured in the
absence (black, N=4) and presence of cGMP (red, 4 µM, N=4). The concentra-
tion of H2O2 (500 µM) that resulted in the greatest increase in basal activity is
highlighted in the boxed region. C) A time course examining PKG Iα oxidation
with 500 µM cGMP wherein the fold-activity (Vmax/Vmin) was monitored (N=4).
D) Representative non-reducing, denaturing SDS-PAGE of PKG Iα exposed to
increasing concentrations of H2O2. The dashed line indicates the point at which
the concentration of hydrogen peroxide overcomes the concentration of TCEP in
the buffer. H2O2 values corrected for the presence of TCEP are shown in red.
Where shown, data are represented as the mean ± SD.
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Figure 3.3: In vitro phosphotransferase assays of PKG Iα under reducing
and oxidizing conditions cGMP-dependent activation of (A) PKG Iα wild-type
(black circles) and PKG Iα C42S (red squares), (B) ∆53 PKG Iα (purple squares),
(C) PKG Iα C117S (green triangles) and (D) PKG Iα C195S (blue triangles)
under reducing (1 mM TCEP, solid lines) and oxidizing (500 µM H2O2, 30 min,
dashed lines) conditions. Data are represented as the mean ± SD. (E) Non-
reducing, denaturing SDS-PAGE of PKG Iα constructs treated with increasing
concentrations of H2O2 (0-2 mM). The dashed line indicates the point at which
the concentration of hydrogen peroxide overcomes the concentration of TCEP in
the buffer. H2O2 values corrected for the presence of TCEP are shown in red.
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Figure 3.4: Stimulation of KCa1.1 channels with PKG Iα constructs un-
der reducing and oxidizing conditions A) The combined results of single
KCa1.1 recordings exposed to PKG Iα constructs under reducing and oxidizing
conditions. Individual measurements are represented as a scatter plot overlaid
with mean ± SEM. P values represent the comparison against PKG Iα under
reduced, unstimulated conditions (first lane). Ba) Representative control (top)
and experimental traces of single KCa1.1 channel openings in excised membrane
patches from mouse cerebral artery myocytes under control conditions and when
exposed to cGMP activated PKG IαWT and C42S constructs. All measurements
were recorded under reducing conditions. Bb) Analysis of channel open dwell
times of KCa1.1 channels from representative patches under control, and expo-
sure to PKG Iα WT and C42S under reducing conditions. Whisker boxes are
represented as the medians bounded by the interquartile ranges (IQR). A non-
parametric Hodges-Lehmann analysis containing the HL-coefficient and error are
shown. *p<0.02; ***p<0.0001
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Figure 3.5: Model of the oxidation-dependent activation of PKG Iα A)
Cysteine residues can be oxidized to multiple states, which proceed through a
sulfenic acid intermediate. When in proximity to a free thiol, sulfenic acids can
be condensed to a disulfide. Further oxidation of sulfenic acids results in the irre-
versible sulfinic and sulfonic acid forms. The sulfonic acid form can also be reached
via a thiosulfinate intermediate. The sulfur acid forms hypothesized to mediate
oxidation-dependent activation of PKG Iα are boxed. B) Sequence alignment of
mammalian PKG Iα (green) and Iβ (gold) isoforms denoting the autoinhibitory
(AI) domain and linker region. The segment within the linker region that is in
close proximity to C117 is boxed in red.C) A structural alignment of the PKG Iα
(green; PDB 3SHR) and the Iβ (yellow; PDB 3OD0) A-sites superimposed with
the RIα:C holoenzyme of PKA (RIα-blue; C-gray; PDB 2QCS). The boxed region
indicates the location of the linker region of PKG Iαand Iβwith their corresponding
residues within close proximity to C117.
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between C42 and C42’ of the opposing protomer was found to correlate with a va-
sodilatory response in isolated perfused rat hearts (Burgoyne et al., 2007). These
observations helped to cement oxidation as an additional mechanism by which
PKG Iα can be activated. Despite an abundance of data ascribing physiological
importance to the formation of the interprotomer disulfide bond between C42
and C42, the structural and biochemical underpinnings of how this disulfide bond
would activate PKG Iα remain unclear. Thus, we sought to expand upon these
initial observations to more thoroughly understand the mechanism of oxidation-
dependent activation in PKG Iα.
Under reducing conditions, the cGMP-dependent activation characteris-
tics of wild-type PKG Iα were consistent with previously reported values (Figure
2C) (Moon et al., 2015, 2018). Furthermore, preincubation of wild-type PKG Iα
with H2O2 induced interprotomer disulfide bond formation (Figure 2D) (Burgoyne
et al., 2007; Kalyanaraman et al., 2017; Landgraf et al., 1991). We observed that
exposure of wild-type enzyme to 500 µM H2O2 for 30 min at 24°C resulted in
the greatest amount of constitutive activation, determined by increase in basal
activity and corresponding decrease in cGMP-dependent activation (Figure 2B).
Although this concentration of H2O2 is significantly higher than what has been
implemented in prior studies, we sought to measure the H2O2 concentration de-
pendence on PKG Iα activity in a similar fashion as Landgraf et al. (Burgoyne
et al., 2007; Landgraf et al., 1991; Kalyanaraman et al., 2017; Muller et al., 2012).
To examine the source of the oxidative phenotype, we expressed constructs of
PKG Iα that contained site mutations at cysteine residues previously suggested
to form disulfide bonds in the presence of oxidizing agents, with a specific focus on
C42 in the dimerization domain and C117 and C195 within the cyclic nucleotide
binding A-site (CBD-A) (Landgraf et al., 1991; Osborne et al., 2011; Qin et al.,
2015).
3.4.1 Characterization of C42S provides insight into rodent models of
oxidation-dependent activation of PKG Iα
When cGMP-dependent activation of C42S was examined under reducing
conditions, we observed that the presence of the serine mutant significantly altered
enzyme activity. This was demonstrated by the shift in its activation constant by
3-fold to 580 nM and a decrease in the measured maximal velocity compared to
wild-type (Figure 3A). This overall shift in efficacy and potency culminated in a
90% reduction in activity for C42S under cGMP concentrations near the KD for
PKG Iα wild type. Even under conditions of maximal cGMP concentrations typi-
cally observed in smooth muscle cells (1-2 µM), C42S exhibited about 30% of the
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maximal activity of PKG Iα wild-type (Figure 3A) (Nausch et al., 2008). Based
upon these results, we conclude that, while the C42S mutant retains sensitivity
to oxidation — unlike the wild-type enzyme — the reduced form of C42S displays
significantly altered kinetic activity toward the synthetic peptide substrate used in
the in vitro phosphotransferase assays. In agreement with previous results, C42S
did not form an interprotomer disulfide bond in the presence of H2O2 (Figure 3E)
(Burgoyne et al., 2007; Kalyanaraman et al., 2017). These results reinforce the
findings of a recent study observing that oxidation of PKG Iα resulted in inter-
protomer disulfide formation, but did not increase phosphorylation of the PKG
substrates RhoA and VASP (Kalyanaraman et al., 2017). In agreement with our
study, the authors also found that the reduced form of C42S exhibited a 5-fold
shift in its activation constant for cGMP. Taken together, these results suggest
that the interprotomer disulfide bond does not mediate the oxidative phenotype,
but does offer an explanation of the detrimental physiological phenotypes associ-
ated with this mutation.
To this end, a PKG Iα C42S knock-in mouse model has been used in pre-
vious studies to investigate the physiological effects of the interprotomer disulfide
bond (Prysyazhna et al., 2012). These mice were found to be hypertensive com-
pared to littermate controls. Based upon our kinetic analyses of PKG Iα C42S, we
suggest that this phenotype may result from the compromised kinetic profile of
the enzyme rather than an inability to be activated by oxidation. This conclusion
is further substantiated by the effects of PKG Iα constructs on KCa1.1 channel
activity. Application of PKG Iα activated either with cGMP (under reducing con-
ditions) or by oxidation increased channel activity (Figure 4A). The similarities in
channel responses between the two conditions suggests that substrate targeting of
PKG through its dimerization domain to KCa1.1 is not compromised by formation
of the interprotomer disulfide bond between C42 and C42’ in the dimerization do-
main.
However, a comparison of KCa1.1 channel characteristics subjected to ei-
ther C42S or WT, exposed that the mean dwell times were shorter for those
patches treated with the mutant kinase. Moreover, we observed an overall in-
crease in the number of channel opening events over an equivalent measurement
time (Figure 4Bb, S4, S5). These short channel openings (flickers) may impact
the calculated -fold activation values reported in Figure 4A. Moreover, the KCa1.1
channel flickers were observed for all patches exposed to C42S (± cGMP, and ox-
idizing conditions) (Figure 4Bb, S4, S5). Within this context, a study examining
pressure-induced constriction of third order mesentery arteries expressing C42S
observed that application of the KCa1.1 channel blocker, paxilline, did not induce
vessel constriction (Khavandi et al., 2016). In light of the modified KCa1.1 chan-
nel characteristics mediated by C42S, the mutation may possess hitherto unknown
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properties, such as unique interactions with the channel pore or altered targeting
to other PKG Iα substrates.
As a corollary, the effects of disrupted substrate targeting has been ob-
served previously for a mutant leucine zipper knock-in mouse model in which
the leucine residues in the dimerization domain were mutated to alanine residues.
This mutant was unable to phosphorylate myosin binding subunit (MBS) and Ras
homolog A (RhoA), despite retaining its sensitivity to cGMP and ability to phos-
phorylate the synthetic substrate BPDEtide (Blanton et al., 2013). Furthermore,
these mice, like the C42S knock-in model, were also hypertensive. Since activation
and substrate targeting through the dimerization domain are both required for
phosphorylation of substrates by PKG Iα, we suggest that either explanation is
possible.
3.4.2 C117S drives constitutive activation of PKG Iα by oxidation
To test our hypothesis that the oxidative phenotype is driven by residues
that lie outside of the N-terminus, we next tested the PKG Iα truncation construct,
∆53 (Moon et al., 2018). Similar to C42S, ∆53 does not form an interprotomer
disulfide bond (Figure 3E), and reduced ∆53 was activated by concentrations of
cGMP similar to wild-type (Fig. 3B). Moreover, oxidation had the most pro-
nounced effect on the cGMP-independent activation of the kinase as indicated by
the complete insensitivity to cGMP. These results corroborate the C42S data and
overwhelmingly demonstrate that the interprotomer disulfide bond is not required
for oxidation-induced activation.
Finally, we tested the contribution of the intraprotomer disulfide bond that
has been shown to form between C117 and C195 in the cGMP-A domain (Landgraf
et al., 1991; Osborne et al., 2011). We observed that, while the cGMP-dependent
activation of reduced C117Swas similar to reduced PKG Iα WT, oxidized C117S
exhibited only a modest increase in basal activity and no reduction in maximal
velocity compared to its reduced form (Fig. 3C). We also consistently observed
robust activation by cGMP under oxidizing conditions, indicating that the C117S
mutation nearly abolishes the oxidative phenotype. These results are corrobo-
rated by the inside-out patching experiments, which found that cGMP-activated,
reduced C117S stimulated an increase in the fold-activation of KCa1.1 that was
similar to wild-type PKG Iα. However, oxidized C117S had no effect on channel
activity. To determine whether this is controlled by disulfide formation between
C117 and C195 or by another oxidation state, we also tested the C195S mutant.
Under reducing conditions, we observed an elevated basal activity compared to
wild-type; however, in response to oxidation, C195S exhibited a profile similar to
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WT. Thus, we conclude that C117 plays a unique role in mediating the oxidative
activation of PKG Iα in vitro.
The initial observation that PKG Iα and Iβ exhibit differing responses to
H2O2 has predominantly focused the field on C42, the cysteine residue specific to
the α isoform. However, the results described herein indicate the oxidative phe-
notype is controlled by C117 in the cyclic nucleotide binding domain-A (CBD-A).
PKG Iα and Iβ are 100% identical in this region, and the residue analogous to
C117 in PKG Iβ is C132. Examination of reduced and oxidized PKG Iβ showed
that oxidation had a significant impact on its maximal velocity that was similar
to the effect on PKG Iα. However, only a slight increase in basal activity was
observed. These results are consistent with a previous study that focused solely
on activation of PKG Iβ with H2O2 in the absence of cGMP (Burgoyne et al.,
2007) and indicate that examination of the cGMP-dependent activation profile is
necessary to observe the full effects of oxidation on PKG Iβ activity. Differences in
PKG Iα and Iβ—cGMP-dependent activation profiles and targeting to substrates
—are attributed to their distinct N-termini (Schlossmann and Desch, 2009; Dost-
mann et al., 2000; Ruth et al., 1997). We propose their N-termini also dictate
their oxidation-dependent phenotypes and suggest a model (described below) by
which this could occur.
3.4.3 A model for oxidation-driven activation in PKG Iα and consid-
erations for pathophysiological conditions
The results obtained using the PKG Iα mutant constructs suggest that
C117 is necessary and sufficient to stimulate constitutive activation of PKG Iα.
Under mild oxidizing conditions, C117 and C195 would form a sulfenic acid in-
termediates, which can be reduced to the free thiol or condensed to a disulfide
form (Figure 5A). Disulfide bond formation between C117 and C195 likely miti-
gates oxidative activation as no discernible structural changes have been observed
within the CBD-A when comparing the reduced and disulfide-bonded forms (Os-
borne et al., 2011; Kim et al., 2016, 2017). This suggests that the site maintains
an inactive conformation. As determined by this study and Landgraf et al., at
higher concentrations of oxidant, the maximum velocity of the kinase begins to
decay, indicating a rise in constitutive activity. The reversibility of the oxidized
phenotype measured previously was determined at concentrations that did not
affect the maximum velocity (Burgoyne et al., 2007; Landgraf et al., 1991). This
may suggest that formation of the sulfinic and sulfonic acid species at C117 drives
the cGMP insensitivity that is observed at high concentrations of H2O2. Based
upon this, we propose a model of constitutive cGMP-independent activation of
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PKG Iα driven by oxidation to either the sulfenic, sulfinic, or sulfonic acid inter-
mediates at C117.
A sequence alignment of PKG Iα and Iβ paired with a structural align-
ment of the PKG I CBD-A and the PKA RIα:C holoenzyme shows that C117
is oriented proximal to the linker region that connects the autoinhibitory do-
main and CBD-A. This region contain very low sequence identity (approximately
6%) between Iα and Iβ (Figure 5B). We propose that the presence of the basic
residues (Arg82 and Lys83) within the linker region of PKG Iα may act to form
hydrogen bonds or a salt bridge with the sulfur acid forms of C117 (Figure 5C).
In comparison, this region in PKG Iβ contains hydrophobic residues (Pro97 and
Phe98) at the equivalent positions. In this model, we propose that an interaction
between the acid form of C117 and the linker region in PKG Iα could alter the
conformation of the linker to release the autoinhibitory segment from the catalytic
domain, resulting in constitutive activation. Since previous mass spectrometry ex-
periments using isotope-coded affinity-tag (NOxICAT)-labeled PKG Iα peptides
showed that C117 and C195 were equally modified by oxidizing agents, the solvent
accessibilities and oxidizing potentials of the two residues are likely similar. Thus,
differences between the C117S and C195S constructs could be attributed to their
locations proximal to other residues within the domain rather than differing oxi-
dizing propensities (Donzelli et al., 2017). Furthermore, this model would provide
an explanation of the differing responses to oxidation between the two isoforms.
Signaling by PKG I isoforms is mediated by both substrate targeting and
activation (Aitken et al., 1984; Alverdi et al., 2008; Blanton et al., 2013; Casteel
et al., 2005; Francis et al., 1996; Kato et al., 2012; Lee et al., 2007; Surks et al.,
1999; Zhou, 2011). More importantly, they can be considered independent since
disruption of either facet disrupts PKG I signaling pathways (Blanton et al., 2013;
Casteel et al., 2005; Feil et al., 1995; Surks et al., 1999). In this study, we sought
to separate these aspects of PKG I signaling to better understand how oxidation
may regulate each of these processes. The use of a synthetic peptide substrate
allowed for a thorough examination of the effect of oxidation independent of sub-
strate targeting through the dimerization domain. Moreover, observations of PKG
Iα activation of the KCa1.1 channel indicate that oxidation does not diminish tar-
geting of PKG Iα to the KCa1.1 channel.
PKG Iα has been reported to be activated by cGMP-independent mecha-
nisms in both physiological and pathophysiological states (Burgoyne et al., 2007;
Landgraf et al., 1991; Muller et al., 2012; Nakamura et al., 2015; Rudyk et al.,
2012). Oxidizing agents, particularly H2O2, have been suggested to play impor-
tant roles in a number of conditions associated with vascular remodeling, including
angiogenesis, atherosclerosis, and hypertension (Chan and Baumbach, 2013a,b;
Gray et al., 2016; Kim et al., 2017; Patel et al., 2017; Rashdan and Lloyd, 2015;
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Schiffrin, 2012; Warren et al., 2015). Typically, hydrogen peroxide concentrations
in mammalian cells are estimated to average between 1-700 nM (Brewer et al.,
2015). However, local levels caused by bursts in H2O2 production are suggested to
greatly exceed the average value and depend on the distance from the source and
local concentrations of antioxidants, such as catalase, glutathione peroxidases, and
thioredoxin reductases. A recently developed H2O2 sensor (HyPer-Tau) coupled
with super-resolution microscopy suggested that local bursts of hydrogen peroxide
can reach 50-100 µM (Warren et al., 2015). The data presented herein indicate
that constitutive PKG Iα activation via oxidation does not occur until 500 µM
and involves long-lived exposure to the oxidant. Thus, this mechanism would be
specifically relevant to PKG Iα anchored near hydrogen peroxide sources or under
pathophysiological states associated with high global intracellular concentrations
of hydrogen peroxide.
3.5 Experimental Procedures
3.5.1 Site-directed mutagenesis of wild-type PKG Iα
Wild-type PKG Iα and PKG Iβ from Bos taurus (NCBI entries NP 776861.1
and CAA70155.1) were cloned into pFAST Bac HTA as previously described (34,
49). The PKG Iα construct was used as a template for site-directed mutagenesis
to produce the following mutants: PKG Iα C42S, PKG Iα C42A, PKG Iα C117S,
and PKG Iα C195S. The forward and reverse primers used to generate these con-
structs were synthesized as follows: C42S- 5-AAG AGG AAA CTC CAT AAA
AGC CAG TCA GTG-3’ (sense) and 5-GGG CAG CAC TGA CTG GCT TTT
ATG GAG-3 (antisense); C42A- 5-AAG AGG AAA CTC CAT AAA GCC CAG
TCA GTG-3 (sense) and 5-GGC AGC ACT GAC TGG GCT TTA TGG-3 (anti-
sense); C117S- 5-ATC CAA GAG ATT GTG GAT AGT ATG TAC CCA GTG-3
(sense) and 5-GCC GTA CTC CAC TGG GTA CAT ACA ATC CAC AAT-
3 (antisense); C195S- 5-GCC ATT GAC CGA CAA TCT TTT CAG ACG-3
(sense) and 5-CCT CAT TAT CGT CTG AAA AGA TTG TCG-3 (antisense).
All site-directed mutagenesis experiments were carried out using the QuickChange
(Stratagene) method.
3.5.2 Expression and Purification of PKG I constructs
PKG Iα and Iβ wild-type, PKG Iαmutant constructs, and PKG Iα ∆53
were expressed in Sf9 cells using the Bac-to-Bac Baculovirus Expression System
as previously described (Moon et al., 2015, 2018). Constructs were purified from
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Sf9 cell pellets by Ni immobilized metal ion affinty chromatography (IMAC) us-
ing either prepacked (5 mL, BioRad) or hand-packed Ni-NTA columns. Protein
purified for use in inside-out patch clamp experiments were prepared without the
N-terminal hexahistidine tag, by incubation with His-tagged tobacco-etch virus
(TEV) protease at a 1:20 mass ratio (TEV:PKG) during the first dialysis step (50
mM MES, 300 mM NaCl, 1 mM TCEP, pH 6.9, 4°C, 16 h). TEV and the histidine
tag were subtracted from the cleaved protein by flowing over a Ni-IMAC column.
The resulting flow-through containing PKG I was concentrated to 1 mg/mL and
dialyzed against 1 L of 50 mM MES, 150 mM NaCl, 1 mM TCEP, 10% glycerol,
pH 6.9 at 4°C. The resulting protein solution was divided into 20-100 µL aliquots,
flash frozen in liquid nitrogen, and stored at -80°C.
3.5.3 Determination of H2O2 concentration
The primary H2O2 stock (stored at 4°C) was measured by absorption spec-
troscopy at = 240 nm ( = 43.6 M-1cm-1) to determine its concentration (Han et al.,
1996; Tan et al.). Fresh dilutions were prepared daily from the stock for use in
experiments.
3.5.4 Measurement of interprotoper disulfide bond formation by SDS-
PAGE gel electrophoresis
PKG I constructs were buffer exchanged (1-4 times) into 50 mM MES, 150
mM NaCl, 1 mM TCEP, pH 6.9 using 3 kDa MWCO ultracentrifugal filter units
(Amicon) to remove glycerol (to below 1%) in the storage buffer. PKG concentra-
tion was determined by measuring the absorbance at 280 nm ( = 81,250 M-1cm-1
as calculated by ProtParam [51]). All constructs were adjusted to 1 mg/mL (13.1
µM of monomer) and PKG (3.6 µL) was added to 1.4 µL of H2O2 (freshly pre-
pared 10×stocks that ranged from 0-50 mM) and 9 µL of 50 mM MES, 150 mM
NaCl, pH 6.9 (in the absence of reducing agent) (14 µL reactions). Reactions
proceeded for 30 min at 24°C and were subsequently quenched by the addition
of 2 L of 1M maleimide (10% DMSO stock) and 4 L of 5x SDS-loading buffer
without reducing agent. Samples were boiled for 2 min at 95°C and separated
by SDS-PAGE using 4-20% TGX gradient gels (BioRad). The resulting gels were
stained with InstantBlue Protein Stain (Expedeon) and imaged using an Odyssey
Infrared Scanner (LI-COR) at 700 nm. Bands were selected and quantified in the
Image Studio Software (LI-COR) using intensity analysis relative to background.
The background was subtracted by implementing the mean intensity background
subtraction method. Images were exported as 600 DPI grey-scale TIFF files for
use as figures. Data analysis was achieved using Prism v7 (GraphPad).
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3.5.5 In vitro phosphotransferase assays
Activation of reduced PKG I constructs by cyclic 3,5-guanosine monophos-
phate (cGMP; BioLog) was assessed by measuring phosphorylation of a synthetic
peptide substrate (W15, TQAKRKKSLAMA) with γ-32P-ATP as previously de-
scribed (Dostmann et al., 2000). To measure the cGMP-dependent activation
under oxidized conditions, PKG I constructs were pre-incubated with 500 µM
H2O2 in 50 mM MES pH 6.9 for 30 min at 24°C. Under these conditions, the 1
mM TCEP in the PKG storage buffer was diluted to a final concentration of 500
nM. Oxidized PKG I was then added to the other reaction components (in the
absence of reducing agent) to initiate the reactions. All subsequent steps were
performed following the same procedure as the reduced PKG conditions.
3.5.6 Measurement of KCa1.1 activation by inside-out patch clamp of
vascular smooth muscle cells
Male C57BL/6 mice (3-6 month old) were euthanized using procedures
approved by the Institutional Animal Care and Use Committee at the University
of Vermont and performed in accordance with the National Institutes of Health
Policy on the care and use of laboratory animals. The anterior and posterior pial
and superior cerebellar arteries were isolated and cleaned of connective tissue. The
arteries were then incubated at 37°C in dissociation solution (55 mM NaCl, 80
mM Na-glutamate, 6 mM KCl, 2 mM MgCl2, 10 mM glucose, 10 mM HEPES, pH
7.3) containing 0.5 U/mL papain (Worthington) and 1 mg/mL dithioerythritol for
12 min followed by 10 min incubation in dissociation solution containing 1 mg/mL
collagenase (Worthington Type 4). Arteries were then removed and placed back in
the isolation solution without enzymes for an additional 10 min before trituration
with a polished Pasteur pipette to yield single smooth muscle cells. Cells were left
to stick to the glass coverslip in the experiment chamber for 10 min before use.
Membrane patches were pulled from the isolated vascular smooth muscle
cells to achieve the inside-out configuration and contained 2-10 KCa1.1 channels
each. KCa1.1 single channel currents were recorded under the following condi-
tions: the pipette solution contained 6 mM KCl, 134 mM NaCl, 1 mM MgCl2,
10 mM HEPES, pH 7.4 (NaOH); the bathing solution contained 135 mM KCl, 2
mM MgCl2, 1.4787 mM CaCl2, 2 mM EGTA, 10 mM HEPES, adjusted to pH
7.2 with 14.85 mM KOH. The concentrations of free Ca2+ on the intracellular
face was calculated to be 500 nM using the online software WEBMAXC Standard
(https://web.stanford.edu/ cpatton/webmaxcS.htm; Stanford University, Stan-
ford, CA, USA). Single KCa1.1 channel recordings were obtained at room temper-
ature (25°C) for at least 5 min at 0 mV and using an Axopatch 200 B amplifier
coupled to a Digidata 1332A digital-to-analog converter. Currents were filtered at
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2 kHz, digitized at 20 kHz using pCLAMP v9.2 software (Axon Instruments), and
then analyzed with Clampfit v9.2 using the half-amplitude threshold method. The
baseline activity was recorded for at least 20 min to ensure patch stability. The
experimental condition was measured after the addition of 100 µMATP and either
reduced, inactive PKG Iα (no cGMP added), PKG Iα constructs activated with 5
µM cGMP, or PKG Iα constructs activated with 500 µM H2O2. For the oxidized
condition, PKG Iα constructs were first buffer exchanged into 50 mM MES, 150
mM NaCl, 1 mM TCEP, pH 6.9 using 3 kDa MWCO ultracentrifugal filter units
(Amicon) to remove the glycerol (to below 1%) in the storage buffer. Assuming a
1:1 negation of TCEP with H2O2 (Han et al., 1996; Tan et al.), PKG Iα constructs
were oxidized with a final concentration of 500 µM H2O2 at 24°C for 30 min before
use in patch clamp experiments. Addition of PKG Iα constructs to the bath solu-
tion (5 mL) resulted in a final concentration of H2O2 that was less than 500 nM.
The fold activation was determined as the open probability of the channels (NPo)
during the experimental condition/ NPo at baseline. The fold activations of the
experimental conditions were compared to the control condition (reduced PKG Iα,
0 cGMP) using unpaired t-tests with Welch’s correction in Prism 7 (GraphPad).
KCa1.1 channel open times within 5 min windows were measured from full-length
PKG Iα, C42S, and their respective baseline recordings using Clampfit v9.2. The
mean channel open dwell times (τ) and interquartile ranges were calculated using
the Mann-Whitney test and the differences between the baseline control and ex-
perimental dwell times were compared using a non-parametric Hodges-Lehmann
analysis in Prism 7 (GraphPad). Channel recordings examining the effects of
C42S on KCa1.1 were run under symmetrical K
+, 5 µM Ca2+ in the presence of
reduced C42S (-cGMP) at +40, 0, and -40 mV.
3.5.7 Sequence Alignments
Sequences for PKG Iα and Iβ sequences were downloaded from the Na-
tional Center for Biotechnology Information (NCBI) database, and a multiple
sequence alignment was performed with JalView Desktop using CLUSTAL-O
(Waterhouse et al., 2009; Sievers et al., 2011). The following accession num-
bers were used: H. sapiens : Iα-NP 001091982.1 and Iβ-NP 006249.1; M. muscu-
lus : Iα-NP 001013855.1 and Iβ-NP 035290.1; F. catus : Iα-XP 023096056.1 and
Iβ-XP 023096055.1; B. taurus : Iα-NP 776861.1 and Iβ-CAA70155.1.
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3.9 Supplemental Figures
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Figure 3.7: Sequence alignment of mammalian PKG Iα and Iβ isoforms
denoting the locations of cysteine residues confirmed to form disulfide
bonds. Sequence alignment colored by BLOSUM62 score denoting A) the place-
ment of C42 within the dimerization domain and B) the location of C117 and
C195 in relation to nearby structural features within the CNB A-site of PKG Iα,
including the A helix, the B/C helix, and the phosphate-binding cassette.
Figure 3.8: Oxidation-dependent activation of PKG Iβ. A) The cGMP-
dependent activation of PKG Iα (black) and Iβ (orange) under reducing (solid
circles and line) and oxidizing (open circles and dashed line) conditions by an
in vitro phosphotranspherase assay. B) Non-reducing, denaturing SDS-PAGE of
PKG Iβ exposed to increasing concentrations of H2O2 (0-2 mM). The dashed line
indicates the point at which the concentration of hydrogen peroxide overcomes
the concentration of TCEP in the buffer. H2O2 values corrected for the presence
of TCEP are shown in red.
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Figure 3.9: Activity of KCa1.1 treated with C42S by patch clamp in
the inside-out configuration. KCa1.1 channels were exposed to C42S under
reducing conditions in the absence of cGMP and ATP. Activity was measured
under symmetrical K+ at +40, 0, and -40 mV.
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Chapter 4
Discussion and Future Directions
The type Iα and Iβ cGMP-dependent protein kinases (PKG Iα and Iβ)
are essential regulators of vascular tone and systemic blood pressure. Located in
the smooth muscle layer of resistance vessels, these proteins phosphorylate multi-
ple intracellular targets, culminating in smooth muscle relaxation and subsequent
vasodilation. Both isoforms are activated by the second messenger, 3’5’-cyclic
guanosine monophosphate (cGMP) (Hofmann et al., 2009). In addition, PKG Iα
can be activated by oxidation (Landgraf et al., 1991; Burgoyne et al., 2007). The
physiological importance of the cGMP-dependent activation of PKG I isoforms
is well-established; however, the importance of the oxidation-dependent mecha-
nism is an active area of investigation (Nakamura et al., 2015; Prysyazhna et al.,
2012; Prysyazhna and Eaton, 2015; Rudyk et al., 2013; Scotcher et al., 2016).
For both mechanisms, there are multiple gaps in our understanding of how the
PKG I isoforms respond to cGMP and/or oxidizing conditions and become active.
Therefore, this dissertation sought to address some of these gaps and—in regard
to the oxidation-dependent mechanism—provide a solid biochemical framework to
support future studies investigating its physiological or pathophysiological roles.
Chapters 2 and 3 present our findings on the cGMP- and oxidation-dependent
activation mechanisms of PKG Iα, respectively.
In Chapter 2, we hypothesized that a functional, monomeric form of PKG
Iα could be expressed that is autoinhibited and activated in a cGMP-dependent
manner, and, furthermore, that this construct could be used to determine the in-
fluence of the dimeric state on cGMP-dependent activation and binding. As antic-
ipated, the truncation construct, ∆53, was expressed and found to be monomeric,
autoinhibited, and activated with cGMP. We also found that ∆53 adopts a similar
3D structure to the PKA holoenzymes, RIα:C and RIIβ:C. While measuring cyclic
nucleotide-dependent activation and binding, we observed approximately 40-fold
discrepancies between the Ka and KD for both cGMP and cAMP, that cyclic nu-
cleotide binding is uncooperative, and that ∆53 lost selectivity for cGMP over
cAMP compared to wild-type. These results led to the following conclusions: 1)
Autoinhibition occurs in cis ; 2) Binding to the A-site is necessary and sufficient
for cGMP-dependent activation; 3) Selectivity for cGMP over cAMP within the
A-site is driven through contacts outside of the regulatory domain A-site (likely
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located in the N-terminus); 4) Cooperativity is driven in trans through interpro-
tomer contacts that are facilitated by the N-terminus which ensures monomers are
within close proximity to form these contacts. These conclusions suggest that co-
operative activation must be controlled through an inducible-dimeric interaction
and not through cooperative binding of cyclic nucleotide sites within the same
protomer (these models were described in Chapter 1.2.5). Furthermore, binding
to 1/4 of the sites appears to be sufficient for full activation of PKG Iα (i.e. acti-
vation of two catalytic domains within the homodimer). Thus, this model further
implies that its structure facilitates rapid activation of two catalytic domains in
response to cGMP.
In Chapter 3, we hypothesized that cysteine residues present in the cGMP-
binding A-site regulate oxidation-dependent activation of PKG Iα. To test this,
we introduced mutations at cysteine residues in PKG Iα that have been previously
implicated in mediating this activation mechanism (Landgraf et al., 1991). These
constructs, as well as the truncation construct that was characterized in Chapter
2, were used to test oxidation-dependent activation using both a synthetic pep-
tide substrate and the full-length substrate, KCa1.1. Using the synthetic peptide
substrate, we found that C42S and ∆53 were activated by oxidation with 500
µM H2O2, and furthermore, that C117S was not activated by oxidation whereas
C195S was. These results were corroborated by the patch clamp experiments in
the inside-out configuration and led to the following conclusions: 1) The interpro-
tomer disulfide bond between C42 and C42 does not mediate oxidative activation
of PKG Iα; 2) Oxidation at C117 is necessary and sufficient for activation via this
mechanism; 3) Activation requires high concentrations of H2O2 that may only
be achieved under pathophysiological conditions. Based on these conclusions, we
proposed a model wherein activation via oxidation is acheived through contacts
between the oxyacid at C117 and residues in the linker region between the au-
toinhibitory and regulatory domains rather than through disulfide formation with
C195.
4.1 Determining the source of cGMP selectivity in the A-
site
The data presented in Chapter 2 indicate that cyclic nucleotide selectivity
in the cGMP-binding site A (A-site) must be conferred through residues outside
of that domain. ∆53 was shown to have decreased selectivity for cGMP over
cAMP based on activity and cyclic nucleotide affinities for the A-site. Further-
more, PKG Iα1-326 also showed decreased selectivity for cGMP based on relative
affinities. Thus, both the catalytic domain and the N-terminus contribute to se-
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lectivity for cGMP. The SAXS analysis of ∆53 suggested that this construct was
similar in overall shape to the PKA holoenzymes (RIα:Cα and RIIβ:Cα). The
structure of PKA (PDB 2QCS) aligned with the crystal structure of the PKG
regulatory domain (PDB 3SHR) supports this hypothesis and indicate that the
guanine moiety of cGMP would be exposed to residues in the catalytic domain
as well as residues upstream of the autoinhibitory domain in the inactive state.
Similar analyses of the N- and C-terminally truncated forms of PKG Iβ
have not been performed to determine whether this isoforms confers selectivity
through contributions from these regions. Since the regulatory domains of both
isoforms are identical, selectivity must be conferred through one or both regions.
PKG Iα and Iβ are only 29% and 6% identical in the dimerization domain and
linker region, respectively (Appendix 2). Assuming the N-terminally truncated
isoforms exhibit the same phenotype of cyclic nucleotide selectivity loss, their
structural dissimilarity would be advantageous for narrowing down which residues
are involved. In the B-site, selectivity for cGMP over cAMP is driven through
binding to O6 of the guanine moiety by a conserved Arg residues at position 297
(Huang et al., 2014). In PKA, selectivity for cAMP appears to be driven by the
lack of residues that bind to the moiety—since the residues in that region are
aliphatic (Gly314 and Ala334)—rather than through specific residues that select
for adenine.
Figure 4.1: cGMP Binding Pocket of CNB-B and Its Comparison with the
PKA:cAMP Complex. Comparison between the PKG Iβ cGMP binding pocket
and PKA RIα cAMP pocket. The cGMP pocket of PKG Iβ in red is shown on
the left panel, and the cAMP binding pocket of PKA RIα (PDB code: 1RGS) in
gray is shown on the right. Key cyclic nucleotide binding residues are shown as
sticks. An ordered water molecule is shown as a blue sphere. (Huang et al., 2014)
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Figure 4.2: Mutational analysis to determine the residues dictate selectivity in
CBD-B. Ka values were measured using a microfluidic mobility shift assay, and
error bars denote SEM. (Huang et al., 2014)
4.2 The physiological role of oxidized PKG I
4.2.1 Observations based on the interprotomer disulfide bond that
forms between C42 and C42’
The observations described in Chapter 3 support the conclusion that ox-
idation at C42 does not mediate oxidation-dependent activation of PKG Iα. In
addition, we found that C42S displayed dramatically different characteristics from
PKG Iα wild-type. The in vitro phosphotransferase assay showed that C42S has a
3-fold higher Ka and a maximal activity that is half that of the wild-type enzyme.
Furthermore, application of inactive, reduced PKG Iα C42S, the reduced form
activated with cGMP, and the form oxidized with H2O2 caused an abundance of
short KCa1.1 channel openings (channel flickers), which were not observed with
PKG Iα wild-type. The phenylalkylamine-type KCa1.1 channel blockers, such as
verpamil and gallopamil, similarly induce flickers in dose dependent manners by
preventing transition of the channels to other states (Ballesteros et al., 2000).
C42S may induce flickers through a similar mechanism. Regardless, these obser-
vations collectively indicate the C42S construct does not behave the same as PKG
Iα wild-type.
The physiological significance of oxidation-dependent activation of PKG
Iα has been supported by experiments using the C42S knock-in mouse model
(Prysyazhna et al., 2012; Rudyk et al., 2013). However, the conclusions of those
studies rely on the assumption that reduced C42S behaves the same as PKG Iα
wild-type. Mutations in the leucine zipper of PKG Iα have been shown to disrupt
substrate targeting and result in hypertensive mouse models (Michael et al., 2008;
Surks and Mendelsohn, 2003; Surks, 2007). Thus, the hypertensive phenotype
observed with the C42S knock-in mouse model may also be due to augmented
substrate targeting abilities. This is supported by the complete inability of C42S
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to bind MYPT1 (Burgoyne et al., 2007). The cysteine to serine mutation intro-
duces hydrogen bond potential and can form different rotameric configurations
from cysteine, which could cause the C-terminal region of the helices to kink
(Ballesteros et al., 2000). This hypothesis could be tested by circular dichroism
to compare the helical contents of isolated wild-type and C42S leucine zipper con-
structs (residues 2-47). The channel flickering caused by application of inactive,
reduced C42S suggests that this phenomenon is independent from kinase activity,
and, thus, not caused by phosphorylation of a different residue on the channel,
and also suggests that KCa1.1 channel activity may be compromised even under
stimuli that induce vasoconstriction.
4.2.2 Measuring differences in substrate targeting between reduced
and oxidized PKG Iα
As discussed in Chapter 3, substrate phosphorylation by PKG Iα appears to
be driven through two independent facets: activation of PKG (i.e. exposure of the
catalytic domain through release of the autoinhibitory segment) and substrate tar-
geting through the dimerization domain. Moreover, loss of either abolishes PKG
Iα’s ability to phosphorylate substrates. Loss of substrate targeting independent
from catalytic activity was shown through mutational disruption of the leucine
zipper; this mutant was unable to phosphorylate the full-length substrates RhoA
and the MBS of MYPT1, but retained cGMP-dependent activation and ability to
phosphorylate the peptide substrate, BPDEtide (Blanton et al., 2013). Catalytic
activity was abolished by the T517A mutation which prevented phosphorylation
of the activation loop residue required to coordinate the catalytic core (Feil et al.,
1995). However, studies have rarely separated effects on targeting from catalytic
function, relying heavily on measurements of the endpoint—substrate phospho-
rylation. In Chapter 3, reduced and oxidized PKG Iα wild-type were shown to
increase the fold activations of the KCa1.1. This was surprising since there is an
approximate 4-fold difference in the maximal velocities of these two mechanisms
of activation (Reduced=4.39 vs. Oxidized=1.13 µmol×min-1×mg-1). Thus, one
could hypothesize that oxidation at C42 in the dimerization domain increases the
binding affinity for KCa1.1, which compensates for the poor catalytic activity. In-
creased substrate affinity of oxidized PKG Iα has been suggested previously, but
has not been highly scrutinized experimentally (Burgoyne et al., 2007; Kalyanara-
man et al., 2017).
To extend this further, one could hypothesize that the dimerization do-
mains of reduced and oxidized PKG Iα have different substrate targeting capabili-
ties, and by extension, that the cGMP and oxidation-dependent activation mech-
anisms preferentially target different substrates. Since cGMP has been shown to
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be ubiquitously produced throughout vascular smooth muscle cells (Nausch et al.,
2008), this would be pertinent to pools of PKG Iα close to sources of reactive oxy-
gen species (ROS) production. A two-pronged approach would be more rigorous
in testing this hypothesis:
1. A dual-labeling proteomics approach to detect differential phosphorylation
patterns of PKG Iα in isolated smooth muscle cells stimulated with either a
nitric oxide (NO) donor to stimulate cGMP production or with H2O2. H2O2
production could be stimulated by direct micro-injection into the cytoplasm.
Initially, a global cytoplasmic approach would be beneficial since there are
multiple intracellular ROS sources. Phosphorylation patterns caused by
stimulation of specific ROS sources could be used to discern their individual
contributions. However, this would require measuring the dose dependencies
of the stimuli used to generate ROS since catalytic activity of PKG Iα is
compromised by high H2O2 concentrations, possibly through formation of
irreversible cysteine oxidation states at C516 in the activation loop (the
region of the catalytic domain that coordinates the active site components).
2. Direct binding measurements of reduced and oxidized full-length PKG Iα and
the isolated leucine zipper domain to full-length PKG Iα substrates. The full-
length substrates could be limited to those that are firmly established in the
PKG field, such as KCa1.1, RhoA, RGS2, and MBS. To further cement the
observations of the PKG Iα C42S construct described in Chapter 3, the
binding affinities between substrates and the full-length C42S contrunct or
the isolated leucine zipper with the C42S mutation could also be tested.
Another critical experiment is to determine the oxidation potentials of the
cysteine residues in PKG Iα through cyclic voltammetry. If C42 is more sensitive
to oxidation than C117 (and assuming the hypothesis above regarding substrates
targeting is true), this would suggest that PKG Iα could have increased affinity
for substrates through its dimerization domain while retaining the ability to be
activated with cGMP. Furthermore, lower concentrations required to oxidize C42
would increase the likelihood that this effect is relevant under physiological condi-
tions. H2O2 concentrations in mammalian cells are estimated to average between
1-700 nM (Brewer et al., 2015). However, local levels caused by bursts in H2O2
production are suggested to greatly exceed the average value and depend on the
distance from the source and local concentrations of antioxidants, such as cata-
lase, glutathione peroxidases, and thioredoxin reductases. A recently developed
H2O2 sensor (HyPer-Tau) coupled with super-resolution microscopy suggests local
bursts can reach 50-100 µM (Warren et al., 2015). Our results in Chapter 3 show
that 100 µM H2O2 slightly increases the basal activity of PKG Iα, though it is
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unclear whether this is sufficient for phosphorylation of physiological substrates
(particularly if it is compensated by increased substrate affinity).
4.2.3 PKG Iβ as the REDOX resistant isoform
In Chapter 3, we found that PKG Iα exhibited a much greater response to
H2O2 compared to PKG Iβ, as shown by the greater increase in minimal velocity.
Since both isoforms displayed similar decreases in their maximal velocities, the
loss in cGMP sensitivity was much greater for oxidized PKG Iα. Conversely, these
data also suggest that PKG Iβ retains more of its cGMP-dependent activation
characteristics and may be considered the more ”oxidation resistant” isoform.
PKG Iβ in vascular smooth muscle cells is found tethered to the endoplas-
mic reticulum (ER) membrane where it phosphorylates the IP3- receptor associ-
ated cGK substrate (IRAG), resulting in decreased Ca2+ efflux from the ER into
the cytoplasm (Kato et al., 2015; Schlossmann et al., 2000). ER and mitochondria
can be in close proximity within cells, which facilitates crosstalk between the two
organelles (Marchi et al., 2014). Thus, some PKG Iβ localized to the ER would
be susceptible to ROS (superoxide) generated during ATP production. The pres-
ence of PKG Iβ, rather than PKG Iα, would ensure there is functional (cGMP
sensitive) PKG I in that cellular microdomain despite fluctuating ROS levels.
PKG Iβ is the only PKG isoform expressed in platelets and controls von
Willibrand factor-induced platelet activation and subsequent thrombus formation
(Li et al., 2003). These cells appear to have the highest metabolic demands rel-
ative to their size (diameter = ∼ 2-3 µm; volume = ∼ 10 µm3) with over half of
their ATP requirements achieved through oxidative phosphorylation (OXPHOS)
(Kramer et al., 2014). In contrast, vascular smooth muscle cells range between
20-500 µm in diameter (on the short and long axes, respectively) with an ap-
proximate cell volume of 800 µm3 (depending on the type of resistance vessel)
and have highly efficient metabolic processes to sustain actin/myosin-dependent
contractility (Luo et al., 2016; Yang et al., 2017). Thus, higher ROS generation
owing to the intrinsic characteristics of platelets (high OXPHOS rates in a small
space) may have exerted selective pressure for PKG Iβ expression over PKG Iα to
maintain cGMP-dependent activation capacity.
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Abstract
PKG is a multifaceted signaling molecule and potential pharmaceutical target due to its role in 
smooth muscle function. A helix identified in the structure of the regulatory domain of PKG Iα 
suggests a novel architecture of the holoenzyme. In this study, a set of synthetic peptides (S-tides), 
derived from this helix was found to bind to and activate PKG Iα in a cGMP-independent manner. 
The most potent S-tide derivative (S1.5) increased the open probability (NPo) of the potassium 
channel KCa1.1 to levels equivalent to saturating cGMP. Introduction of S1.5 to smooth muscle 
cells in isolated, endothelium-denuded cerebral arteries through a modified reversible 
permeabilization (RP) procedure inhibited myogenic constriction. In contrast, in endothelium-
intact vessels, S1.5 had no effect on myogenic tone. This suggests that PKG Iα activation by S1.5 
in vascular smooth muscle would be sufficient to inhibit augmented arterial contractility that 
frequently occurs following endothelial damage associated with cardiovascular disease.
Introduction
In arterial smooth muscle, type I cGMP-dependent protein kinase (PKG I) functions as a 
central signaling node for the nitric oxide (NO) and natriuretic peptide pathways that 
activate soluble and particulate guanylyl cyclases, respectively (Bian and Murad, 2007; 
Hofmann et al., 2009; Kemp-Harper and Schmidt, 2009; Kuhn, 2003; Potter et al., 2009). 
The subsequent production of cyclic guanosine-3’,5’-monophosphate (cGMP) by these 
enzymes leads to the activation of PKG. This is accomplished through direct binding of the 
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second messenger to the kinase (Lincoln et al., 1977; Pfeifer et al., 1999; Ruth et al., 1991). 
PKG I isoforms modulate excitation-contraction coupling in smooth muscle by reducing 
intracellular Ca2+ levels and promoting dephosphorylation of regulatory myosin light chains 
(Carrier et al., 1997; Feil et al., 2002; Kawada et al., 1997; Wellman et al., 1996; Wu et al., 
1998). This is complemented by PKG Iα phosphorylating the large conductance Ca2+-
activated potassium (KCa1.1/BK) channel (Schubert and Nelson, 2001). The PKG-mediated 
activation of the channel increases the flow of potassium ions across the membrane, 
hyperpolarizing the cell, inhibiting voltage dependent calcium channels (VDCCs), and 
thereby promoting vasodilation (Hofmann et al., 2014; Robertson et al., 1993; Sausbier et 
al., 2000).
All major therapies aimed at modulating blood flow through PKG-dependent mechanisms 
rely on regulating the rate of cGMP turnover, rather than the activity of PKG itself (Bryan et 
al., 2009; Evgenov et al., 2006; Kots et al., 2011; Salloum et al., 2012; Schlossmann and 
Hofmann, 2005). The use of PKG isoforms as pharmaceutical targets has been hampered by 
a lack of understanding of their mechanisms of activation due to their complex architectures. 
However, elucidating the regulatory mechanism of the PKG holoenzymes is central to 
guiding pharmacological discoveries relevant to prevention and treatment of vascular 
diseases. Recently, we solved the crystal structure of the intact regulatory domain of PKG I 
(Osborne et al., 2011). This structure exposed a unique helical domain that stabilizes an 
unexpected dimer interface between monomers in the asymmetric unit. Here we present the 
development of cGMP-independent peptide activators of PKG Iα, derived from this helical 
segment found bridging the regulatory and catalytic domains, and demonstrate their utility in 
intact tissue.
Results
PKG structure, design and synthesis of S-tides
The structure of of PKG Iα (78–355; PDB ID: 3SHR) identified an interaction formed by 
two bridging alpha helices between opposing protomers (Figure 1A) (Osborne et al., 2011). 
The complementary docking sites observed in either subunit are characterized by 
hydrophobic pockets located adjacent to the low-affinity cGMP binding sites. Each pocket 
buries over 1350 Å2 of surface area, and these interacting elements are conserved in PKG I 
isoforms (Moon et al., 2013). The C-terminal residues on the helix (F350, F351, N353, and 
L354) and a constellation of van der Waals and hydrogen bonds that form the 
aforementioned pocket were termed the “knob” and “nest,” respectively (Figure 1B). The 
hallmark of this interaction is the direct contact between the knob and residues that compose 
the nest, which also contribute to the formation of the phosphate binding cassette (PBC) 
(Figure 1C). It is the PBC — and its closure upon cyclic nucleotide binding — that 
facilitates the structural reorganization to release the catalytic domain in PKG. In full length 
PKG Iα, cooperativity was abolished through disruption of this unique interaction site 
(Osborne et al., 2011). Thus, we concluded that targeting the knob-nest site through 
synthetic, helical peptides may affect kinase activity. To this end, we synthesized the full 
alpha helical segment in PKG I comprising residues 329–358 (S1.1) and a series of peptides 
derived from this central sequence, subsequently denoted “S-tides” (Table 1).
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Preparation of cyclic nucleotide-free type I PKG isoforms
Previous purification methods of recombinant PKG I isoforms involved the use of cyclic 
nucleotide affinity chromatography, typically via agarose-linked cAMP (Dostmann et al., 
2000; Feil et al., 1993). However, in order to examine the cyclic nucleotide-independent 
effects of the aforementioned peptides on PKG I activity, enzyme preparations were 
required that did not encounter elevated cyclic nucleotide concentrations during the 
purification process. To meet this need, we engineered PKG Iα and Iβ constructs carrying a 
cleavable N-terminal hexahistidine tag for isolation by Ni-IMAC chromatography (see 
methods).
For both isoforms, purified kinase preparations reconstituted in in vitro assays demonstrated 
similar kinetic constants as have been previously reported (Figure S1A, S1B) (Dostmann et 
al., 1999; Dostmann et al., 2000; Feil et al., 1995; Feil et al., 1993; Landgraf et al., 1991; 
Ruth et al., 1991; Scholten et al., 2007). We found that cleavage of the hexahistidine tag did 
not alter kinase activation kinetics (Figure S1C). To further examine the influence of the 
purification method on the activity of the enzyme, we isolated the His-tagged PKG Iα by 6-
AEA-cAMP agarose affinity chromatography and observed no significant differences in its 
activation constants (Figure S1D). Although residual quantities of cAMP were detected 
following dialysis of PKG Iα purified by 6-AE-cAMP agarose, no detectable levels of 
cGMP or cAMP were found following the Ni-IMAC purification procedures of PKG Iα 
(Figure S2). In general, for our Ni-IMAC-purified PKG preparations, we observed low basal 
activities. This resulted in 20-fold and 15-fold increases in activity under saturating 
quantities of cGMP for PKG Iα and Iβ, respectively (Figure S1A, S1B).
S-tides act as cGMP-independent activators of PKG Iα
Any effect of S-tides on PKG Iα activity must be preceded by a binding event. Using 
surface plasmon resonance spectroscopy (SPR), we first examined the binding of the kinase 
to immobilized peptides. Repeated, single injections of PKG Iα on sensor chips covalently 
bound to a subset of S-tides found that PKG Iα associated with immobilized S1.1 and S1.5 
(Figure S3Aa, S3Ab), but not S-tides lacking the knob residues by deletion or mutation 
(S1.3 and S1.6). The sequence-scrambled derivative (S1.7) also did not bind to the kinase 
(Figure S3Ac). While the projected maximal association was predicted to be within 10 
minutes, this slow association was accompanied by an even slower dissociation of the kinase 
from the peptide-affixed surface (Figure S3Aa). To assess the reversibility of binding, 
peptide-affixed sensor chips were cleared of PKG using 1% SDS. Identical binding profiles 
were obtained for repeated injections of PKG followed by SDS washes. Next, PKG Iα was 
immobilized on the sensor chip and then probed with S-tides. Using this method, similar 
results were obtained (Figure S3B). However, these surfaces were unable to be regenerated 
by SDS, indicative of the sensitivity of PKG to denaturation by the detergent.
To examine the concentration-dependent effect of the S-tides on PKG activity, we needed to 
account for their apparent slow rate of association as assessed by SPR. Thus, all activity 
assays were performed under pre111 incubation conditions (15 minutes at 30°C, see 
methods). We observed robust and cooperative activation of PKG Iα by the parent 
compound, S1.1. As a control, we verified that S1.1 did not affect the KM for the substrate 
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peptide W15 (Figure S4) (Dostmann et al., 1999). An activation constant of 35 µM in the 
absence of cGMP reached maximal efficacy of 80% as compared to cGMP controls (Figure 
2A, Table 1). Shorter incubation periods resulted in dampening of the peptide’s potency (Ka 
= 300 µM) (Figure S5). Based on this observation, we concluded that our preincubation 
strategy provides the time necessary for S-tide association with the kinase, as corroborated 
by SPR.
Next, a series of S1.1 derivatives was analyzed to probe the roles of the C-terminal amino 
acids in activating PKG Iα (Table 1). Deletion of the first three C-terminal residues (S1.2) 
maintained native potency (Ka=35 µM) but exhibited decreased efficacy (60% of 
maximum). Further deletion of C-terminal residues that include the knob (S1.3) completely 
abolished kinase activity (Figure 2A), suggesting that these residues play a vital role in 
promoting kinase activation. Finally, we found that alanine substitution of two knob residues 
(F350A and F351A, as found in peptide S1.6) was equivalent to removal of the entire knob. 
Likewise, a scrambled control of the parent peptide (S1.7) did not activate the kinase (Figure 
S5A).
In general, we found that this first set of S-tides possessed helical secondary structure as 
assessed by circular dichroism (CD) spectroscopy (Figure 2C). Peptides S1.1 and S1.2 
displayed a similar degree of helicity; however, when the knob resides were deleted (S1.3), 
helicity was compromised but not completely lost. Mutation of the knob (S1.6) resulted in 
an increased degree of helicity. In contrast, the sequence-scrambled control (S.17) was 
found to not be helical (Figure S5B).
Next, we probed N-terminal deletions of S1.1. The S-tides S1.4 and S1.5, which had three 
and 6 amino acids truncated (Table 1), showed step-wise increases in potency to a minimal 
activation constant of 3 µM (S1.5), while retaining similar maximal velocities at 80% 
(Figures 2B and S6A). Further N-terminal truncations through single amino acid removal 
(S1.9–S.11) reversed this trend (Figures 2B and S6B). While the activation constants for 
S1.9 and S1.10 returned to values similar to S1.1, removal of one additional amino acid 
(D337, S1.11) resulted in a complete loss of activity. Moreover, for all N-terminal deletions, 
we observed a correlation between the loss in helicity and the loss in potency (Figures 2B, 
2D, and S7). Given that S1.5 was found to be the most potent activator for PKG Iα, we 
investigated its efficacy and potency for activating PKG Iβ. Interestingly, we observed no 
detectable activation of PKG Iβ using the S1.5 peptide (Figure S8).
S1.1 and S1.5 but not scrambled peptide increases KCa1.1 channel open probability in 
inside-out patches from VSM
To assess the functional relevance of the S-tides, we investigated their effects on the large 
conductance calcium-activated potassium channel (KCa1.1), as it is one of the few well-
established molecular targets of PKG Iα in VSM (Robertson et al., 1993; Sausbier et al., 
2000). Inside-out membrane patches derived from freshly isolated cerebral artery myocytes 
demonstrated consistent KCa1.1 channel openings in the presence of 500 nM Ca2+ for every 
experimental condition tested (Figure 3A, left panel). Upon addition of recombinant PKG Iα 
to the bath solution (cytosolic face) and in the presence of 50 nM cGMP to mimic basal 
levels of cGMP typically found in VSM (Francis et al., 1988; Jiang et al., 1992), we 
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observed no significant change in KCa1.1 open probability (NPo) (Figure 3A, right panel, 
3B). The addition of 5 µM cGMP to evoke saturating conditions was sufficient to raise the 
NPo eight-fold above the control (p<0.002) (Figure 3B). Similar to the activation by 
saturating cGMP, we observed that 100 µM S1.1 pre-incubated with PKG Iα substantially 
increased (6-fold, p<0.05) KCa1.1 channel activity. Likewise, 10 µM S1.5 gave near-
identical results (5-fold, p<0.002). This increase in NPo is consistent with PKG-mediated 
stimulation of the channel as previously described (Alioua et al., 1995; Alioua et al., 1998). 
In contrast, introduction of the scrambled control peptide S1.7 did not stimulate KCa1.1 
(Figure 3A, lower panel).
Paxilline-induced constriction is augmented in S1.5-treated arteries
Smooth muscle KCa1.1 activation represents a predominant vasodilatory, negative feedback 
mechanism in myogenically-active blood vessels (Nelson et al., 1995). Thus, we 
investigated the physiological effects of S1.5 on vessel diameter in the presence or absence 
of the KCa1.1 blocker paxilline. We selected S1.5 for its potency and selectivity toward 
recombinant PKG Iα. Because S1.5 was unable to cross the plasma membrane unaided, we 
introduced the molecule to intact arteries using a reversible permeabilization (RP) procedure 
as previously described (Earley et al., 2004) (see methods). RP utilizes the activation of 
P2X7 receptors that are specifically expressed in endothelium and VSM cells (Lesh et al., 
1995).
To test whether S1.5 was able to enter VSM cells through RP, we synthesized an S1.5 
analog containing an N-terminal fluorescein tag (FITC-S1.5). Posterior cerebral arteries 
(PCA) were exposed to either S1.5 or FITC-S1.5 using the RP protocol. Individual VSM 
cells were dissociated using papain and collagenase, and analyzed by confocal fluorescence 
microscopy. Smooth muscle cells from arteries treated with FITC-S1.5 showed clear 
internalization of the peptide with diffuse staining throughout the cytosol. VSM cells from 
arteries treated with non-labeled S1.5 did not fluoresce (Figure 4).
Next, we studied the functional effects of S1.5 in isolated arteries. S1.5 significantly reduced 
myogenic tone development in endothelium-denuded PCAs, as compared to controls (39% 
vs. 66%; p<0.05) (Figure 5Aa, 5Ab, 5Ac). Subsequent addition of the KCa1.1 inhibitor 
paxilline (1 µM) resulted in an additional constriction that was significantly greater in S1.5-
treated arteries than controls (26% vs. 5%; p<0.001) (Figure 5Ad). Interestingly, the 
maximal constriction (% constriction in the presence of paxilline) was not different between 
control and S1.5 treated arteries (Figure 5Ae). This indicates that the reduction in myogenic 
tone in the S1.5-treated arteries was due primarily to augmented KCa1.1 activity.
In PCAs with intact endothelium, we observed no significant difference in myogenic tone 
between control and S1.5-treated arteries, but found that paxilline caused a larger 
constriction in S1.5 treated arteries as compared to controls (12% vs. 4%; p<0.02) (Figure 
5Ba–d). However, as with endothelium-denuded vessels, maximal constriction in the 
presence of paxilline was not different between control and S1.5 treated arteries (Figure 
5Be). These data indicate that activation of endogenous PKG Iα by S1.5 leads to a net, 
KCa1.1 channel-driven relaxation of smooth muscle cells in intact posterior cerebral arteries.
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Discussion
PKG I activation is mediated through the modulation of cellular levels of cGMP and the 
activity of this kinase is a critical component of vascular function (Francis et al., 2010; 
Hofmann et al., 2009). The cGMP-independent modulation of PKG Iα activity in relation to 
KCa1.1 activity represents an attractive avenue toward novel therapeutic treatments of age-
related cardiovascular disease. Traditionally, exogenous stimulation of PKG has been 
accomplished by the use of cGMP analogs (Butt, 2009; Schwede et al., 2000). Although 
these compounds have served as valuable tools for studying PKG signaling, their clinical 
utility has remained elusive due to off-target effects, such as cross-activation of other cyclic 
nucleotide-binding proteins and modulation of phosphodiesterase activity. Here, we 
introduce a set of synthetic peptide activators (S-tides) derived from a novel structural 
element within the PKG I protein kinase. S-tides represent a potential new class of 
compounds, capable of eliciting vasodilation through a mechanism similar to that of nitrates 
and phosphodiesterase inhibitors (i.e., activation of PKG), but without the need for cGMP 
(Bryan et al., 2009; Kots et al., 2011; Schlossmann and Hofmann, 2005).
Biochemistry
We observed that isoform-specific PKG Iα activity can be promoted by S-tides in a cGMP-
independent manner. Truncation of the C-terminus of the S1.1 parent peptide in a form that 
removes or modifies the knob residues (F350, F351) produces peptides that do not stimulate 
kinase activity. The N-terminal truncations of the parent molecule provided an increase in 
potency followed by a dramatic reduction and, u ltimately, a complete loss of activity that 
was dependent on how many amino acids were removed. Concomitant with these shifts in 
the activation constant, we observed a positive correlation between activation of the kinase 
and helicity (Figure S7). We propose that stabilization of this helix by chemical means, as 
has been demonstrated with AKAP disruptors, may pose an additional avenue for further 
development of these activators (Kennedy and Scott, 2015; Wang et al., 2015).
The most potent peptide activator for PKG Iα (S.15) was unable to activate PKG Iβ, even 
though the type I isoforms of PKG retain 99% identity outside of their dimerization and 
autoinhibitory domains (Hofmann, 1995; Orstavik et al., 1997; Pfeifer et al., 1999; Sandberg 
et al., 1989; Wernet et al., 1989). The 10-fold difference in activation constants observed for 
PKG I isoforms by cGMP (Figure S1A, S1B) has been linked directly to these regions in the 
N-terminus (Ruth et al., 1997). The selectivity of S-tides for PKG Iα over Iβ may be 
governed by these differences.
The cGMP B-site can be divided into two parts; one containing the nest, and the other 
containing the cGMP-binding site (Figure 1C). Of note, part of the nest is formed by 
residues that construct the cGMP binding site. Residue W288 in addition to E291 and L294 
from the phosphate binding cassette (PBC) help form the ridge of the nest (Figure 1B). In 
the reported structure, L294 comes into proximity with F351’ upon docking of the knob. It is 
feasible that the interaction of the knob with the nest may affect the geometry of the PBC to 
mimic a closed, cGMP-bound state, not captured in the reported structure. Even in the 
absence of supporting structural data, we found that deletion or mutation of the knob 
residues in S-tides resulted in retarded activation of the kinase. This suggests a mechanism 
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indicative of the knob/nest interaction observed in the crystal structure of the intact 
regulatory domain. In any case, these molecules are efficacious and provide an unexplored 
avenue for the development of potent and selective cGMP-independent activators of PKG 
Iα.
Vascular Biology
In inside-out patches from posterior cerebral artery myocytes, S-tide incubation with PKG 
Iα stimulated KCa1.1 activity to a similar magnitude as saturating levels of cGMP. Basal 
level activity of PKG Iα in the presence of low nanomolar quantities of cGMP did not affect 
KCa1.1 open probability. Based upon these findings, we advanced the hypothesis that S-tide 
mediated stimulation of PKG Iα provides a basis for future attempts to modify PKG activity 
and effect physiological responses. This hypothesis was further supported by our 
observation that cerebral vascular myogenic tone was reduced in endothelium-denuded 
arteries exposed to S1.5. Of particular interest was our observation that paxilline-induced 
constriction was significantly augmented, suggesting that S1.5 stimulates KCa1.1 activity in 
vascular myocytes in situ. The minimal augmentation of tone by paxilline in endothelium-
intact vessels treated with S1.5 suggests that simultaneous activation of endothelial PKG and 
smooth muscle PKG has opposing effects. There is precedent for this interpretation, as 
activation of endothelial PKG acts as a negative regulator of NO release (Borysova and 
Burdyga, 2015; Dora et al., 2001). Our finding that endothelium-denuded vessels have 
decreased myogenic tone in the presence of S1.5 further reinforces this concept, and shows 
that activation of smooth muscle PKG could be sufficient to oppose the exaggerated 
myogenic tone that develops in response to endothelial damage associated with 
cardiovascular diseases such as hypertension and diabetes (Sun et al., 1994)(Huang et al., 
1993; Zimmermann et al., 1997). An important advantage of this type of potential 
therapeutic intervention is that S1.5 does not appear to negatively affect the development of 
tone in vessels where the endothelium is functioning normally.
Significance Statement
The control of vascular smooth muscle dilation and the regulation of blood flow are tightly 
linked to the rise and fall of cGMP, a small molecule that is made by vascular cells and is 
integral to proper circulatory function. This molecule controls the activation of a key 
enzyme, the cGMP-dependent protein kinase (PKG Iα), which is responsible for controlling 
a host of processes that regulate dilation of blood vessels independent of input from other 
body systems. All existing therapeutics that target this pathway either increase cGMP 
production or inhibit its breakdown. Here, we describe a novel class of small molecules, 
called S-tides, capable of activating PKG Iα, directly and selectively. S-tides also blunted 
the excessive constriction of blood vessels typical of arteries whose innermost layer is 
destroyed, which is often seen in hypertension and diabetes.
Materials and Methods
Recombinant Expression and Purification of PKG I isoforms
Expression in Sf9 cells using the Bac-to-Bac Baculovirus system (Life Technologies) was as 
previously reported (Dostmann et al., 2000). His-tagged proteins were isolated from Sf9 
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cells by homogenization followed by trapping on a Mini Profinity IMAC column (BioRad). 
Proteins were eluted using 250 mM imidazole and dialyzed into a final buffer of 50 mM 
MES, pH=6.9, 100 mM NaCl, 1 mM TCEP, and 10% glycerol. Full methods can be found 
in the SI Materials and Methods.
Peptide Synthesis
The solid-phase synthesis of the peptides was carried out as previously described (Nickl et 
al., 2010; Tegge et al., 2010). A full description of the methods can be found in the SI 
Materials and Methods.
Surface Plasmon Resonance
SPR measurements were conducted on a SR7500 dual-channel surface plasmon resonance 
spectrometer connected to an SR7100 autosampler using a standard, dual channel flow cell 
(Reichert Technologies). Gold sensorchips coated with 500 kDa carboxymethyl dextran 
hydrogel (Reichert Technologies) were used to immobilize PKG Iα or S-tides to the surface 
using EDC/NHS coupling chemistry at 25°C (Schasfoort and Tudos, 2008). Typically, 
250nM PKG Iα was injected onto the surface for 7 minutes. Dissociation times of 15 
minutes were recorded. A full description can be found in the SI Materials and Methods
Kinetic Analysis
Activity of recombinant PKG Iα toward the synthetic substrate peptide (W15, 
TQAKRKKSLAMA) was measured by γ32P-ATP incorporation assay as described with 
some modifications (Dostmann et al., 2000). Briefly, reactions were initiated when 0.1 mM 
γ32P-ATP (200–300 cpm/pmol) was incubated with vials preincubated with 50 mM MES, 
pH=6.9, 1 mM MgAcetate, 10 mM NaCl, 10 mM DTT, 1 mg/mL BSA, 10 µM W15 
substrate, 1 nM PKG Iα, and 10 µL of 10× S-tide stocks, in 100 µL reaction volume at 30°C. 
Prior to the initiation of the reaction, all components excluding γ32P-ATP were allowed to 
pre-incubate for 15 minutes. Each reaction was run for 90 seconds and terminated by 
blotting on 25 mm phosphocellulose circles (Whatman P81 filter paper, GE Life Sciences). 
Filters were washed 3 times in 0.8% phosphoric acid and measured by liquid scintillation 
counting. Data was analyzed using Excel (Microsoft), Prism 6 (GraphPad), and plotted using 
DataGraph (Visual Data Tools).
Circular Dichroism Spectroscopy
CD spectra were collected on a JASCO J-815 circular dichroism spectrometer at 22°C using 
a 2mm cuvette (Starna Cells). Data were collected on samples containing 10 µM peptide in 
10 mM PBS pH=7.4. A sampling range from 260 to 190 nm with a 0.5 nm sampling interval 
and 2 s integration time. A total of 10 accumulations were collected at 100 nm/min and 
averaged to produce the final spectra for each peptide.
Electrophysiology
Potassium channel activity was recorded as previously described (Brayden and Nelson, 
1992). Briefly, inside284 out membrane patches were obtained from enzymatically 
dispersed cerebral artery smooth muscle cells. The bathing solution (intracellular face) 
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contained (in mmol/L) 140 KCl, 2 MgCl2, 0.1 Mg-ATP, 10 HEPES (pH=7.3), and 3 EGTA. 
CaCl2 was added to the bath solution to achieve a concentration of 500 nM. The pipette 
solution contained (in mmol/L) 120 NaCl, 20 KCl, 2 MgCl2, 1 CaCl2, and 10 HEPES 
(pH=7.4). Single BK channel recordings were obtained over at least 5 minutes at a holding 
potential of +10mV in the absence and presence of purified PKG and various derivatives of 
the SW peptide. See SI Materials and Methods for a complete description.
Reversible Permeabilization and Myography
To introduce S1.5 peptide into the smooth muscle cytosol, isolated rat posterior cerebral 
arteries were reversibly permeabilized as described previously, see SI Materials and 
Methods (Earley et al., 2004; Lesh et al., 1995). Vessels were then placed in physiological 
saline solution (PSS) containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 KH2PO4, 24 NaHCO3, 
1.2 MgCl2, 2.0 CaCl2, 11 glucose, 0.026 EDTA (pH 7.4 at 37°C), and cannulated to 
resistance-matched micropipettes filled with PSS. Endothelial denudation was achieved by 
passing air bubbles through the vessel lumen. Intraluminal pressure was increased to 40 or 
80 mmHg using an electronic servo-pressure transducer (Living Systems, St. Albans, VT 
USA), and myogenic tone was allowed to develop (~45 minutes) prior to the addition of 
drugs. In endothelium-denuded vessels, denudation was confirmed by the absence of 
vasodilation to the SK/IK activator NS-309 (1 µM). During the experiment, vessel diameter 
was monitored continuously using a CCD camera and edge-detection software (Living 
Systems). At the end of each experiment, vessels were exposed to Ca2+-free PSS containing 
5 mM EGTA to determine the maximal passive diameter. All data were then normalized to 
the maximal passive diameter.
Smooth Muscle Cell Isolation and Confocal Fluorescence
Microscopy S1.5 peptide or FITC-S1.5 peptide were introduced into rat posterior cerebral 
arteries as described above. Vessels were then digested, using papain (0.5 mg/ml) with 
dithioerythritol (1 mg/ml) followed by Type F collagenase (1 mg/ml; Sigma Aldrich, USA). 
Smooth muscle cells were isolated by gentle trituration, and allowed to adhere to glass 
coverslips at RT for 30 minutes. Cells were then imaged using a Zeiss LSM 510 Meta 
confocal laser scanning microscope with a 63× oil-immersion objective (NA=1.4). Identical 
imaging conditions were used for smooth muscle cells containing control (S1.5) and 
fluorescent (FITC-S1.5) peptide.
Statistical Analysis
Arterial diameter data were analyzed using LabChart 7 Pro software (ADInstruments, 
Colorado Springs, CO, USA). Electrophysiological data were analyzed using pCLAMP 9 
software (Molecular Devices). For comparisons of two samples of equal variance, statistical 
significance between groups was determined using two-tailed, unpaired Student’s t-tests (α 
= 0.05). For multiple sample comparisons, one- and two-way ANOVA were used followed 
by Bonferroni’s post hoc analysis to compare individual means. P-values ≤ 0.05 were 
considered significant. These and all other relevant calculations were performed using 
Microsoft Excel (Microsoft Corporation, USA) and GraphPad Prism (GraphPad Software 
Inc., USA).
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Highlights
• S-tides are a new class of molecule capable of selectively activating PKG Iα
• S-tides target PKG Iα and elevate the open probability of K+ channels (BK, 
KCa1.1).
• S-tides modulate vascular contractility via PKG Iα effects on BK channels.
• S-tides dilate damaged arteries that have exaggerated myogenic tone.
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Figure 1. 
Structure of the cGMP B-sites (B and B’) from the regulatory domain of PKG Iα (A) 
emphasizing the asymmetric interaction of helical segments between protomers (PDBID: 
3SHR) (Osborne et al., 2011). The arrow indicates the directional view depicted in (B) 
detailing the interaction of the knob residues (F350’, F351’, L354’) with the nest (N353’ not 
depicted). C) Electrostatic surface representation of the cGMP B-site demonstrating its 
amino acid composition, the boundaries of the nest, and its location relative to the cGMP342 
binding site.
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Figure 2. 
Activation of PKG Iα by S-tides. Activity of PKG Iα was measured using peptides with (A) 
C-terminal truncations, modifications and (B) N-terminal truncation mutants derived from 
the parent compound S1.1. Activity is expressed as a percentage relative to 5µM cGMP for 
individual experiments. Values indicated are the mean +/− SD. Secondary structure 
determination of (C) C-terminal and (D) N-terminal truncation mutants as measured by CD 
spectroscopy. Mean residue ellipticity (θ) is expressed as mdeg × cm2/dmol × residue.
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Figure 3. 
Effects of peptide- or cGMP-treated PKG Iα added to the cytosolic face of excised, inside-
out membrane patches containing KCa1.1 channels A) Representative control (left) and 
experimental traces (right) of single KCa1.1 channel openings in excised membrane patches 
from cerebral artery myocytes. The combined results of single KCa1.1 recordings (B) 
demonstrate a substantially increased NPo versus control for saturating cGMP levels and S-
tides S1.1 and S1.5 († P<0.002, * P<0.05). Mean values with SEM are represented. Dashed 
line indicates normalized channel activity from control patches.
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Figure 4. 
Posterior cerebral arteries were subjected to reverse permeabilization with FITC-βAla2-S1.5 
(experimental, left panel) and S1.5 (control, right panel) peptides. Following digestion using 
papain and collagenase, single smooth muscle cells were imaged using differential 
interference contrast microscopy (DIC) and confocal fluorescence microscopy (CFM).
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Figure 5. 
A) Diameter measurements for endothelium-denuded, reversibly permeabilized arteries 
demonstrating myogenic tone response in (Aa) control and (Ab) S1.5-treated arteries. (Ac-
Ae) Summarized results of diameter measurements for endothelium-denuded arteries in 
control and permeabilized treatments are shown with values represented as the mean +/− 
SEM. Differences in myogenic tone in response to pressure (Ac) as well as paxilline-
induced constriction (Ad) are shown (P<0.05). Diameter measurements from endothelium-
intact arteries for controls (Ba) and S1.5-treated arteries (Bb) show unaltered myogenic tone 
response (Bc) but small differences in paxilline-induced constriction of control and S1.5 
treated arteries (Bd, P<0.02). For both sets of experiments, total constriction (Ae, Be) was 
unchanged between controls and S1.5-treated arteries.
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Table 1
S-tide composition and activation kinetics for PKG Iα
Name Sequence Ka (µM) nH N
S1.1 Ac-DVSNKAYEDAEAKAKYEAEAAFFANLKLSD-NH2 35 ±4 2.2 ±0.4 14
S1.2 Ac-DVSNKAYEDAEAKAKYEAEAAFFANLK-NH2 35 ±4 3.6 ±0.8 6
S1.3 Ac-DVSNKAYEDAEAKAKYEAEAA-NH2 - - 4
S1.4 Ac-NKAYEDAEAKAKYEAEAAFFANLKLSD-NH2 12 ±1 1.9 ±0.6 6
S1.5 Ac-YEDAEAKAKYEAEAAFFANLKLSD-NH2 3 ±1 2.4 ±0.6 8
S1.9 Ac-EDAEAKAKYEAEAAFFANLKLSD-NH2 43 ±5 2.7 ±0.7 6
S1.10 Ac-DAEAKAKYEAEAAFFANLKLSD-NH2 45 ±4 3.0 ±0.7 6
S1.11 Ac-AEAKAKYEAEAAFFANLKLSD-NH2 - 6
S1.6 Ac-DVSNKAYEDAEAKAKYEAEAAAAANLKLSD-NH2 - 4
S1.7 Ac-ALKSENYADKVEFKDAKYEASALANEFADA-NH2 - 4
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SI Methods: 
Recombinant Expression and Purification of PKG Iα.
 
Sf9  Expression:  PKG Iα and PKG Iβ from Bos  taurus  was sub-cloned from vectors containing PKG Iα 
(pCDNA3.1) and PKG Iβ (pAS2) into the pFAST-Bac HTA plasmid (Invitrogen). Sf9 cells (Invitrogen) were 
grown on plates in Graces media (Invitrogen) in the presence of 5% fetal bovine serum and 10µg/mL 
gentamicin. Upon observation of confluency, Cells were transferred into suspension in serum-free SF900-III 
media (Invitrogen) supplemented with 10 µg/mL gentamicin, lipids, and 0.1% Pluronic F-68 (Sigma). 
Maximum yield of protein expression was achieved between passages 9 and 14. Typically, 1 L of cell culture at 
1.2x106 cells/mL in 2.8 L Fernbach flasks with baffling (Chemglass) were infected in a 1:300 or 1:100 v/v ratio 
using a third amplification stock of baculovirus containing recombinant PKG Iα. Cell suspensions were 
incubated by shaking (80 rpm) at 27ºC for 72 hours. Cells were harvested via centrifugation at 500 x g for 15 
minutes at 4ºC. The supernatant was decanted and the pellet was resuspended in 15 mL of lysis buffer (5 mM 
TES pH=7.4, and 300 mM NaCl) for every 1L of cell culture. The pellets were flash frozen in liquid nitrogen 
and stored at -80ºC. 
Purification of PKG I isoforms by Ni-NTA: Pellets were thawed in a 37ºC H2O bath for 15 minutes. 1 mL of 
protease inhibitor cocktail (2 mM AEBSF, 0.3 µM Aprotinin, 130 µM Bestatin, 1 mM EDTA, 14 µM E-64, 1 
µM Leupeptin (Sigma)) was added to every liter of cell culture thawed and gently mixed by inversion. For 
every pellet, an equal volume of fresh lysis buffer was added and gently mixed. The resuspended cells were 
twice passed through a french pressure cell (SLM-AMINCO) at 25,000 psi. The lysed cells were then 
centrifuged at 30,000 x g for 30 minutes to separate insoluble cell debris from soluble protein. The pellets were 
either diverted to Ni-NTA or 6-AE-cAMP agarose purification. 
 For Ni-NTA purification, the supernatant was filtered (0.22 µm PES, Nalgene) and loaded onto a 5 mL 
Mini Profinity IMAC column (Bio-Rad) at room temperature. The column was washed with 20 mL of lysis 
buffer and loaded onto a Profinia purification system (Bio-Rad).  The column was washed with 30 mL of 5 mM 
TES, pH=7.4, 500 mM NaCl, and 20 mM imidazole and eluted by switching to buffer containing 250 mM 
imidazole. The peak fraction dialyzed twice against 2 L of 50 mM MES, pH=6.9, 100 mM NaCl, 1 mM TCEP 
and once against 1 L of 50 mM MES, pH=6.9, 100 mM NaCl, 1 mM TCEP, and 10% glycerol using 
SpectraPore 12-14 kDa MWCO dialysis tubing (SpectrumLabs). Typical concentrations of protein following 
dialysis were 1 mg/mL as determined by Bradford assay.  Proteins samples were aliquoted, flash frozen in liquid 
nitrogen, and stored at -80ºC. 
Purification of PKG Iα by 6-AEA-cAMP: 0.6 mL of 6-AEA-cAMP agarose resin was equilibrated with 
approximately 85 column volumes (CV) of lysis buffer (5mM TES, 300mM NaCl, pH 7.4). Clarified 
supernatant was passed over the column at a rate of approximately 1 mL/min and flow-through was collected. 
The resin was washed once with 20 CV of cold lysis buffer. PKG Iα was eluted with lysis buffer supplemented 
with 3 mM cAMP in 1CV or 2CV fractions. Eluates were collected with 15-minute incubations between 
collections. Fractions with protein were pooled and dialyzed overnight at 4°C into 50 mM MES, 100 mM NaCl, 
2 mM DTT, pH 6.9. The following day, protein was dialyzed three additional times with 3h incubations each at 
4°C and then dialyzed overnight into 50 mM MES pH=6.9, 100 mM NaCl, 1 mM TCEP, and 10% glycerol. 
PKG Iα was filtered post-dialysis and the final concentration was determined using the Bradford method. PKG 
Iα was aliquoted, flash frozen in liquid nitrogen, and stored at -80°C.  
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His-tag cleavage: The 3kDa N-terminal hexahistidine tag was cleaved from the purified protein by a 1:20 mass 
ratio incubation with TEV protease (Sigma) for 14 hours at 4ºC in 50 mM MES, pH=6.9, 100 mM NaCl, 1 mM 
TCEP, and 10% glycerol.  The hexahistidine tag and the TEV protease were removed by incubation of the 
reaction mixture with 0.5mL of PureProteome Ni-magnetic beads (Millipore) for 15 minutes at 4ºC. PKG Iα 
(beginning sequence “GAMDPSELEED…”) was recovered using a magnetic stand (Fisher Scientific) to isolate 
the beads from the supernatant containing the cleaved, recombinant enzyme. Final protein concentrations were 
assayed using the Bradford method.  Typical protein concentrations were 0.5 mg/mL following TEV cleavage. 
Protein samples were aliquoted and flash frozen in liquid nitrogen and stored at -80ºC. 
Peptide Synthesis. 
 Peptides were synthesized on a scale of 50 µmole with a Syro multiple peptide synthesizer 
(MultiSynTech, Witten, Germany) on Rapp S RAM resin (Rapp Polymere, Tübingen, Germany) for peptide 
amide formation. Fmoc chemistry with TBTU / diisopropylethyl amine activation with tenfold excess was 
employed. Coupling time was 1 h. Side chain protections of the amino acids were as follows: Asp, Glu, Ser, Thr 
and Tyr: t-Bu; Asn, Cys, Gln and His: Trt; Arg: Pbf; Lys and Trp: Boc. Peptides were cleaved from the resin and 
deprotected by a 3 hour treatment with TFA containing 3% triisopropylsilane and 2% water (10 ml/g resin). 
After precipitation with t-butylmethyl ether, the resulting crude peptides were purified by preparative HPLC 
(RP-18) with water/acetonitrile gradients containing 0.1% TFA and characterized by MALDI-MS. Final 
products were lyophilized from water. For the calculation of the concentration of stock solutions of the peptides 
for each basic amino acid (Arg, Lys and His) and for the free N-terminus one counter ion of trifluoroacetic acid 
(mol. weight 114.02) was taken into account. Fluorescein peptide labeling was carried out as previously 
described [1].  
Surface Plasmon Resonance.
SPR measurements were conducted on a SR7500 dual-channel surface plasmon resonance spectrometer 
connected to an SR7100 autosampler using a standard, dual channel flow cell (Reichert Technologies). Gold 
sensorchips coated with 500 kDa carboxymethyl dextran hydrogel (Reichert Technologies) were used to 
immobilize PKG Iα or S1.X peptides to the surface using EDC/NHS coupling chemistry at 25ºC. The standard 
buffer used for all loading and experimental data collection was composed of 50 mM MES, pH=6.9, 150 mM 
NaCl, 1 mM EDTA, 1mM TCEP, and 0.05% v/v Tween-20. Surfaces were cleared of electrostatically bound 
contaminants using a solution of 2 M NaCl and 10 mM NaOH injected for 5 min at 20 µL/min. A mixture of 90 
mM N-hydroxysuccinimide (NHS) and 250 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbiodiimide (EDC) in 1 
mL of 0.5 M MES, pH=5.5 was injected onto the surface for 5 minutes, followed by a buffer wash for 6 
minutes. Typically, 150 pmol of PKG Iα or 4 nmol of peptide was bound to the left channel in a buffer of 20 
mM Sodium Acetate, pH=5.0 over 10 min. Surfaces for both channels were protected using a 1 M solution of 
ethanolamine HCl, pH=8.0. To measure peptide binding to the PKG Iα-bound surface, 100 µM peptide in 
diluted into SPR running buffer was injected onto the surface for 7 minutes. For measurements of PKG binding 
to S1.X-coupled surfaces, 250nM PKG Iα was injected onto the surface for an equal amount of time. 
Dissociation time of 15 minutes were typically recorded. Data were analyzed using Integrated SPRAutolink 
(Reichert Technologies), Scrubber (BioLogic), and plotted using DataGraph (Visual Data Tools). 
Cyclic Nucleotide Analysis 
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 Preparations of PKG Iα were precipitated to release bound cyclic nucleotides.  Acetonitrile was added at 
a 1:1 v/v ratio by volume to 1.2 nmol (92.9 µg) of PKG Iα, buffer alone, or a 20 µM cAMP control. Samples 
were vortexed and incubated on ice for 1h with additional vortexing at 15 min intervals. Samples were 
centrifuged at 14,000 x g for 10min. Analytical gradient HPLC was performed with a LaChrom Elite instrument 
consisting of a L-2130 pump (set at 1.0 mL / min), a L-2400 UV detector (255 nm), a L-2350 column oven (30 
°C), and EZChrom software version 3.3.1 SP1 (all VWR-Hitachi, Hannover, Germany). YMC ODS-A 12 nm, 
S-11 µm (YMC, Dinslaken, Germany) was used as stationary phase in a 250 x 4.6 mm stainless steel column 
with Gemini C18, 4 x 3 mm security guardTM column (Phenomenex, Aschaffenburg, Germany). The mobile 
phase was 2.5 % 2-propanol, 25 mM triethylammonium formate (TEAF), pH 6.9. 
 Electrophysiology.
Middle cerebral, posterior cerebral, and cerebellar arteries were removed from 12-to-16 wk-old Sprague-
Dawley rats (Charles River Laboratories; St. Constant, Quebec, Canada) after euthanasia by a lethal dose of 
pentobarbital sodium and exsanguination. Arteries were then cleaned of connective tissue, cut into 2-mm 
segments, and placed in the following cell isolation solution (in mM): 60 NaCl, 80 Na glutamate, 5 KCl, 2 
MgCl2, 10 glucose, and 10 HEPES; pH 7.2. The segments were incubated at 37°C in 0.5 mg/ml papain and 1 
mg/ml dithioerythritol for 11 min, followed by 13 min incubation in 1.0 mg/ml type F collagenase. The digested 
segments were then washed three times in ice-cold bath solution and triturated to release myocytes. Cells were 
stored on ice in isolation solution for use the same day.
Single-channel currents were recorded from inside-out membrane patches obtained from freshly isolated 
arterial myocytes using an Axopatch 200B amplifier equipped with a CV203BU headstage (Axon Instruments). 
Recording electrodes (resistance, 4-5 MΩ) were pulled from borosilicate glass (1.5 mm OD, 1.17 mm ID; Sutter 
Instrument, Novato, CA). Currents were filtered at 0.5 kHz, digitized at 10 kHz, and recorded using pCLAMP 
software  (Axon Instruments), and were analyzed offline using Clampfit version 9.2. Patches were initially held 
at a membrane potential of 0 mV and single channel currents were recorded at a holding potential of +10 mV. 
All recordings were performed at room temperature (22°C). The bathing solution contained (in mmol/L) 140 
KCl, 2 MgCl2, 3 EGTA, 2.415 CaCl2, and 10 HEPES (pH 7.3). Free calcium in this solution was calculated as 
500 nM using the Ca-Mg-ATP-EGTA MaxChelator program (v1.0) (http://www.stanford.edu/~cpatton/
CaMgATPEGTA-NIST.htm). The pipette solution contained (in mmol/L) 120 NaCl, 20 KCl, 2 MgCl2, 1 CaCl2, 
10 HEPES (pH=7.4). Channel open probability (NPo) was calculated using the following equation: 
Where Po is the open state probability, tj = time spent in seconds with j = 1,2,....N channels open, N = max 
number of channels observed, and T = duration of measurement. 
Reversible Permeabilization 
Segments were first incubated for 20 minutes at 4oC in the following solution (in mM): 120 KCl; 2 MgCl2; 10 
EGTA; 5 Na2ATP; 20 TES; pH 6.8. Arteries were then placed in a similar solution containing S1.5 peptide (10 
µM) for 120 minutes at 4oC and then in a similar S1.5–containing solution with elevated MgCl2 (10 mM). 
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Materials and Methods
Recombinant Expression of PKG I↵. PKG I↵ from Bos taurus was cloned into
the pFAST-Bac HTA plasmid (Invitrogen) and expressed in Sf9 cells as previously
reported with some alterations [1]. Sf9 cells (Invitrogen) were grown on plates in
the presence of Graces media (Invitrogen) in the presence of 5% fetal bovine serum
and 10g/mL gentamicin. Upon observation of confluency, Sf9 cells were transferred
into suspension in SF900-III media (Invitrogen) supplemented with 10µg/mL gen-
tamicin. Maximum yield from protein expression was achieved between passages 9
and 14. Typically, 1 L of cell culture at 1.2x10
6
cells/mL in 2.8 L Fernbach flasks
with ba✏ing (Chemglass) were infected in a 1:300 or 1:100 v/v ratio with a third
amplification stock of baculovirus expressing recombinant PKG I↵. Cell suspensions
were incubated with shaking (80 rpm) at 27
 
C for 72 hours. Cells were harvested
through centrifugation at 500 x g for 15 minutes. The supernatant was decanted and
the pellet was resuspended in 5 mL of 5 mM TES pH=7.4, 300 mM NaCl for every
1L of cell culture. The pellets were flash frozen in liquid nitrogen and stored at -80
 
C.
Purification of PKG I↵ from insect cells. Sf9 cells expressing PKG I↵ con-
taining an N-terminal hexahistidine tag were thawed in a 37
 
C H2O bath for 15
minutes. 1mL of protease inhibitor cocktail (2 mM AEBSF, 0.3 µM Aprotinin, 130
µM Bestatin, 1 mM EDTA, 14 µM E-64, 1 M Leupeptin) (Sigma) was added to
every liter of cell culture thawed (15 mL) and gently mixed by inversion. Following
thawing of the pellet, an equal volume of fresh lysis bu↵ r (5 mM TES, pH=7.4, 300
mM NaCl) was added and gently mixed. The resuspended cells were passed, twice,
through a french pressure cell (SLM-AMINCO) at 25,000 psi. The lysed cells were
then centrifuged at 30,000 x g for 30 minutes to separate in oluble cell debris from
soluble protein. Following centrifugation, the supernatant was decanted and passed
through a 0.22 µm PES filter (Nalgene) and loaded at room temperature onto a 5
mL Mini Profinity IMAC column (Bio-Rad), that had been pre-equilibrated with lysis
bu↵er, at 0.5 mL/min. Following column loading, the column was washed with 20 mL
of lysis bu↵er. The column was loaded onto a Profinia purification system (Bio-Rad),
where the column was washed with 30 mL of 5 mM TES, pH=7.4, 500 mM NaCl,
20 mM imidazole, followed by an elution step of 50 mL of 5 mM TES, pH=7.4, 300
mM NaCl, 250 mM imidazole. The peak fraction was collected and dialyzed twice for
14 hours against 2 L of 50 mM MES, pH=6.9, 100 mM NaCl, 1 mM TCEP usi g
SpectraPore 12-14 kDa MWCO dialysis tubing (SpectrumLabs). A fi al dialysis into 1
L of 50 mM MES, pH=6.9, 100 mM NaCl, 1 mM TCEP, 10% glycerol for 3 hours was
performed prior to freezing. The N-terminal hexahistidine tag was cleaved from half
of the purified protein by a 1:500 molar ratio incubation with TEV protease (Sigma)
for 14 hours at 4C. The hexahistidine tag and the TEV protease were removed by
incubation of the reaction mixture with 0.5mL of PureProteome Ni-magnetic beads
(Millipore) for 15 minutes at 4C. PKG I↵ was recovered using a magnetic stand to
isolate the beads from the supernatant containing the cleaved, recombinant enzyme.
Final protein concentrations were assayed using the Bradford method. Protein sam-
ples were aliquoted and flash frozen in liquid nitrogen and stored at -80C.
Kinetic Analysis. Activity of recombinant PKG I↵ toward the synthetic sub-
strate peptide (TQAKRKKSLAMA) was measured by  32P-ATP incorporation assay
as described [XX]. Briefly, reactions were initiated when 1 nM PKG I↵ was incubated
with 50 mM MES, pH=6.9, 1 mM Mg(CH3CO2)2, 10 mM NaCl, 10 mM DTT, 1
mg/mL BSA, 10 µM substrate, and 0.1 mM  32P-ATP, in 100 µL reaction volume.
Each reaction was run for 90 seconds and terminated by blotting on Whatman P81
filter paper (GE Life Sciences). The blots were washed 3 times in 0.8% phosphoric
acid, and activity for each concentration measured by liquid scintillation counting.
Data were analyzed using Excel (Microsoft) fit to a dose-response curve using Prism
6 (GraphPad) and graphed using DataGraph (Visual Data Tools).
Peptide Synthesis. Synthesis of peptides was achieved as reported previously
[XX].
Surface Plasmon Resonance. SPR measurements were conducted on a SR7500
dual-channel surface plasmon resonance spectrometer connected to an SR7100 au-
tosampler using a standard, dual channel flow cell (Reichert Technologies). Gold sen-
sorchips coated with 500 kDa carboxymethyl dextran hydrogel (Reichert Technologies)
were used to immobilize PKG I↵ to the surface using EDC/NHS coupling chemistry
at 25
 
C. The standard bu↵er used for all loading and experimental data collection was
composed of 50 mM MES, pH=6.9, 150 mM NaCl, 1 mM EDTA, 0.05% v/v Tween-
20. The surface was cleared of electrostatically bound contaminants using a solution of
2 M NaCl and 10 mM NaOH injected for 5 min at 20 µL/min. A mixture of 90 mM
N-hydroxysuccinimide and 250 mM 1-Ethyl-3-(3-dimethylaminopropyl)carbiodiimide
(EDC) in 1 mL of 0.5 M MES, pH=5.5 was injected onto the surface for 5 minutes,
followed by a bu↵er wash for 6 minutes. Next, 150 pmol of PKG I↵ was bound to the
left channel in a bu↵er of 20 mM Sodium Acetate, pH=5.0 over 10 min. The surface
for both channels was protected using a 1 M solution of ethanolamine HCl, pH=8.0.
To measure peptide binding to the PKG I↵-bound surface, 100 µM peptide in diluted
into SPR running bu↵er was injected onto the surface for 7 minutes before washing for
15 minutes. The binding event was measured by subtracting the observed change in
refractive index units between the left and right channels. Data were collected using
Integrated SPRAutolink (Reich rt Technologies), analyzed with Scrubber (BioLogic),
fit to an association/dissociat on curve using Prism 6 (GraphPad), and graphed using
DataGraph (Visual Data Tools).
Electrophysiology. Middle cerebral, posterior cerebral, and cerebellar arteries were
removed from 12- to 16-wk-old Sprague-Dawley rats (Charles River Laboratories; St.
Constant, Quebec, Canada) after euthanasia by a lethal dose of pentobarbital sodium
and exsanguination. Arteries were then cleaned of connective tissue, cut into 2-mm
segments, and placed in the following cell isolation solution (in mM): 60 NaCl, 80
Na glutamate, 5 KCl, 2 MgCl2, 10 glucose, and 10 HEPES; pH 7.2. The segments
were incubat d at 37
 
C i 0.5 mg/ml papai and 1 mg/ml dithioerythritol for 11
min, followed by 13 m n incubation in 1.0 mg/ml type F coll genase. The digested
segments were then wash d three times in ice-cold bath solution and triturated to
release myocytes. Cells were stored on ice in isolation solution for use the same day.
Single-channel currents were recorded from inside-out membrane patches obtained
from freshly isolated arterial myocytes using an Axopatch 200B amplifier equipped
with a CV203BU headstage (Axon Instruments). Recording electrodes (resistance,
4-5 M⌦) were pulled from borosilicate glass (1.5 mm OD, 1.17 mm ID; Sutter In-
strument, Novato, CA). Currents were filtered at 0.5 kHz, digitized at 10 kHz, and
recorded using pCLAMP software (Axon Instruments), and were analyzed o✏ine using
Clampfit version 9.2. Patches were initially held t a membrane potential of 0 mV and
single channel curr nt were recorded at a holding po ential of +10 mV. All record-
ings were performed at room temperature (22
 
C). The bathing s lution contained
(in m ol/L) 140 KCl, 2 MgCl2, 3 EGTA, 2.415 CaCl2, and 10 HEPES (pH 7.3).
Free calcium in this solution was calculated as 500 nM using the Ca-Mg-ATP-EGTA
MaxChelator program (v1.0) (http://www.stanford.edu/ cpatton/CaMgATPEGTA-
NIST.htm). The pipette solution contained (in mmol/L) 120 NaCl, 20 KCl, 2 MgCl2,
1 CaCl2, 10 HEPES (pH 7.4). Channel open probability (NPo) was calculated using
the following equation:
NPo =
✓ NX
j=1
tj • j
◆
/T
Where Po is the open state probability, tj = time spent in seconds with j =
1, 2, ....N channels open, N = max number of channels observed, and T = du-
ration of measurement.
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Permeabilization was reversed by placing the arteries for 30 minutes in a MOPS buffered physiological solution 
containing (in mM): 140 NaCl; 5 KCl; 10 MgCl2; 5 glucose; 2 MOPS; pH 7.1, 22oC. Ca2+ was gradually 
increased in the latter solution from nominally calcium free to 0.01, 0.1, and 1.8 mM over a 45 minute period. 
Supplemental Figure Legends 
Figure S1 
Kinetic characterization of recombinant PKG Iα and Iβ expressed in Sf9 cells. A) Ni-NTA purified PKG Iα (see 
inset).  An overall robust stimulation (>20-fold) results from relative low basal activity. B) Ni-NTA purified 
PKG Iβ (see inset) is activated by cGMP and demonstrates >20-fold stimulation. Values for all traces are 
represented as the mean +/- SD. Velocity units are given in µmol PKG x min-1 x mg-1 substrate. C) Activation of 
PKG Iα in the presence (black) and absence (red) of a hexahistidine purification tag showed invariant activation 
parameters.  D) Activation of PKG Iα as purified by Ni-NTA (black) or cAMP-agarose (blue) chromatography. 
Although the Vmax of the cAMP-agarose purified kinase is somewhat dampened, we observed low basal activity 
and similar Ka values for both preparations. 
Figure S2 
HPLC-UV analysis of cyclic nucleotide content of purified, recombinant PKG Iα from Sf9 cells. HPLC traces 
for control quantities of buffer blank, 25µM cGMP, and 10µM cAMP are shown (top panel). The elution of 
cNMPs are plotted and listed at discrete times as standards. Resulting cNMP analysis from the extraction of Ni-
IMAC and cAMP-agarose purified PKG Iα (bottom panel). The Ni-IMAC purified PKG Iα did not show 
evidence of the presence of any cNMPs whereas the cAMP-agarose purified PKG Iα sample contained trace 
amounts of cAMP. 
Figure S3 
Surface plasmon resonance (SPR) recordings for peptide-affixed (Aa-Ac) and PKG Iα-affixed (B) sensor chips. 
(Aa) S1.1, (Ab) S1.5, and (Ac) control peptides were affixed to individual sensor chips and exposed to single 
injections of PKG Iα. To confirm these observations, PKG Iα was affixed to the surface (B) and exposed to 
single injections of the indicated peptides. The kinase/peptide complexes did not readily dissociate during either 
of these experiments.  
Figure S4 
A) Michealis-Menten analysis of substrate (W15) dependence on PKG Iα activation by cGMP and S1.1. 
Normalized activity of PKG Iα from activation with cGMP (black) or S1.1 (red) under varying concentrations 
of peptide substrate. The Km values (2µM) for substrate in S1.1 activation is invariant from cGMP. This result 
indicates that the binding of the parent peptide does not interfere with substrate binding in the catalytic domain.  
B) S1.1 activation of recombinant PKG Iα normalized to 5µM cGMP activity under preincubation (black) and 
direct exposure (red) conditions. For direct exposure conditions, S1.1 was added into the reaction mixture in the 
absence of PKG. To initiate these reactions, PKG was added to the mixture. The reactions were terminated after 
90 sec by blotting on P81 filter paper (see methods). Under direct exposure, the activation of PKG Iα by S1.1 is 
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shifted compared to that of preincubation conditions. The observation corroborates the SPR data collected 
indicating that the peptide requires minutes to fully associate with the kinase. 
Figure S5 
A) An asssay of S1.1 with PKG Iα compared to S1.7 scrambled control shows that the sequence scrambled 
control does not activate the kinase. Further, the scrambled control is disordered (B) as determined by CD 
spectroscopy. 
Figure S6 
The complete set of N-terminal truncation peptides and their activation of PKG Iα. Kinase activities were 
measured using modified peptides with (A) 3 and 6-residue truncations compared to S1.1 activity and (B) single 
amino acid truncations thereafter. We observed that as single amino acid changes were introduced starting at 
E336, potency was lost. This loss in potency seems to correlate with the secondary structure of the peptide 
(C,D). Even though the knob residues were present, the overall secondary structure of the peptide contributes to 
the ability of the peptide to activate the kinase. Activity is expressed as a percentage of activation relative to that 
of 5µM cGMP velocities for individual experiments. Values indicated are the mean +/- SD. Mean residue 
ellipticity (θ) is expressed as mdeg x cm2/dmol x residue. 
Figure S7 
Plot of mean residue ellipticity (θ at 222nm) and activation constants observed for PKG Iα for the indicated 
peptides shows a positive correlation between helicity and activity. In general, we observed that as helicity 
increased, as seen from S1.1 to S1.5 and S1.5, potency also increased. Moreover, the loss of activation of PKG 
Iα associated with S1.9-S1.11 was also correlated with a loss of helicity, provided that the knob residues were 
unmodified. 
Figure S8 
Activation assay of PKG Iα (blue) and Iβ (red) by S1.5 demonstrating that S-tides selectively activate PKG Iα. 
Activity is represented as a percentage relative to 5µM cGMP. Values indicated are the mean +/- SD. 
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Appendix B
Sequence alignment of PKG Iα and Iβ isoforms
expressed in placental mammals.
PKG Iα and Iβ sequences were obtained from the National Center for
Biotechnology Information (NCBI) database on Feb. 19, 2018. The initial search
for ”cGMP-dependent protein kinase” and ”placentals” resulted in 4586 hits. The
list was filtered by sequence length (600-700) and excluding of predicted and re-
dundant sequences. The final list included 45 sequences (Iα=24; Iβ=21) and were
organized by order. Sequences were aligned and analyzed in Jalview V2 using
Clustal OWS and colored using BLOSUM62 scoring (Sievers et al., 2011; Water-
house et al., 2009).
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Appendix C
Protocol Development
C.1 Sf 9 cell culture
C.1.1 Growth and maintenance of Sf 9 cells
C.1.1.1 Starting Sf 9 cell culture from frozen stocks
Reagents: Grace’s Insect Cell Culture Medium (Life Technologies, 11300-043);
heat inactivated fetal bovine serum (FBS; Life Technologies, 10082-139); 1000×
lipid mix (Sigma, L5146); Sf900 III medium (Life Technologies, 12658-027); 10%
Poloxamer 188 Solution (Sigma, P5556).
1. Prepare Grace’s Insect Cell Medium
(a) Dissolve Grace’s Insect Cell Medium in approximately 500 mL of sterile
ddH2O.
(b) Add 0.35 g NaHCO3.
(c) Add 50 mL of FBS (0.5% final).
(d) Adjust the pH to 6.0.
(e) Add 1 mL of 10 mg/mL gentamicin (10 µg/mL final).
(f) Sterile filter the medium into an autoclaved bottle for light sensitive
solutions or wrap in aluminum foil.
(g) Store medium at 4°C.
2. Prepare Suspension Medium
(a) To 1 L of Sf900 III medium, add 1 mL of 10 mg/mL gentamicin, 1 mL
of 1000× lipids, and 10 mL of poloxamer 188 solution (0.01% final).
3. For culturing cells in Grace’s Insect Cell Culture Medium:
(a) Thaw 10×106 Sf 9 cells by warming the vial(s) in your hands.
(b) Transfer cells to 25 mL of Grace’s medium in a 25 mL cm2 flask.
(c) Let the cells adhere 1 h and then replace the old medium with fresh 25
mL of Grace’s medium.
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(d) Incubate cells at 27 °C.
(e) Replace medium the following day and again thereafter every 2 days.
(f) When cells are 85-90% confluent, mechanically detach cells by hitting
the side of the flask a few times.
(g) Centrifuge the cells at 500 ×g.
(h) Decant the supernatant and suspend the cells in 25 mL of suspension
medium; transfer the cells to a sterile, baffled flask. The medium should
cover the entire bottom surface of the flask, but the volume should not
exceed 30% of the total flask volume (for sufficient aeration).
(i) Incubate cells at 27°C, 80 rpm.
(j) Cells should be passaged every 3.5 days to 1.2×106 cells/mL. Check
the cells viability and density as described in Section C.1.2. My obser-
vations of cell growth patterns have suggested that healthy cells secrete
growth factors that promote continued rapid proliferation. Therefore,
medium should be added to the flask rather than performing a complete
medium change.
4. Frozen cell stocks that are very healthy can be directly grown in Suspension
Medium rather than Grace’s Insect Cell Medium. For culturing in Suspen-
sion Medium:
(a) Thaw cells as described above. Suspend 10×106 Sf 9 cells in 25 mL of
Suspension Medium.
(b) Transfer the cells to a sterile, baffled flask (see above for more details
regarding flask volume).
(c) Incubate cells at 27°C, 80 rpm.
(d) Allow cells to proliferate for 5 days or until cells reach between 7-10
×106 cells/mL (whichever occurs first).
(e) Passage cells every 3.5 days as described above.
C.1.2 Determination of cell density and viability
Goal: Determine Sf 9 cell viability and density.
Reagents: 1x Phosphate buffered saline pH 7.4; trypan blue (stock is 20×).
1. Make a 10× stock of PBS: 87.6 g NaCl, 5.52 g NaH2HPO4 (sodium phos-
phate monobasic, monohydrate), 16.1 g Na2HPO4 (sodium phosphate, diba-
sic, heptahydrate), 20 mL tween 20. Adjust pH to 7.4 and QS to 1 L.
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2. Add 200 µL of Sf 9 cells to 800 µL of 1× PBS in a 10 mm tissue culture
dish.
3. Let cells adhere for 10 min and then visualize by light microscopy at 10×
magnification.
4. Most of the cells should be adherent to the surface of the dish. Move the
solution in the dish gently to confirm. Cells should be golden yellow in color
with nuclei that encompass approximately 50% of the total cell volume.
Cells that are dead/dying will look gray.
5. Dilute cells in 1× PBS with 1×trypan blue using a dilution factor between
20 and 50. The optimal dilution factor (DF) will depend on the density of
the cells.
(a) 20 = 20 µL cells + 380 µL trypan/PBS;
(b) 30 = 20 µL cells + 580 µL trypan/PBS;
(c) 40 = 20 µL cells + 780 µL trypan/PBS;
(d) 50 = 20 µL cells + 980 µL trypan/PBS.
6. Load 10 µL of diluted cells into each chamber of the hemacytometer.
7. Count ten squares (5 from each side) as shown in Figure C.1. There should
be between 100-200 cells total in the ten squares. If not, make a new dilution
with a different dilution factor and recount.
8. The following formula is used to calculate the approximate cell density:
Cells
Squares
×DF × 104
C.2 Expression of PKG I constructs using the Sf 9/Baculovirus
system
C.2.1 Blue-White Screening
Goal: Transpose the gene of interest from pFAST Bac HTA into bacmid.
Reagents: construct (pFAST Bac HTA containing your protein of interest); LB
medium; KGTI plates (LB agar containing 50 µg/mL kanamicin; 7 µg/mL gentam-
icin; 10 µg/ mL tetracycline, and 40 µg/mL isopropyl β-D-1-thiogalactopyranoside
(IPTG)).
178
Figure C.1: Setup for counting Sf 9 cells on a hemacytometer. For each side of
the hemacytometer, the cells from the 5 squares shown below (red boxes) should
be counted.
1. Thaw vial of chemically competent DH10 Bac E. coli on ice for 10 min.
2. Add approximately 50 ng of construct to E. coli.
3. Incubate E. coli tube on ice for 30 min.
4. Incubate E. coli tube at 42°C for 30 sec and then on ice for 2 min.
5. Under semi-sterile conditions, add 100 µL of LB medium to the tube.
6. Place the tube in a 125 mL flask and shake E. coli for 5 h, 220 rpm, 37°C.
7. Prepare a 20 mg/mL stock of X-gal in 100% DMSO; spread 120 µL onto
a KGTI plate and let dry. The X-gal and spreading on the plate should
always be performed the same day as use.
8. Plate E. coli on KGTIX plate.
9. Grow E. coli at 37°C for approximately 24 h. The cells should be approxi-
mately 1-2 mm in diameter without growing into each other.
10. Incubate the plate at 4°C until blue and white colonies are easily distin-
guishable.
11. Choose two single colonies that are clearly and completely white.
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12. For each colony, use a 10 µpipette tip to pick up the colony and deposit it
on a new KGTIX plate. Use a sterile loop to streak the colony 3× as shown
in Figure XX.
C.2.2 Bacmid Isolation
Goal: Isolate bacmid from single, white DH10 Bac E. coli colonies
Reagents: 1x LB broth, 50 mg/mL kanamicin; 7 mg/mL gentamicin; Qiagen
buffers P1, P2, and N3; 100% isopropanol; 70% ethanol; sterile ddH2O; 3 M KOH
(optional).
1. Suspend white colonie(s) in 6 mL of LB with 50 µg/mL kanamicin and 7
µg/mL gentamicin. Grow suspensions overnight (approximatyely 16 h) at
37°C, 220 rpm.
2. Centrifuge suspensions at approximately 3000 ×g for 5 min and discard
supernatant.
3. Suspend pellet in 300 µL of 50 mM Tris-HCl, 10 mM EDTA, pH 8.0, 50-100
µg/mL RNase A (Qiagen Buffer P1). Transfer suspension to a 1.5 mL tube.
4. Add 250 µL of 200 mM NaOH, 1% SDS (Qiagen Buffer P2); solution turns
blue if the LyseBlue indicator is present.
5. Add 350 µL of 4.2 M guanidine hydrochloride (GuHCl), 0.9 M potassium
acetate, pH 4.8 (Qiagen Buffer N3). Invert tubes gently to mix.
6. Centrifuge samples at approximately 15,000 ×g for 20 min.
7. Transfer supernatant to a 2 mL tube, add 800 µL of 100% isopropanol, and
mix gently by inverting the tube.
8. Store samples at -20°C overnight (the longer the better). Samples can be
stored for at least one month to preserve bacmid potency.
9. Centrifuge sample at approximately 15,000 ×g for 30 min at 4°C to pellet
the DNA. The pellet should be easily visible.
10. Discard supernatant and add 1 mL of ice cold 70% ethanol. Incubate sample
at 4°C for 10 min.
11. Centrifuge sample for 10 min. at 4°C
12. Repeat steps 10-11 at least 6 times to ensure sufficient removal of salts.
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13. Discard supernatant. With the tube cap open, invert the tube over a kim
wipe and allow pellet to dry. The pellet will change from white to translu-
cent.
14. Add 200 µL of sterile ddH2O, and store bacmid at 4°C overnight. Do not
mix the sample, because pipetting can shear the DNA.
15. The bacmid should be in solution. However, if pellet is still visible, pipette
gently a few times to bring into solution. Do not pipette too many times;
the bacmid will not go into solution if the concentration is very high. Check
the concentration of DNA using a Nanodrop. Add more sterile ddH2O to
achieve a final concentration of 500 ng/µL. Pipette the bacmid up and down
a few times to ensure it is fully in solution.
16. If the salt concentration is too high (260/230 < 1.7), add KOH to a final
concentration of 0.3 M. Add 2 volumes of cold 100% ethanol (1 V = sample
+ KOH). Invert to mix and incubate at -20°C for at least 30 min. Return to
step 9 and complete procedure to step 15 with more wash steps than were
performed previously.
C.2.3 Bacmid Analysis by M13 PCR
Goal: Analysis of bacmid to confirm successful transposition of the gene of interest
into pFAST BAC HTA. This protocol uses DreamTaq (Invitrogen); however, it
can be adapted to use other polymerase/buffer sets.
Reagents: M13 forward primer- CCCAGTCACGACGTTGTAAAACG; M13 re-
verse primer-AGCGGATAACAATTTCACACAGG; DreamTaq polymerase; agarose;
SYBR Safe.
1. Set up PCR reaction(s) as shown in Table C.1.
Table C.1: M13 PCR Reaction Setup
Reagent Volume (µL)
Bacmid (500 ng/µL) 0.3
DreamTaq (2x) 25.0
Forward primer (5 µM) 1.0
Reverse primer (5 µM) 1.0
ddH2O 22.7
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2. Spin down the samples and run the PCR reaction(s) in the Thermocycler
as shown in Table C.2. Note that the annealing temperature is lower than
the value recommended in the Bac-to-Bac Baculovirus Expression System
protocol (Invitrogen).
Table C.2: M13 PCR Thermocycler Procedure
Step Temperature Time (min) Description
1 95°C 1:30 Hot start
2 95°C 0:45 Denaturation
3 50°C 0:45 Annealing
4 68°C 5:00 Extension
5 Go to 2, 30x - Cycle
6 68°C 7:00 Final extension
7 4°C Forever Storage
3. Load the sample(s) and a DNA ladder on a 1% agarose gel. Separate the
bands (approximately 100 V for 30 min). Image bands at 230 nm.
4. Successful transposition of the gene of interest into pFAST Bac HTA is
determined based on the size of the bands. Bands should be approximately
2430 bp + insert size bp.
C.2.4 First Amplification Baculovirus
Goal: Transfect bacmid into Sf 9 cells to produce first amplification baculovirus.
Reagents: Sf 9 cells in mid-log phase; Cellfectin (Invitrogen); unsupplemented
Sf900 III (Invitrogen) (no lipids, gentamicin, or poloxamer-81), Sf900 III sup-
plemented with 1× lipids (Sigma), 10µg/mL gentamicin (Sigma), and 0.01%
poloxamer-81 (Sigma).
Notes: This protocol is for a single, white bacmid isolate that has been confirmed
for successful transposition of the gene of interest by M13 PCR. All steps should
be performed in the hood under sterile conditions. Sf 9 cells should be in mid-log
phase of growth and appear healthy as described in Appendix 3.2.
1. Passage Sf 9 cells at 0.5 × 106 cells/mL in 15 mL of unsupplemented Sf900
III medium.
2. Add 2 mL of cells per well to a 6 well tissue culture plate (tissue culture
treated, non-pyrogenic, polystyrene).
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3. Incubate cells in the hood for 30 minutes to allow them to adhere to the
bottom of the wells. Replace medium with fresh 2 mL of unsupplemented
Sf9000 III medium. Label plate as shown in Figure C.2.
Figure C.2: Plate setup for transfection of Sf 9 cells with bacmid
4. Prepare bacmid in 1.5 mL tubes as shown in Table C.3. Bacmid stocks
should be 500 ng/µL. There will be two wells per bacmid condition. How-
ever, this preparation step assumes there are 3 wells per condition to ensure
there is enough material for subsequent steps. Once the bacmid have been
added to the tubes, add 300 µL of unsupplemented Sf900 III medium to
each tube (100 µL per well).
Table C.3: Bacmid preparation for transfection into Sf9 cells
Well Condition (µg Bacmid) Bacmid (µL) Wells Total (µL)
0 µg 0 3 0
1 µg 2 3 6
2 µg 4 3 12
5. Prepare Cellfectin in a 10 mL conical. Each well will contain 6 µL of Cell-
fectin during the transfection:
• 6 µL Cellfectin × 9 wells (3 per condition) = 54 µL Cellfectin
• + 900 µL of unsupplemented Sf900 III medium to the conical (100 µL
per well).
6. Add 300 µL of Cellfectin to each bacmid tube condition. Incubate tubes in
the hood at room temperature for 30 min.
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7. Add 200 µL dropwise of either Cellfectin alone (control), the 1 µg bacmid/
Cellfectin condition, or the 2 µg bacmid/ Cellfectin condition to the corre-
sponding wells in the tissue culture plate containing the Sf 9 cells. Tilt the
plate back and forth a few times to ensure the cells are evenly coated in the
added solutions.
8. Incubate cells in the hood at room temperature for 5 h.
9. Remove the medium and replace with Sf900 III medium supplemented with
1× lipids (Sigma), 10µg/mL gentamicin (Sigma), and 0.01% poloxamer-81
(Sigma).
10. Incubate cells at 27°C and monitor daily for signs of infection as indicated
in Table C.4 and Figure C.3. The infection should be easily apparent by
day 4 post transfection.
Table C.4: Characteristics of Sf 9 cell infection with baculovirus
Stage of Infection Day Control Condition Bacmid Condition
Early 1-2 Some fibroblastic Some fibroblastic
Golden yellow cytoplasms
Cessation of cell growth
Mid 3-5 90-100% confluent Increased cell diameter
Large, dense, granular nuclei
Golden yellow cytoplasms
Cells detach from the plate
Some cellular debris
Late 6-7 Growing on top Many cells turn dark
of each other Many lysed cells
Much cellular debris
11. When cells reach late stage infection, scrape cells from the bottom of the
wells using a cell scraper. Pool liquid from both wells of the same condition.
12. Centrifuge samples at 500 × g for 5 min.
13. Transfer supernatant to a light sensitive 15 mL conical. Label the conical
with the construct information, viral amplification number, colony isolate
number, and the date. E.g. PKG Iα P1.1.1 022718 (first amplification; first
colony isolate, first batch). The labeling is important if these stocks will be
used for subsequent amplification batches after the initial third amplification
stock has lost its effectiveness.
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Figure C.3: Stages of Sf9 cell infection A. Healthy Sf9 cells. The white box
indicates a representative healthy cell characterized a golden-colored cytoplasm
and nucleus that is approximately 50% of the total cell body; B. Overgrown Sf 9
cells. Cells are very dense and starting to grow on top of each other. C. Sf 9 cells
that have reached mid stage infection. The white box indicates a representative
infected cell characterized by a large, dense nucleus that occupies greater than 50%
of the total cell body. D. Sf 9 cells that have reached late stage infection. Most
cells have lost their golden color, which is indicative of cell death. There is much
cellular debris due to cell lysis. The white box indicates a large, representative
dead cell characterized by a dark cytoplasm. All images were captured using an
Apple iPhone SE and a light microscope at 10× magnification.
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14. Store virus at 4°C.
C.2.5 Second Amplification of Baculovirus
Goal: Perform second amplification of baculovirus.
Reagents: Sf 9 cells; Suspension Medium (Sf900 III supplemented with 1× lipids,
10µg/mL gentamicin, and 0.01% poloxamer 188 solution.
Notes: Sf 9 cells should be in mid-log phase of growth and appear healthy as
described in Appendix 3.2.
1. Seed cells at 1 × 106 cells/mL (25 mL) in a 75 cm2.
2. Allow cells to adhere for 1 h.
3. Add 200 µL of first amplification virus to the cells; tilt the flask back and
forth to ensure even distribution of the virus.
4. Monitor cells daily for signs of infection based on Table C.4.
5. At late stage infection, the virus should be harvested (approximately 7 days
post infection).
6. Dislodge cells from the bottom of the flask using a cell scraper.
7. Collect media and transfer to a sterile 15 mL conical.
8. Centrifuge the conical for 5 min at 500 ×g, 4°C.
9. Transfer the supernatant to a sterile light sensitive 15 mL conical. Label
using the same scheme as described for the first amplification virus (e.g.
Construct; P2.1.1; Date of harvest; Initials).
10. Store virus at 4°C.
C.2.6 Third Amplification of Baculovirus
Goal: Perform third amplification of baculovirus.
Reagents: Sf 9 cells; Sf900 III supplemented with 1× lipids (Sigma), 10µg/mL
gentamicin (Sigma), and 0.01% poloxamer 188 (Sigma).
Notes: Sf 9 cells should be in mid-log phase of growth and appear healthy as
described in Appendix 3.2.
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1. Seed cells at 1.0 × 106 cells/mL (40 mL) in a 125 mL baffled flask.
2. Add 2.5 mL of second amplification virus to the flask.
3. Incubate cells at 27°C at 80 rpm.
4. Monitor cells for signs of infection (Table C.4) every other day by viewing
a sample by light microscopy.
5. At late stage infection, harvest the virus by centrifuging at 500 ×g for 5 min
and transferring the supernatant to a 50 mL light sensitive conical.
6. Label conical with virus information as described for the first amplification
virus (e.g. Construct; P3.1.1; Date of harvest; Initials).
7. Store virus at 4°C.
C.2.7 Test Expressions of PKG I
Goal: Test the expression potency of third amplification baculovirus.
Reagents: Sf 9 cells; Sf900 III supplemented with 1× lipids (Sigma), 10 µg/mL
gentamicin (Sigma), and 0.01% poloxamer 188 (Sigma).
Notes: Sf 9 cells should be in mid-log phase of growth and appear healthy as
described in Appendix 3.2.
1. Prepare 4 flasks of Sf 9 cells seeded at 1.5 × 106 cells/mL (40 mL) in 125
mL baffled flasks.
2. Let cells recover for at least 1 h.
3. Add third amplification baculovirus at 1:100 (400 µL), 1:500 (80 µL), 1:1000
(40 µL), and 1:10,000 (4 µL).
4. Incubate cells at 27°C at 80 rpm.
5. Harvest 1 mL samples daily for 96 h
(a) Transfer 1 mL of cells from each flask into 1.5 mL epis.
(b) Centrifuge samples at 500×g for 5 min.
(c) Discard supernatant and store pellets at 20°C.
6. Harvest text expressions at 72 h
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(a) At 72 h post infection, transfer 25 mL of cells from each test expression
to 50 mL conicals.
(b) Centrifuge samples at 500×g for 30 min.
(c) Discard supernatant
(d) Flash freeze pellets in liquid nitrogen and store them at 80°C.
7. Discard remaining cells after taking the 96 h sample.
C.2.8 Western blot analysis of PKG I test expression samples
Goal: Perform a Western blot to determine the potency of the third amplification
baculovirus using the 1 mL samples from the previous step.
Reagents: 10× Electrophoresis Buffer (250 mM Tris, 1.92 M glycine); Transfer
Buffer stored at 4°C (1 L = 100 mL of electrophoresis buffer, 200 mL methanol,
700 mL dH2O); 5×Laemmli Buffer with reducing agent.
Notes:
C.2.8.1 Sample Preparation
1. Prepare 10 mL of lysis buffer: 5 mM TES pH 7, 300 mM NaCl, 1% igepal,
1× protease inhibitor cocktail.
2. Add 500 µL of lysis buffer to each text expression sample.
3. Vortex samples to suspend pellets and incubate on ice for 30 min.
4. Centrifuge samples at approximately 15,000×g for 25 min at 4°C (highest
speed on the tabletop centrifuge).
5. Transfer supernatant to fresh tubes.
6. Prepare samples for gel electrophoresis: 80 µL of sample + 20 µL of 5×
Laemmli buffer with reducing agent. Boil samples for 2 min at 95°C.
7. Prepare a sample of PKG to use as a control (if available).
C.2.8.2 Separate Proteins by SDS-PAGE
1. Using either a hand-made or precast gel, remove the comb and wash wells
with electrophoresis buffer. Ensure the sides of the wells are upright. If not,
straighten them using a 22.5 gauge needle.
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2. Load 15 µL of sample per lane (for a 10 well gel). Remember to include a
molecular weight ladder.
3. Separate proteins at constant voltage (between 130-150 V). The starting
amperage should be between 0.3-0.8 A. This step will take 0.5-1 h depending
on the voltage used.
C.2.8.3 Transfer proteins to PVDF (wet transfer)
1. Remove the stacking gels and place the remaining gels in transfer buffer.
2. Cut out a piece of polyvinylidene difluoride (PVDF) membrane. It should
be slightly larger than the dimensions of the gel. For two gels, proteins from
both can be transferred to the same PVDF membrane.
3. Soak the membrane in 100% methanol for 1 min.
4. Soak the membrane in transfer buffer for 10 min.
5. Soak the other components of the transfer sandwich (Figure C.4).
6. Under completely wet conditions (in transfer buffer), prepare transfer sand-
wich as shown below. After adding each of the filter papers, use a roller to
remove air between the layers.
7. Close sandwich and place in the transfer apparatus.
8. Transfer proteins at constant voltage (100 V) for 1 h.
Figure C.4
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C.2.8.4 Probe PVDF and image bands
1. Remove membrane (molecular weight standard bands should be visible) and
transfer to Odyssey blocking buffer (enough to completely cover the mem-
brane).
2. Block membrane overnight at 4°C with rocking.
3. Incubate membrane with RαHis6 (1:500 in Odyssey blocking buffer) for 1 h
at 4°C with rocking.
4. Wash membrane 3× in PBS for 20 min per wash (4°C with rocking).
5. Incubate membrane with GαR Alexa 680 (LiCor) for 1 h at 4°C with rocking.
6. Wash 3× with PBS as before.
7. Image membrane using the LiCor system on the 700 channel. Quantify
bands to determine which condition resulted in the most protein production.
C.2.9 Full Expression of PKG I
Goal: Prepare a large expression of PKG I based on the optimum conditions
determined by the Western blot
Reagents: Sf 9 cells; Sf900 III supplemented with 1× lipids (Sigma), 10 µg/mL
gentamicin (Sigma), and 0.01% poloxamer 188 (Sigma).
Notes: If the optimum conditions have not been determined, 1:500 of baculovirus
for 72 h is usually a good place to start.
1. Prepare 1 L of Sf 9 cells at 1.5 × 106 cells/mL in a 2.8 L baffled flask.
2. Based on the Western blot analysis, add baculovirus at the dilution which
produced the highest PKG expression.
3. Incubate cells at 27°C, 80 rpm.
4. Harvest the cells at the time which resulted in the most PKG. Centrifuge
cells at 500×g for 30 min. Discard supernatant and flash freeze the pellet
in liquid nitrogen. Store pellet at -80°C.
5. The pellet should be labeled as shown in the example below (description in
red):
FL NHis6 PKG I....................Full-length, N-terminal His6 tag, Construct
Sf9-SF P3.1.1 1:500 021315.....Cells, Serum free, Virus info
72 h 1L 042318........................Expression time, Volume, Date of harvest
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C.3 Ni-IMAC column Regeneration
Reagents: Deionized or ddH2O 0.5 M EDTA 1 M NaCl 1 M NaOH 1 M NiSO4
Equilibration Buffer: 50 mM NaOAc pH 5.2, 300 mM NaCl Lysis Buffer: 50 mM
MES pH 6.9, 300 mM NaCl, 10 mM imidazole
The Lysis Buffer conditions will depend on the protein being purified (close
to the proteins PI). Regardless, 10 mM imidazole is always included to prevent
nonspecific binding of proteins to the column.
Ensure the column is uniformly packed and has never been introduced to air
(without bubbles). If bubbles/nonuniform packing are observed, repack the column
before following the regeneration protocol.
CV=column volume
Procedure:
• 10 CV EDTA
• 2 CV H2O
• 1 CV NaCl
• 2 CV H2O
• 1 CV NaOH
• 10 CV H2O
• 5 CV Equilibration Buffer
• 4 CV NiSO4
After this step, it is preferred to incubate overnight NiSO4. This provides
time for the NiSO4 to interact with the resin. The column can also be stored
longterm in NiSO4 to prevent microbial growth.
• 5 CV Equilibration Buffer
• 10 CV H2O
• 5 CV Lysis Buffer
At this point, the column is ready to load with clarified, filtered cell lysate
for purification of His-tagged proteins.
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C.3.1 Worksheets
Figure C.5: Checklist for performing the in vitro 32P-γ-ATP phosphotransferase
assay.
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Figure C.6: Layout sheet for gel electrophoresis- 10-well. Courtesy of Dr. Jay
Silvera in the Tracy Laboratory, University of Vermont.
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